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Introduction 
Pre-clinical and clinical phannacokinetics plays an important rote in the development of new 
anticancer agents and in the refinement of already existing therapies. In clinical studies, 
phannacokinetic parameters, including area under the plasma concentration-time curve and/or time 
above a certain threshold concentration, have previously been shO\vn to be related to the 
phannacodynamic outcomes, such as myelosuppression or anti-tumor response. In order to obtain 
reliable phannacokinetic parameters, analytical methodologies have to be developed and validated, 
enabling accurate detennination of concentrations of anticancer dmgs in biological matrices. These 
methodologies have to be validated in terms of selectivity, precision, accuracy and sensitivity, to 
obtain meaningful phannacokinetic results. 
During the last decade several analogues of the topoisomerase I inhibitor camptothecin have 
entered clinical practice. Topoisomerase I is a nuclear enzyme involved in the replication of DNA, by 
fonning a cleavable complex, i.e. the covalent interaction between DNA and the enzyme. The 
cleavable complex results in a single strand break of the DNA, resulting in relaxation, followed by 
replication and resealing of the break. The camptothecin topoisomerase I inhibitors reversibly 
stabilize the cleavable complex, resulting in single·strand DNA breaks and thus termination of 
DNA replication, subsequently followed by cell death. 
The camptothecin analogues share a pH-dependent reversible conversion between their 
pharmacologically active lactone form, which is able to diffuse across cell membranes, and their 
inactive ring·opened carboxylate form. The existence of the two forms of the camptothecin 
analogues requires quick sample handling at the site of the patient in order to acquire real·time 
pharmacokinetic data. In chapter 1, an overview of methodologies for the determination of 
camptothecin analogues is described and their applicability for pharmacokinetic analysis is 
discussed. 
In this thesis, methodologies for the quantitative determination of the topoisomerase I 
inhibitors topotecan, 9·aminocamptothecin and lurtotecan are described. The applicability of 
these assays is shown in both clinical pharmacokinetic and in vitro studies. 
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Chapter 1 
Determination of camptothecin analogues in 
biological matrices by high-performance liquid 
chromatography 
Loos WJ, de Bmijn P, Verweij J, Sparreboom A 
Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed 
Kliniek) and University Hospital Rotterdam, The Netherlands 
Anti-Cancer Dmgs II: 315-324,2000 
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ABSTRACT 
Several analogues of the topoisomerase I inhibitor camptothecin (CPT) have been introduced 
in clinical practice in the last decade. All CPT analogues are sensitive to a pH-dependent 
reversible conversion between a pharmacologically active lactone form and its inactive, lactone 
ring opened, carboxylate form. The reversible conversion is also depending on the, sometimes 
species dependent, protein binding properties of the two forms, resulting in different lactone to 
carboxylate plasma ratios for the various analogues. Pharmacokinetic analysis of the CPT 
analogues is helpful in understanding pharmacodynamic outcome of drug treatment, in clinical 
as well preclinical studies. Measurement of these analogues is habitually complicated by the 
chemical instability of the lactone moiety and necessitates a rapid centrifugation of the blood 
sample, preferable at the bedside of the patient, to collect the plasma supernatant. Since the 
lactone forms of these drugs are able to diffuse across cell membranes, including those of the red 
blood cells, rapid collection and processing is even necessary in case only the total 
concentrations of the CPT analogues are to be measured. Sample pretreatment procedures of the 
CPT analogues topotecan, irinotecan, 9-aminocamp~othecin and lurtotecan are summarized and 
discussed in this review. 
INTRODUCTION 
The naturally occurring lactone form of camptothecin (CPT; Figure 1) is a poorly water-
soluble inhibitor of DNA synthesis, by reversibly stabilizing the cleavable complex between 
topoisomerase I and DNA This results in single-strand DNA breaks and thus termination of 
DNA replication, subsequently followed by cell death [1-4]. Since CPT itself was water-
insoluble, the drug was formulated as the water-soluble sodium salt (NSC 100880). 
Unfortunately, due to this formulation, the delicate balance between the lactone and carboxylate 
forms was shifted toward the latter at neutral pH Poor response rates in conjunction with severe 
toxicities were observed in early clinical trials with this agent, and the sodium salt of CPT was 
shown to yield only 10% of the activity of CPT against mouse leukemia while no anti-tumor 
activity was found in xenograft models [1]. During the last decade, various types of more or less 
water-soluble analogues of CPT, such as topotecan'(TPT), irinotecan (CPT-II), 9-aminocamp-
tothecin (9-AC) and lurtotecan (LRT) have been introduced into clinical practice (Figure I). 
CPT and its analogues share a pH dependent reversible conversion between the lactone and 
carboxylate form (Figure 1), from which the intact lactone form is able to diffuse across cell 
12 
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Fig. 1: Chemical structures of the lactone (A) and ring-opened carboxylate (B) forms of 
camptothecin and analogues in clinical development. 
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membranes, while the pharmacologically inactive ring-opened carboxylate is trapped into the 
extra-cellular compartments, i.e. cell growth medium in the case of in vitro experiments and 
plasma water in in vivo studies [5]. The percentages of CPT analogues present in the lactone 
form at equilibrium in phosphate buffered saline are in the same order for the different CPT 
analogues, with values of 17.0 ± 2.0%, 15.3 ± 0.8%,13.0 ± 2.0%,15.3 ± 1.7% and 19.0 ± 1.0% 
for CPT, TPT, CPT-II, SN-38 (active metabolite of CPT-II) and 9-AC respectively. Addition 
of human serum albumin (HSA) at a concentration of 40 mg/mL. shifts the percentage of lactone 
at equilibrium for CPT and 9-AC below 2%, while for CPT-II and SN-38 the percentage 
increased to respectively 24.0 ± 1.0% and 34.8 ± 1.7%. No change has been observed for 
topotecan in the presence of HSA, with 17.1 ± -0.4% in the lactone form at equilibrium. This 
phenomenon is caused by a preferential binding of the carboxylate forms of CPT and 9-AC to 
HSA, resulting in a shift of the equilibrium towards the carboxylate. In contrast, for TPT, CPT-
II and SN-38, the substituents at the Rl- and R2-positions (Figure I) hinder the binding of the 
carboxylate forms to HSA, and so stabilize the lactone form [6]. No data are available for LRT, 
from which we expect a stabilized lactone moiety, by the substitution at the RI-position. 
However, the binding to serum albumin has been shown to be clearly species-dependent; In the 
case of 9-AC, which demonstrated high antitumor activity in preclinical mouse xenograft 
models [7J, the lactone moiety is stabilized by murine serum albumin (MSA) but not by HSA, 
with 35.0 ± 6.2% in the pharmacologically active lactone form in the presence ofMSA and only 
0.63 ± 0.10 % in the presence of HSA [5]. Pharmacokinetic analyses of the camptothecins are 
thus important in clinical as well preclinical studies and are complicated by the chemical 
instability of the lactone moiety. 
To ensure adequate measurements of the pharmacologically active lactone forms of the CPT 
analogues in kinetic studies, blood samples have to be processed directly after sampling at the 
site of the patient; either by (i) direct analysis of the samples, or by (ii) direct extraction of the 
lactone form from the plasma or by (iii) stabilizing the lactone to carboxylate ratio. Stabilization 
of the lactone to carboxylate ratio is preferable since this is the less laborious approach. In 
general, separations of the topoisomerase I inhibitors and endogenous compounds were 
performed by reversed-phase high-performance liquid chromatography (HPLC) methods, 
coupled with fluorescence detection. In this review we summarize the methods for sample 
treatment and detection of each CPT analogue in biological matrices, and the lower limit of 
quantitation (LLQ) or lower limit of detection (LLD) for each assay. The LLQ is of great 
importance for accurate pharmacokinetic analysis and is defined as the lowest concentration of 
the eamptothecin, which can be measured accurate and precise. While the LLD, which is 
unreliable regarding accuracy and precision, is defined as the lowest detectable concentration 
that can be distinguished from the background noise [8]. 
14 
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SAMPLE TREATMENT OF CPT ANALOGUES FOR HPLC MEASUREMENTS 
Topotecan 
Topotecan (TPT, Hycamtin®, SKF 104864, NSC 609699, (S)-9-dimethylaminomethyl-IO-
hydroxycamptothecin; Figure 1) is a semisynthetic waterMsoluble CPT analogue, prepared by 
synthetic modification of IOMhydroxycamptothecin [1]. The intravenous formulation ofTPT has 
been registered for the treatment of ovarian cancer in Europe and the USA [4]. The 
determination of the lactone, carboxylate and total (i.e., lactone plus carboxylate forms) 
concentrations of TPT in human plasma have been described in several pUblications. The 
plasma sample pretreatment in these published methods is based on a simple methanolic protein 
precipitation step immediately after the collection of the plasma according to the method of 
Beijnen et al. [9]. The ratios of the lactone to carboxylate concentrations in the methanolic 
extracts were found to be stable for at least 4 and 15 months when stored at a minimum of M 70°C 
[IO,IIJ. 
The first assay, published by Beijnen et a!. [9J, described the simultaneous determination of 
the lactone and carboxylate form of TPT with a LLD for both compounds of 0.2 nglm!. A good 
baseMline separation between the lactone f~)fm and endogenous material was achieved, however, 
in blank plasma samples an interfering peak for the carboxylate form was found. In order to get 
reliable results the chromatograms were reprocessed with subtraction of each corresponding 
blank chromatogram. 
One of the assays described by Rosing et a!. [l2l is among the most sensitive with a LLQ of 
0.05 nglml (Table I) for the lactone and the total form of TPT. The total concentration of TPT 
was measured in a second analysis, where the samples were acidified with perchloric acid, 
which results in the conversion of the carboxylate form in the lactone form, followed by the 
determination of the lactone form. The amount of the carboxylate form was calculated as the 
difference between the total and lactone concentration. These authors have also described the 
impact of column temperature for the assay of topotecan in rat and dog plasma [13]. The sample 
treatment is based on the same method, while the column must be thermostated at 19M2loC to 
obtain sufficient baseline separations between peaks of endogenous compounds in rat and dog 
plasma and of TPT. The LLQs were established at 0.10 nglml for the lactone and lactone plus 
carboxylate concentrations in rat plasma and at 0.20 nglml for the concentrations ofTPT in dog 
plasma (Table I). 
The method by Loos et al. [10] describes the simultaneous determination of the lactone and 
the carboxylate forms ofTPTwith sufficient separation between chromatographic peaks of 
15 
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Table 1: lIPLC-methods with corresponding LLQ values for the analysis ofTPT 
Ref Year Matrix Sample Detection LLQ (nglml) 
Treatment Ex (nm) Em (nm) Carbox Lactone Total 
12 1995 lIP PP 361 527 0.05 
PP/AC 361 527 0.05 
13 1996 RP PP 361 527 0.10 
PP/AC 361 527 0.10 
DP PP 361 527 0.20 
PP/AC 361 527 0.20 
10 1996 lIP PP 381 525 0.10 0.10 
HU AC 381 525 10 
20 1997 HP PP 390 520 0.25 0.50 
350-470 510-650 0.50 0.75 
II' 1999 HP PP 380 527 0.1 
PP/AC 380 527 0.1 
HU AC 380 527 25 
E 380 527 0.3 
Abbreviations: Ex = excitation wavelength, Em = emission wavelength, HP = human plasma, RP = rat plasma, DP= dog plasma, 
HU = human urine, HF = human feces, PP = protein predpilation, AC = acidification, E = c:\iraction \\;Ih acetonitrile/ammonium 
acelate, a = simUltaneous determination ofN-desmelhyUopotecan, b = concentration in Ilglg feces 
16 
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endogenous materials and of the carboxylate and lactone forms of TPT, with the LLQ 
established at 0.10 ng/ml for both TPT forms (Table I). In this manuscript, also a method for the 
determination of total TPT in urine is described. Total TPT, with a LLQ of 10 nglml, is 
measured after acidification of the urine sample with orthophosphoric acid, resulting in the 
conversion of the carboxylate form into the lactone form. 
\Varner et al. [14] describe non-validated HPLC methods for the simultaneous determination 
of the lactone and ca~boxylate forms of several camptothecin analogues in phosphate buffered 
saline and for topotecan also in human plasma. The only concentration tested is 2.5 ng/ml for 
both TPT forms, with a broad peak for the lactone form. Therefore, their application for 
simultaneous TPT lactone and carboxylate measurements in human plasma is not suitable for 
pharmacokinetic analysis in clinical trials after low intravenous dosages or oral administrations 
ofTPTwherelowconcentrationsofthetwoformsoftopotecan were expected [15-19]. Another 
publication of the same group [20] described an improved sensitivity of simultaneous 
determination of the lactone and carboxylate forms oftopotecan in human plasma in comparison 
with already existing methods (Table I). However, the LLQ for the lactone and carboxylate form 
were respectively 0.50 and 0.25 nglml using a tunable fluorescence detector with excitation and 
emission wavelengths of 390 nm and 520 nm respectively. Using a filter detector, with an 
excitation filter of350 - 470 nm and an emission filter of 510 - 650 nm, the LLQ values were 
respectively 0.75 and 0.50 ng/ml, which are still much higher than described earlier [10,12]. 
Recently. an assay has been published for the simultaneous determination of TPT and N-
desmethyltopotecan, one of the known metabolites of TPT, in human plasma, urine and feces 
[11]. For the determination of drug levels in plasma, two assays were developed, one for the 
determination of the 'lactone concentration and one for the determination of the total 
concentrations of TPT and its metabolite. The LLQ for the lactone as well as the total 
concentration ofTPT and N-desmethyltopotecan was established at 0.1 nglml. In urine and feces 
only total levels of TPT and its metabolite were measured. The sample pretreatment for urine 
samples involved a dilution step in methanol, followed by acidification with phosphoric acid, 
resulting in LLQ values of 25 and 2.5 ng/ml of TPT and N-desmethyltopotecan, respectively. 
Fecal samples were homogenized in distilled water, followed by a double extraction with a 
mixture of acetonitrile and ammonium acetate pH=4. The LLQ for total topotecan in feces was 
0.3 ~g/g, while the LLQ for N-desmethyltopotecan was established at 0.03 flg/g feces. 
17 
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Irinotecan 
Irinotecan (CPT-II, 7-ethyl-1 0-{4-(piperidino )-I-piperidino} -carbonyloxycamptothecin; 
Figure 1) is a semisynthetic water-soluble analogue of CPT, with limited intrinsic cytotoxic 
activity. In biological systems, CPT-II is converted by carboxylesterases into its 100 to 1000 
fold more active metabolite SN-38 (7-ethyl-IO-hydroxycamptothecin; Figure I). The drug has 
been marketed in the USA and Europe for the treatment of 5-fluorouracil-refractory (metastatic) 
colorectal cancer [1,4]. Over the last years, several HPLC methods have been reported for the 
determination of CPT-l1 and its pharmacologically active metabolite SN-38 in plasma. The 
analysis of these compounds is rather complicated because of the existence of chromatographic 
peaks of other CPT-II metabolites and the poor peak-shapes. The peak-shapes were optimized 
by using the cationic ion-pairing reagent tetrabutylammonium phosphate (TBAP) and 
analogues, which also enables the simultaneous determination the lactone and carboxylate forms 
of CPT-II and SN-38 by increasing the retention times of the carboxylate forms on the 
analytical columns. 
The first assay for the determination of total concentrations of CPT-II and SN-38 in human 
plasma was described by Barilero et al. [2IJ, with a LLD for both compounds of 1.0 ng/ml. In 
the described method, a good separation was achieved between the total drug in the lactone 
form for both CPT-II and SN-38 after acidification and solid phase extraction of the plasma 
sample. 
Rivory et al. [22J developed a HPLC method for the simultaneous determination of the 
lactone and carboxylate forms of CPT-I I and SN-38 in human plasma. The plasma clean up step 
involved a protein precipitation with a mixture of ice-cold methanol/acetonitrile (1:1, v/v). 
Adequate separation was achieved and the LLQs were established at respectively 10 and 2 ng/ml 
for both forms of CPT-II and SN-38 (Table 2). The addition of mobile phase prior to injection 
to the protein-free supernatant was found to be an essential step in the assay. Omission of this 
buffer resulted in a complex of unresolved peaks. Two other metabolites were found under the 
chromatographic conditions, one of whic~ has been identified as the B-glucuronide form of SN-
38. A second method for the simultaneous determination of the lactone and carboxylate forms of 
CPT-II and SN-38 in human plasma has been developed and validated by Herben et al. [23]. 
The sample pretreatment was based on the same principle as described above, with the LLQs 
established at 1.0 ng/ml for CPT-II lactone and carboxylate, and at 0.5 nglml for the lactone and 
carboxylate forms of SN-38 (table 2). A minor disadvantage of the latter published assay is the 
rather long overall run time of 20 min, which does not allow the analysis of large number of 
samples, since the protein-free extracts have to be injected directly after the addition of mobile 
phase. 
Sumiyoshi et a!. [241 developed a -method for the simultaneous determination of total 
concentrations of CPT-II and SN-38 in human plasma. The sample clean-up consisted of 
18 
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precipitation of plasma proteins with methanol. Subsequently, the samples were evaporated and 
reconstituted in acidified (pH~2) mobile phase. The LLQs were established at 30 ng/ml for 
CPT-II and I ng/ml for SN-38 (Table 2). The rather high LLQ of CPT-I I is due to the selected 
excitation and emission wavelengths of 380 nm and 556 nm, respectively, to obtain maximum 
sensitivity for the determination of the pharmacologically active metabolite SN-38. No other 
metabolites of CPT-I I than SN-38 were reported in this publication. 
A method for the simultaneous determination of the carboxylate and lactone forms of SN-38 
has been described by Kaneda et al. [25]. The described method is performed in rat plasma, with 
the LLQs of 5 ng/ml for both forms of SN-38 (Table 2). The sample preparation consists of a 
protein precipitation with cold (-80°C) methanol followed by addition of aquolls zinc sulphate 
(10%, w/v), followed by centrifugation and direct injection into the HPLC-system. 
The most sensitive assays available thusfar for the simultaneous determination of lactone and 
total levels of CPT -II and SN-38 have been developed and validated by De Bmijn et al. [26J, 
with a LLQ for the lactone of 0.5 ng/ml for CPT-II and SN-38 (Table 2). The plasma sample 
clean-up for the lactone measurement consisted of a single liquid-liquid extraction technique 
with acetonitrilefn-butylchloride (I :4, v/v). The measurement for the determination of the total 
forms was carried out in a second analysis with LLQs of2.0 ng/ml for both compounds (Table 
2). The plasma samples were acidified and deproteinized with a mixture of perchloric acid and 
methanol, which resulted in the conversion of the carboxylate forms into the lactone forms, 
followed by determination of the lactone form. Six other peaks were found in the plasma 
samples of patients in the assay for the determination of the total forms of CPT-II and SN-38. 
Two of them disappeared after incubation of a plasma sample with fi-glucuronidase, while the 
concentration of SN-38 increased, which is indicative for the presence of a fi-glucuronide 
conjugate (SN-38G) of SN-38 in plasma samples of cancer patients treated with CPT-II. This 
method was subsequently modified to allow analysis of other metabolites in plasma, urine and 
feces samples as well [27]. Two metabolites of CPT ~ II were analyzed and validated in human 
plasma, known as SN-38G and 7-ethyl-10-[4-N-(5-aminopentanoic acid)-I-piperidino)-
carbonyloxy-camptothecin (also referred to as APe). The described method for the 
determination of both metabolites in human plasma was based on the assay described by De 
Bruijn et aL [26) with a slightly modified mobile phase and the plasma extract was necessarily 
diluted 2-fold with mobile phase prior to chromatography, because of unusual chromatographic 
behavior of compounds APC and SN-38G. The LLQ was established at 10 ng/ml APC and SN-
38G. The change in mobile phase as compared to the earlier described method, resulted in poor 
accuracy and precision for CPT-II and SN-38, due to severe tailing bands, particularly below 
100 nglm!. CPT-II and SN-38 measurements in plasma samples were carried out by re-injection 
of the plasma supernatant using the earlier described method [26]. Urine and homogenized fecal 
samples were diluted (1: I, v/v) III blank plasma and further processed as 
19 
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Table 2: HPLC-methods with corresponding LLQ values for the analysis of CPT -IIISN-38 
Ref Year Matrix Sample Detection LLQ CPT-II (ng/ml) 
Treatment Ex (nm) Em (nm) Carhox Lactone Total 
22 1994 HP PP 355 515 10 10 
24 1995 HP PP/AC 380 556 30 
25 1997 RP PP 380 540 
26 1997 HP LL 355 515 0.5 
PP/AC 355 515 2.0 
23 1998 HP PP 3751385' 460/525' 1.0 1.0 
27 1998 lIUIHF PP/AC 355 515 200 
29 1998 HP AC/SP 380 532 
30 1999 lIP PP/ACILL 380 556 
31 1998 DPIRP PP 362/375' 425/560' 4.8 5.9 
32 1999 RP AC/SP 3731380' 420/540' 5 
33 1999 lIS PP MS 10 
LL MS 
20 
LLQ SN-38 (ng/ml) 
Carbox Lactone Total 
2 2 
5 5 
0.5 
2.0 
0.5 0.5 
100 
0.004 
0.005 
16 2.4 
5 
0.5 
Metabolites 
(No.) 
2 
21 
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Abbreviations: Ex = excitation wa\'clcngth, Em = 
emission wavelength, lIP = human plasma, RP = rat 
plasma, DP= dog plasma, HU = human uline, HF = 
human feces, HS= human serum, PI' = protein 
precipitation, AC = acidification, SP = solid phase 
c:x1raction, LL = Liquid-liquid extraction, Metabolites 
.. number of identified metabolites, others than SN· 
38,· = setting for CPT-IIISN-38 respectively, MS = 
detection using mass spectrometry. 
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described for human plasma samples, followed by a 10-fold dilution in mobile phase. The 
LLQs were established at 100 ng/ml for SN-38 and SN-38G and at 200 ng/ml for CPT-II and 
APC (Table 2). The method was also validated for a second major oxidative metabolite of CPT-
II, viz. NPC, in human plasma samples with similar validation characteristics [28]. 
Since the terminal disposition half-life ofSN-38 in cancer patients treated with CPT-II could 
not be estimated accurately in early pharmacokinetic studies, an assay for the determination of 
SN-38 at lower concentrations was needed. The first very sensitive assay was reported by Rivory 
et aJ. [29]. The plasma sample was acidified prior to solid-phase extraction and the LLQ for the 
total concentration of SN-38 was established at 10 pM (-4 pg/ml) (Table 2). However, the 
recovery of SN-38 was concentration dependent and ranged from 48 up to 92% and therefore 
log-log calibration curves with least-square linear regression were required. CPT-II did not 
interfere with the assay. Compared to this method for the determination of SN-38 at low 
concentrations, a simplified method with comparable sensitivity has been described recently 
[30J. The method described by Rivory et a1. consisted of a time consuming solid-phase 
extraction and showed concentration dependent recoveries. In the assay described by de Bruijn 
et al., protein precipitation followed by a one-step solvent extraction with chloroform, was used 
for sample clean up. The LLQ was established at 5 pg/ml (Table 2), with standard curves being 
linear over nearly three orders of magnitude. The use of acetonitrile as organic modifier in the 
mobile phase in stead of methanol, resulted in sharpening of the peaks and improved peak 
symmetry. No interference of CPT-II was observed in the analytical nills. 
Chollet et al. described a method for the simultaneous determination of the lactone and 
carboxylate forms of CPT -II and SN-38 in rat and dog plasma [31]. This is yet another method, 
in which the lactone and carboxylate forms could be determined simultaneously, after cold 
methanol (-20°C) protein precipitation. The LLQs in dog and rat plasma were similar and were 
validated at 4.8 and 5.9 ng/ml for the carboxylate and lactone forms of CPT-I I respectively, and 
at 1.6 and 2.4 ng/ml for the carboxylate and lactone form ofSN-38 respectively (Table 2). 
Kurita et aJ. [32J have also described a method for the determination of total levels of CPT-
II and its metabolites SN-38 and SN-38G in rat plasma. The LLQs were established at 5 ng/ml 
for CPT-II and SN-38 in rat plasma (Table 2). The method described determination of the 
compounds with a fully automated on-line solid-phase extraction system, which may have 
potential advantage for processing large numbers of samples simultaneously. 
Recently, a non-fluorescence HPLC-method has been developed [33J, using electrospray 
mass spectrometry, for the detection of CPT-I I and SN-38 concentrations in human serum. The 
sample clean up for the measurement for CPT -II involved a protein precipitation with a LLQ of 
10 ng/ml, while the LLQ for SN-38 was validated at 0.5 ng/ml after a liquid-liquid extraction 
(Table 2). The use of a mass spectrometer as detector, does not increase the sensitivities of the 
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determinations of CPT-II and SN-38 compared to previously reported methods, using an 
ordinary fluorescence detector. 
9-aminocamptothecin 
9-aminocamptothecin (9-AC, NSC 603071; Figure I) was the first synthetic analogue of CPT 
with promising antitumor efficacy in ill vivo models. However, 9-AC was inappropriate for 
further clinical development, due to its poor water solubility. Eventually, the solubility problems 
were solved by the development of a colloidal dispersion formulation, and 9-AC has since been 
implemented in numerous clinical trials with the drug given either by bolus or prolonged 
continuous-intravenous infusion schemes or orally (l,4,34). 
Up to now, 4 analytical methods have been published for the determination of the lactoneand 
the lactone plus carboxylate form of9-AC in human plasma. In the presence ofHSA, the lactone 
form of 9-AC is rapidly converted to the carboxylate form with the equilibrium at the site of the 
carboxylate, which also necessitates a rapid processing of the blood samples for 
pharmacokinetic studies. In all methods, the blood sample was centrifuged directly, although the 
plasma was processed using totally different methods. The method published by Supko et at 
[35] for the measurement of the intact lactone-of 9-AC requires a rapid deproteinization of the 
plasma sample with methanol, foll9wed by direct injection of diluted supernatant into the 
HPLC-system. For the measurem.ent of the total drug concentration, the plasma sample was 
acidified using perchloric acid, followed by methanolic deproteinization. To increase the 
sensitivity of the assays, an inline postcolumn acidification of the eluent to pH 1.8-2.2 was 
necessary, which results in a LLQ of 5.0 ng/ml for the lactone and total concentration of 9-AC 
(Table 3). 
A more sensitive assay was developed by Takimoto et at [36J with a LLQ of 0.09 and 0.9 
nglml (Table 3) for the lactone and total concentrations of 9-AC, respectively. Using a solid 
phase extraction for the determination of the lactone form immediately after collecting the 
plasma, which separated the lactone from the carboxylate, the sample could be stored for at least 
two months at -70°C prior to analysis. For the measurement of total 9-AC concentrations, the 
plasma samples were acidified prior to solid phase extraction by a 10-fold dilution with 
phosphoric acid (Table 3). 
Another, more convenient and sensitive assay was developed later and does not require a 
direct sample clean-up step [37J. The lactone to carboxylate ratio of 9-AC was stabilized, for at 
least 4 months, by immediate freezing of the plasma samples at the site of the patient. After 
thawing the samples, the lactone form was extracted into an organic phase using liquid-liquid 
extraction, with a mixture of acetonitrile/n-butylchloride (1:4, v/v), while the carboxylate form 
remains in the water-phase. For the determination of the total 9-AC concentrations, the sample 
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clean-up consists of a simultaneous protein precipitation! acidification step with a mixture of 
methanol and perchloric acid. The LLQs were established at, respectively, 0.05 and 0.10 nglml 
for the lactone and lactone pIllS carboxylate forms (Table 3). 
Table 3: HPLC-methods with corresponding LLQ values for the analysis of9-AC 
Ref Year Matrix Sample Detection LLQ (nglml) 
Treatment Ex (nm) Em (nm) Lactone Total 
35 1992 HP PP 352 418 5.0 
ACIPP 352 418 5.0 
36 1994 HP SP 365 440 0.09 
AC/SP 365 440 0.9 
37 1997 HP LL 370 450 0.05 
PP/AC 370 450 0.10 
38 1998 HP PP/SP 370 450 0.2 
PP/AC 370 450 0.2 
Abbreviations: Ex = cxcilalion wavelength, Em = emission wavelength, HP = human plasma, PI' = protein precipitation, 
AC = acidification, SP = solid phase c:\ilaclion, LL = liquid-liquid extraction 
A sample dean-up procedure involving a direct deproteinization of the plasma at the site of 
the patient with cold methanol has been reported recently [38J. For the determination of the 
lactone form, the methanolic extract should be further processed within 48 h after sampling, 
using a solid phase extraction procedure, while for the determination of total dntg levels the 
methanolic extract was acidified prior to injection into the HPLCMsystem (Table 3). The LLQs 
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for the lactone and total concentrations of 9-AC in human plasma were established at 0.2 ng/ml 
for both the lactone as well the total drug levels. 
Lurtotecan 
Lurtotecan, (LRT, GIl 4721 I, 7-(4-methylpiperazinomethylene)-IO,lI-ethylenedioxy-20(S)-
camptothecin; Figure I) is also a semisynthetic analogue of CPT and has recently been 
formulated as a liposomal preparation with the intent to stabilize the lactone moiety of the 
compound, and so improve the efficacy ofLRT [39J. 
Only two methods were validated and published for the determination of the drug after 
administration of non-liposomal LRT; Stafford et al.[40J published the first of these, and 
describe the quantitation of the lactone and carboxylate forms ofLRT in dog plasma using solid-
phase extraction techniques. For the lactone-only determination the plasma was diluted with a 
buffer of pH 7.4 and applied on a solid phase cartridge, followed by a wash step which removes 
the carboxylate, while the lactone form remains at the cartridge and was eluted and concentrated 
before injection into the HPLC-system. For measurement of the total concentration of LRT, the 
plasma was acidified with hydrochloric acid before solid phase extraction. The excitation and 
emission wavelengths were set at 378 and 420 nm, respectively. The LLQ was established at 
0.05 and O.I 0 ng!ml for the lactone and total plasrna concentrations, respectively, which was the 
most sensitive determination of any camptothecin analogue reported at that time. 
The second method was developed and published by Selinger et al. [4IJ, in which only a 
method for the determination of the lactone form ofLRT is described, using human whole blood 
as matrix. The advantage of using whole blood instead of plasma, is the rapid and simple sample 
handling at the site of the patient. After drawing the blood sample, it can be kept for a maximum 
of30 min in an ice-water bath, before freezing at -70°C. On the day of analysis the blood sample 
is further processed using a liquid-liquid extraction, with a mixture of acetonitrile!n-
butyl chloride (I :4, v/v), for the measurement of the lactone form. The LLQ has been validated at 
0.15 nglml, lIsing fluorescence detection as described above. 
A method for the determination of total LR T levels in human plasma and urine after 
administration ofNX211, i.e. liposomal LRT, has been recently developed and validated [42]. 
The sample clean up for the determination of total drug levels in plasma involved a 
deproteinization with 10% (w!v) aqueous perchloric acidwacetonitrile (2:1, v!v), while for the 
determination of the unchanged drug in urine a single solvent extraction with n-butanol-diethyl 
ether (3:4, v/v) was accomplished after acidification of the urine sample. Fluorescence detection 
in both assays was performed with excitation and emission wavelengths ofrespectively 378 and 
420 nm. The LLQ in plasma was established at 1.0 nglml, which is sufficient for 
pharmacokinetic analysis of patient samples in an ongoing phase I trial. The fluorescence signal 
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ofLRT in the urine assay was increased 14-fold prior to detection by post-column exposure of 
the eluent to UV-Iight, resulting in an LLQ of 0.50 nglml in the human urine samples. 
CONCLUSIONS AND PERSPECTIVES 
Camptothecins form a class of antineoplastic agents demonstrating significant antitumor 
activity against a broad range of human malignancies, including refractory ovarian and colorectal 
cancers. In recent years, a substantial amount of publications has yielded valuable insights into 
mechanisms of action'and resistance, clinical pharmacodynamics and considerations of dosage 
and schedule, and route of drug administration. Many of these studies have been made possible 
by the development of selective analytical methodologies to specifically monitor the parent 
drugs and individual biotransformation products, with sufficient sensitivity to detect the 
compounds at levels achieved after therapeutic dosing. 
The pH-dependent instability of the lactone moiety in the core structure of the camptothecins 
necessitates a rapid centrifugation of the blood sample, preferably at the site of the patient, to 
collect the plasma supernatant. Even whe~ only total concentratioris of the camptothecins are to 
be measured, this rapid collection of tpe plasma is necessary since the lactone forms of these 
drugs are able to diffuse across cell membranes, including those of the red blood cells, and thus 
. a change in the lactone to carboxylate ratio has an effect on the total drug concentrations in the 
plasma compartment. To ensure adequate measurements of the lactone concentrations, the 
plasma samples have to be further processed immediately after centrifugation. 
The most laborious methods for the determination of the lactone-only concentrations are 
those in which each individual plasma sample has to be analyzed or extracted directly after 
collection of the plasma. Clearly, the most convenient approach at the site of the patient is the 
one in which the lactone to carboxylate ratio is stabilized by direct freezing of the plasma or 
whole blood samples. For the lactone only measurements, the samples were further processed 
using either solid-phase or liquid-liquid extraction techniques. In both cases, only the lactone 
form is extracted, while the carboxylate form is eluted during the wash steps in the case of the 
solid-phase extractions, or remains in the water-phase in case of the liquid-liquid extractions. 
The total concentrations of the camptothecins in the directly frozen plasma samples were 
analyzed after acidification of the samples followed by solid-phase extractions of the total 
amount of the drugs in the lactone form, or by measurements of the compound in the lactone 
form after injection of supernatants of deproteinized and acidified samples. Another practically 
convenient approach to stabilize the lactone to carboxylate ratio is by methanolic 
deproteinization of plasma samples directly at the site of the patient. The methanolic extracts 
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should be stored upon analysis at a minimum of -70°C to prevent degradation of the lactone 
form. The advantage of this stabilization is the possibility of simultaneous measurement of the 
lactone and carboxylate forms of the camptothecins in one single run. However, this approach is 
not feasible for all CPT analogues, except for TPT and CPT-II, since the separation between 
the hydrophilic carboxylate forms and endogenous compounds (with similar fluorescence 
characteristics) in the reversed-phase HPLC methods are not sufficient enough for adequate 
determination of the carboxylate forms. Moreover, the overall run times have to be as short as 
possible to enable determination of complete runs of patient samples during day time, since the 
lactone to carboxylate ratio is not stable at 4°C {1O], making automated injections overnight 
infeasible. For methods in which insufficient separation between the carboxylate form and 
endogenous compounds was achieved, the methanolic extracts were acidified and the total 
concentrations of the drugs were measured in a second analysis. Since the camptothecins have 
strong fluorescence characteristics, relatively low concentrations of these compounds could be 
measured in biological matrices, even after simple protein-precipitation extraction procedures 
without the need of any concentration step. 
The new dimension in chemotherapy provided by TPT. CPT-II and other analogues in the 
treatment of a variety of (solid) tumors assures growth in the area of camptothecin-related 
chemotherapeutic drugs. In general, with the continued application of clinical pharmacokinetic 
studies, coupled with new approaches in camptothecin drug design and formulation, more 
rational and selective chemotherapy should be possible in the future. 
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Chapter 2a 
ABSTRACf 
A sensitive reversed-phase high-perfonnance liquid chromatographic fluorescence method is 
described for the simultaneous detennination oftopotecan (I) and the hydrolyzed lactone ring-opened 
product hydroxy-acid (II) in plasma and for the detemlination of I in urinc. To 250 JlI of plasma a 
volume of750 Ml of cold methanol was added to stabilize the pH dependent conversion of! into II. In 
plasma the lower limit of quantitation for both compounds was 0.10 ng/IllI. The between-day 
variation forI at the LLQ was 7.1% and for n 5.5%. Prior to injection, urine samples were acidified 
with ortho-phosphoric acid and diluted with phosphate buffered saline (PBS). In urine the calibration 
cllrve was linear in the range of 10 to 250 ng/ml and the lower limit of quantitation was lOng/mi. 
The assay was developed to enable phannacologic analysis of I in ongoing phase I and n shldies in 
patients with solid tumors. 
INTRODUCfION 
Compound I [(S)-9-dimethylaminomethyl-10-hydroxy-camptothecin, SKF I04864-Aj is a 
semisynthetic water-soluble analogue of camptothecin presently evaluated in clinical phase I 
and IT trials. I is an inhibitor of the nuclear enzyme topoisomerase L It stabilizes the cleavable 
complex between DNA and topoisomerase I, resulting in single-strand breaks of the DNA and 
finally cell death. Antitumor activity has been demonstrated in preclinical models and in phase I and 
II studies [1-6]. The results of preclinical and clinical studies indicate enhanced antineoplastic activity 
of! when administered daily for prolonged periods oftime [2, 5-9j. 
Compound I is not stable at physiological pH in an aqueous solution. It is reversibly hydrolyzed 
from the closed-ring lactone (I) to an opelHing (ll) jn aqueous solution (figure 1). Compound II is not 
phamlacologically active [10, Ilj. 
An HPLC-assay for the analysis of I and II in human plasma has previously been developed by 
Beijnen et al. [11] with a lower limit of quantitation, for both compounds, of 1 nglmL The present 
methodology was developed because blank plasma samples revealed an interfering peak at almost the 
same retention time as II. In addition, the plasma concentrations in our clinical study, where I is 
administered orally for prolonged periods of time, were anticipated to be much lower than the LLQ 
of the previously developed methodology. Furthennore, an assay for I in urine was developed to 
detcnnine the magnitude of the renal clearance of! in studies after i.v. administration. 
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Fig. 1: pH-dependent interconversion ofI and II 
EXPERIMENTAL 
Chemicals and reagents 
Compound I was obtained from Smith Kline Beecham Phannaceuticals (King of Pnlssia, PA, 
USA). Methanol (HPLC-grade) was obtained from Rathburn and supplied by Bnmschwig 
(Amsterdam, Netherlands). Triethylamine, potassium dihydrogenphoshate, sodium hydroxide and 
acetic acid (all analytical grade) were obtained from Baker (Deventer, Netherlands). Ortho-
phosphoric acid (analytical grade) was obtained from Merck (Amsterdam, Netherlands). Phosphate 
buffered saline (PBS) was obtained from Oxoid and supplied by Boom (Meppel, Netherlands). PBS 
consisted of sodium chloride (8.0 gil), potassium chloride (0.2 gil), disodium hydrogenphospate 
(1.15 gil) and potassium dihydrogenphosphate (0.2 gil) and was supplied in tablets. One tablet was 
dissolved in 100 ml purified water. The water was purified with a Milli-Q-UF system (Millipore, 
Etlen-Leur, Netherlands). 
A stock solution of 1.0 mglml I was made by dissolving 50.0 mg I in 50.00 ml purified water. To 
5.00 ml of the stock solution in water 45.00 ml of a 0.10% acetic acid solution were added. This 
solution contained 0.10 mglml of!. To another 5.00 ml of the stock solution 45.00 ml ofa 0.10 N 
sodium hydroxide solution were added. This solution contained 0.10 mglml ofn. 
Chromatographic system 
The HPLC-system consisted of a constaMetric 4100 pump (Thenno Separations), a Rheodyne 
7125 injection port and a fluorillionitor 4100 fluorescence detector (LDC Analytical). The data were 
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analyzed by the Chrom-Card data analysis system (Fisons). These apparatus were delivered by 
Interscience (Breda, Netllerlands). The separation was achieved on a Shandon Hypersil BDS C18 
column (100 mm * 3 mm ID, 3~ particle size), delivered by LC-service (Emmen, Netherlands). A 
model SpH 99 column oven, delivered by Spark Holland (Meppel, Netherlands), was set at 3S"C for 
the assay in plasma and at 60°C for the assay in urine. The excitation wave length was set at 381 11m 
and the emission wave length at 525 om. 
For the assay in plasma the mobile phase consisted of a 10 mM potassium dihydrogenphosphate 
(filtered through a O.4S HA Millipore filter, Millipore, Etten-Leur, Netherlands) with 2S% methanol 
and 0.2% triethylanline. The pH was adjusted to pH 6.0 by addition of ortho-phosphoric acid. The 
mobile phase was degassed by ultrasonic and helium. The f1ow~rate was set at 0.70 mUmin. 
For the assay in urine the mobile phase consisted of20% methanol instead of 25%, The flow-rate 
was set at 1.00 mUmin. 
Sample preparation and calibration curves in plasma 
Immediately after preparing the standards 250 fll plasma were added to 7S0 fll of cold methanol of 
-20°C, according to the method ofBeijnen et al. [II). After mixing on a whirl mixer for lO seconds 
the samples were centrifuged for 5 min at 4000g at 4°C and stored at -80°C. Plasma samples of 
patients were stored after mixing at _80eC and centrifuged on the' day of analysis. Prior to analysis, 
2S0 fll ofthe supernatant were added to 7S0 fll of PBS and mixed on a whirl mixer for 10 seconds. A 
volume of200 fll was injected into the HPLC. 
For the validation of the assay in plasma a nine-points calibration curve was processed in duplicate 
(table I) and analyzed on 3 occasions. For the detennination of the lower limit of quantitation (LLQ), 
6 plasma samples of 6 independent individuals were taken and spiked with a concentration of 0.1 0 
ng/ml of both compounds. Also 4 pools of quality control (QC) samples were prepared. Plasma pools 
Table 1: Preparation of the ca.libratio~ curves in plasma. 
Final concentration of! and II (ng/ml) 
S.OO 3.00 2.00 LOO O.SO 0.30 0.20 O.IS 
Plasma added (~II) SOO 700 800 1800 SOO 700 800 850 
10.0 ng/ml I and II added (~II) 500 300 200 200 
LOO ng/ml I and II added (,tI) SOO 300 200 ISO 
The solutions of 0.1 0 mg/ml I and 0.10 mg/ml II were separately diluted 100-fold with PBS and again I O-fold with plasma. 
A 200)11 volume of both solutions was added to 1600)11 of plasma. Th.is solution c{)ntaincd 10.0 ng/mll and II. 
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were spiked with 0.50, 2.00, 4.00 and 20.00 nwml for both compouuds. The QC-sample of 20.00 
nglml was used for dilution. Each run the QC-samples were analyzed 5 times. 
The recovery of! and II was determined at concentrations of 2.00 and 4.00 nglml in plasma. The 
peak heights of 5 analyzed plasma samples were compared with the peak heights of 2 spiked 
concentrations of2.00 and 4.00 nwml in PBS. 
Calibration curves were made by linear regression analysis of peak heights versus concentration. 
For the concentration accepted as the LLQ, the %DEV of at least 80% of the samples assayed should 
be:::; 20%. The average within- and between-nm precision (%CV) for each concentration, excluding 
the LLQ, should be,; 15% and should be,; 20% for the LLQ. The average accuracy (%) for each 
concentration, including the LLQ should be within 85-115%. 
Sample prepal'ation and calibration CUiye in urine 
In urine the total concentration ofI was measured after conversion of II into 1. To 250 III urine 250 
III of 100-fold diluted pure ortho-phosphoric acid were added, After mixing on a whirl mixer for 10 
seconds the mixture was incubated for at least 10 min at room temperature. Prior to injection 50 III of 
this mixture were added to 950 gI of PBS and mixed on a whirl mixer for 10 seconds. A volume of 
20 f1I was injected into the HPLC. 
Table 2: Preparation of the calibration curve in urine. 
Urine added (Iti) 
1000 nwml I added (~I) 
100 nwml I added (Iti) 
50 nwml I added (~I) 
Final concentration of! (nwml) 
250 200 150 100 
750 
250 
800 
200 
850 
150 
900 
100 
50 25 
500 500 
500 
500 
A solution containing 0.10 mg/ml ofl was diluted 100-fold in urine. This results in a 1000 ng/ml solution oft 
25 
900 
100 
For the validation of the assay in urine a seven-points calibration curve was prepared (table 2). The 
calibration curves were made in duplicate and analyzed on 3 occasions. For the detemlination of the 
LLQ, 10 urine samples of 10 independent individuals were taken and spiked with a concentration of 
10 nwml ofl Pools ofQC-samples were spiked with concentrations of25, 100, 200 and 1000 nwml 
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I. The QC-sample of I 000 nglml was used for dilution. In each run the QC-samples were processed 5 
times. 
The recovery of! was detenllined at concentrations of 1 00 and 200 ng/ml in urine. The procedure 
is the same as the procedure described for plasma. 
Calibration curves were constmcted by linear regression analysis of peak heights versus 
concentration. The same acceptance criteria were applied as described for plasma samples. 
Stability ofI and II in plasma and urine 
The stability of I and n was tested in plasma-extracts and in urine at different temperatures. In 
plasma the stability of both compounds was tested by incubating plasma-extracts with only I or only 
II for 24 h at room temperature (22°C), 4°C and -20°C. The stability at ·80°C, the storage temperature 
for patient samples, was tested with methanolic plasma mixtures containing both compounds. 
In urine the stability of I was tested by incubation of urine with I for 24 h at 4°C, 22°C, 37°C and 
in I-fold with ortho-phosphoric-acid (I: 1 00) diluted urine at 22'C. Also the stability of! in urine was 
tested at -80'C. 
Human experiments 
In an oral phase I study the starting dose was 0.15 mg/m2. On day 1 and day 8 blood samples were 
collected up to 12 h. One of the first patients was treated with a dose of 0.4 mg. Immediately after 
sampling, the blood was centrifuged for 5 min at 3500g and the plasma was treated as outlined. 
In another study where I is administered intravenously at a low daily dose of 0.5 mglm2 also urine 
samples were collected. 
RESULTS 
Assay in plasma 
The calibration curves of I and II in plasma were linear in the range of 0.10 to 5.00 nglml with 
correlation coefficients of at least 0.9986. The retention time of II is 2.5 min and ofI 6.5 min (figure 
2). No significant interfering peaks were found in 6 independent blank plasma samples. The LLQ for 
both compounds in plasma was 0.10 nglml. The mean recovery in plasma of I was 99.3% and of II 
100.6%. The within-run precision of the LLQ-samples ofI was 4.4% and of II 9.7%. The accuracy 
was 93.2% and 106.6% respectively. The between-run precision of the LLQ was calculated with the 
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Fig. 2: Chromatograms ofa blank blood sample (A) and ofa blood sample containing 0.78 ng/ml 
of I and 0.24 ng/ml ofII (B). 
Table 3: The average (av.) accuracy, the average within~run precision and the bet\Veen~run 
precision of the QC~samples in plasma of I and II 
QC-sample 
(ng/ml) 
0.50 
2.00 
4.00 
20.00 
avo accuracy (%) 
II 
102.7 IOU 
108.4 106.5 
102.8 102.6 
103.3 102.3 
precision (%) 
avo within-run between-nm 
II I II 
2.8 1.5 6.9 6.3 
3.8 1.3 8.6 5.2 
3.1 l.0 5.0 5.5 
3.9 3.7 3.0 3.5 
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lowest concentration of the individual calibration curves used by the validation of the assay. The 
between-nm precisions were respectively 7. I% and 5.5%. The values of the average accuracy, the 
average within-run precision and the between-run precision of the QC-samples are given in table 3. 
Assay in urine 
The calibration curves of I in urine were linear in the range of 10 to 250 nglml with correlation 
coefficients Drat least 0.9984. Also for the assay in urine no significant interfering peaks for I were 
found. The LLQ was established at 10 nglml (concentrations in the clinical studies were not expected 
to be lower than 10 nglml). The mean recovery of I in urine was 101.9%. The within-run precision of 
the LLQ-samples was 7.2%. The between-run precision of the LLQ was S.4%. The accuracy of the 
LLQ was 97.6%. The values of the average accuracy, the average within-run precision and the 
between-run precision of the QC-samples are given in table 4. 
Table 4: The average (av.) accuracy, the average within-nm precision and the between-nm 
precision qfthe QC-samples in urine of1 
QC-sample avo accuracy (%) precision (%) 
(ng/ml) avo within-run between-run 
25 99.7 4.4 3.3 
100 97.5 4.1 0.6 
200 97.8 5.3 1.8 
1000 98.9 3.2 2.0 
Stability ofI and II in plasma and I in urine 
The reversible hydrolysis of I in plasma-extracts is dependent of the temperature. I and II were 
found to be unstable at 4'C and 22'C. There was no hydrolyses at -20'C (figure 3). I and II were 
stable in methanolic plasma mixtures for at least 4 months at -SO°c. 
The stability of I in urine was also dependent of the temperature. At 37°C I was found to be 
unstable, at 22°C it was moderately stable and at 4°C I was stable for 24 h. I was stable at 22°C 
after dilution with ortho-phosphoric acid (figure 4). At -SO°C I was stable for more than 3 
months. 
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Fig. 3: Stability of I and II in plasma extracts at different temperatures. 
Human experiment 
The plasma concentration-time curves of I and II of the patient treated with 0.4 mg I are given in 
figure 5. 
The concentration of I in the urine samples of patients who where treated in the intravenous 
protocol were all > 10 nglml (data not shown). 
DISCUSSION 
The described methodology for the assay in plasma with an LLQ of 0.10 nglml for I and II is 
appropriate for the measurement of plasma samples in ongoing clinical studies where low daily doses 
are administered. For the assay in urine the LLQ of 10 nglml was also satisfactory. Both compounds 
were unstable in plasma-extracts at 4°C and 22°C. In urine, I was found to be unstable at 37°C and 
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moderately stable at 22°C. Metnanolic plasma mixtures and urine stored at -80DC were found to be 
stable for respectively at least 4 and 3 months. 
In urine only I was measured after acidification to ensure total conversion ofII into 1 
100 ---."",,!~. • 
------. 
• 
80 ~. ~ .. ~ 1:1 in Hl04 
~.~ 37"C 
~ 60 0 ~,.~ 22"C 
40 ~.~ 4°C 
20 
o 
o 5 10 15 20 25 
Time (h) 
Fig. 4: Stability of I in urine at different temperatures and when diluted I-fold with lliP04. 
CONCLUSION 
A sensitive, selective, accurate and reproducible isocratic reversed phase HPLC method has been 
developed for the simultaneous analysis of I and II in plasma and the analysis of I in urine. Plasma 
sample pretreatment was carried out immediately after sample collection by deproteinizing with cold 
methanol as previously described [II}. Prior to injection the sample was diluted with PBS. The urine 
samples were analyzed after acidification with ortho-phosphoric acid and dilution with PBS. The 
methodology described for the measurement of plasma concentrations of both compounds and urine 
concentrations of I can be used to determine the phammcokinetics in clinical studies with I 
administered at low doses. 
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ABSTRACT 
The objective of this study was to determine the influence of pJeural and ascitic fluid on the 
pharmacokinetics of the antitumor camptothecin derivative topotecan. Four patients with 
histologic proof of malignant solid tumor received topotecan 0.45 or 1.5 mg/m2 orally on several 
occasions both in the presence and absence of third space volumes. Serial plasma and pleural or 
ascitic fluid samples were collected during each dosing and analyzed by high-performance 
liquid chromatography for both the intact lactone form of topotecan and its ring-opened 
carboxylate form. The apparent topotecan clearance (eL/i) demonstrated substantial interpatient 
variability, but remained unchanged within the same patient in the presence [lIO±5S.6 L/h/m2 
(mean±SD of 8 courses)] or absence of pleural and ascitic fluid [I !8±31.1 Llhim' (7 courses)]. 
Similarly, terminal half~lives and AUe ratios of lactone to total drug in plasma were similar 
between courses within each patient. Topotecan penetration into pleural and ascitic fluid 
demonstrated a mean lag time of 1.6! h (range, 1.37 to 1.86 h) and ratios with plasma 
concentration increased with time after dosing in all patients. The mean ratio of third space 
topotecan total drug AUC to that in plasma was 0.55 (range, 0.26 to 0.87). These data indicate 
that topotecan can be safely administered to patients with pleural effusions or ascites, and that 
there is substantial penetration oftopotecan into these third spaces that may proof beneficial for 
local antitumor effects. 
INTRODUCTION 
The increased risk of toxicity following chemotherapy in patients with pleural effusions and 
massive ascites is wid~ly known, and has been well documented for several compounds 
including methotrexate [1,2] and fludarabine [3]. This phenomenon is most likely related to 
greater drug accumulation in the peripheral compartment and a slower transport back to the 
central compartment, ultimately resulting in prolonged drug exposure. For this rcason, it is 
advised to evacuate large pleural and ascitic effusions prior to administration of these agents. On 
the other hand, penetration of the delivered chemotherapeutic agent should be sufficient to 
produce adequate drug distribution into the pleural or ascitic fluid to induce relevant local 
antitumor effects [4]. 
Diffusion of orally or systemically administered drugs into the peritoneum may be 
diminished by fibrous tissue due to prior surgery or prior regional i.p. chemotherapy, as reported 
for mitomycin C [4]. In addition, several other factors including molecular weight, 
hydrophobicity, blood and lymph flow and capacity of the capillary wall and intervening 
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interstitium have been shown to affect the peritoneal~blood barrier [5]. The same factors may 
also be applicable for pleural effusions and the pleural fluid-blood barrier, although only few 
paired plasma/pleural fluid pharmacokinetic data are available for antineoplastic agents [5~ 7]. 
In the absence of any pharmacokinetic data on third space sequestration for topotecan, a 
topoisomerase I inhibitor with substantial antitumor activity against various malignancies 
[reviewed in Ref. 8], we have prospectively evaluated the extent of penetration of this drug in 
pleural and ascitic fluid in cancer patients, and assessed the influence of these third spaces on 
topotecan plasma pharmacokinetics. 
MATERIALS AND METHODS 
Patients and treatment 
A total of 4 patients with a histologically confirmed diagnosis of a malignant solid tumor that 
was refractory to standard forms of therapy was studied (Table 1). All patients had adequate 
hematopoietic, hepatic and renal functions [9]. The study drug topotecan was supplied as 
capsules containing either 0.25 or 1.0 mg of the active compound (SmithKline Beecham 
Pharmaceuticals Inc., Harlow, UK), and was administered orally once daily, after an overnight 
fast, either for 5 consecutive days and repeated every 3 weeks (3 patients) or for 2 consecutive 
days and repeated every week (1 patient). In all 4 patients, comedication was uniform and 
consisted of cisplatin (50 or 70 mg/m2 administered as a 3~h i.v. infusion immediately before 
topotecan on day 1 of every course) and onclansetron (8 mg, i.v.) combined with dexamethasone 
(10 mg, i.v.) given 30 min before cisplatin. During therapy, the patients did not use any other 
medication that might have interfered with topotecan absorption and disposition. The clinical 
protocol was approved by the institutional review board, and patients signed informed consent 
before entering the study. 
Sample collection 
Material for pharmacokinetic analysis was collected during the first treatment course on days 
1, 2 and 5 from patients on the 5~day schedule, and during courses 1, 2 and 3 on days I and 2 
from the patient on the 2~day schedule. Blood samples were collected in 4.5-mL glass tubes 
containing lithium heparin as anticoagulant (Becton Dickinson, MeyIan, France) and were 
obtained at the following time points: prior to dosing, and 0.5,1,1.5,2,3,4,6,8 and 12 h after 
topotecan administration. The blood samples were immediately placed in an ice~bath and 
centrifuged within 10 min at 3000xg for 5 min at 4°C, to separate the plasma. Subsequently, a 
volume of 250-~L of the plasma sample was added to 750-~1 of ice-cold (-20°C) methanol in 
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2.0 mL polypropylene vials (Eppendorf, Hamburg, Germany). After vortex-mixing for 10 s, the 
samples were stored at ~80°C until the day of analysis. Pleural and ascitic samples were obtained 
at the same time points as described for blood samples using a Medicut 16GA cannula 
(45x1.7mm internal diameter; Sherwood Medical, Tuliamore, Ireland) and were collected in 
4.5-mL polypropylene tubes, afier discarding the first 10-mL of fluid. These samples were 
processed as described above for plasma. 
Table 1: Patient characteristics 
Characteristic Patient I Patient 2 Patient 3 Patient 4 
Age (yrs) 41 65 40 35 
Gender (M/F) M M M F 
Carcinoma ACUP' rectum ACUP ovarian 
Third space pleural pleural ascites ascites 
Treatment schedule dl-5 q3wb dl-5 q3w dl-5 q3w dl-2qlw' 
Drug dose (mg/m'/d) 1.50 1.50 1.50 0.45 
Drug dose (mg/d) 3.00 2.75 3.25 0.75 (dl) 
1.00 (d2/ 
a: ACUP, adenocarcinoma of unknown primary origin; b: dl-S q3w, once daily for 5 consecutive days, repealed c\'cr), 3 weeks; c: 
dl-2 q Iw, once daily for 2 consecutive days, repeated e\"ef)' week; d: As a result of body-surface area-based uosing, and givcn the 
availability ofO.25-mg and I.D-mg topotecan capsules only, the calculated weekly dose was split into uncqual daily doses. 
Topotecan assay 
The samples, plasma as well as pleural liquid and ascites, were analyzed using a reversed-
phase HPLC assay with fluorescence detection, as described earlier [101, with minor 
modifications. In brief, samples were centrifuged for 5 min at 23,000 x g at 4°C, foHowed by a 
5-fold dilution in phosphate-buffered saline prior to injection of 200-~L aliquots into the HPLC 
system. Chromatographic separations of topotecan carboxylate and lactone forms and 
endogenous compounds were achieved on a Hypcrsil BDS column (lOOx3 mm lD, 3,1m particle 
size; Shandon, Cheshire, UK), which was maintained at 35°C. The mobile phase, composed of 
10 mM potassium dihydrogenphosphate-methanol-triethylamine (1750:500:4, v/v/v) with the 
pH adjusted to 6.0 (orthophosphoric acid), was delivered at a flow rate of 0.70 mL/min. The 
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excitation and emission wavelengths of the Jasco FP920 fluorescence detector (Tokyo, Japan) 
were set at 381 and 525 nm, respectively, with an emission band width of 40 nm. 
Chromatographic data analysis was performed based on peak height measurements relative to 
injected standards using the ChromCard system ofFisons (Milan, Italy). 
Pharmacokinetic analysis 
Individual plasma concentrations of topotecan lactone and carboxylate forms were fit to a 
linear two-exponential equation, using the software package Siphar version 4 (SL.\tIED, Creteii, 
France), based on a variety of considerations including Akaike's and Schwarz' information 
criterion. The concentration-time profiles were obtained after zero-order input, with a weighted 
least-squares algorithm applying a weighting factor of l/y. The area under the concentration-
time curve (AUe) were determined for both the lactone (AUCL) and carboxylate forms (AUCc) 
on the basis of the best fitted curves. The apparent plasma clearance of topotecan lactone (CL/£) 
was calculated by dividing the dose administered by the observed Aue. The apparent terminal 
disposition half-life (TI/2) was calculated as In2Ik-el, where kel is the observed elimination rate 
constant of the terminal phase. The peak plasma concentrations (Cmax) were determined 
graphically from the observed experimental values. The ratio of the systemic exposure of 
topotecan lactone to total drug (LIT ratio) was defined as AUCLI (AUCL + AUCc). The fraction 
of drug penetrating into pleural or ascitic fluid was derived from the ratio of the topotecan total 
drug AUCs in the third space and plasma. 
RESULTS 
Plasma phal'macokinetics 
Peak plasma concentrations and AUCs of topotecan lactone following an oral dose of 1.50 
mg/m2 to patients I and 2 were similar before and after pleural fluid was drained (fluid volumes, 
3. I and 1.I L, respectively) (Table 2). Data from patient 3, who had recurrent ascites during all 
topotecan administrations with volumes of 8.4 and 9.4 L drained on days 2 and 6, respectively, 
indicated no difference in pharmacokinetic parameters between treatment days. Similarly, 
ascites (estimated to be 4.0, 1.0 and 1.0 L on 3 occasions by ultrasonography and percutaneous 
drainage) had no measurable effect on topotecan plasma pharmacokinetics in patient 4 (Table 2). 
Overall, the apparent topotecan clearance (CL/£) demonstrated substantial interpatient 
variability, but remained unchanged within the same patient in the presence [11O±55.6 L/h/m2 
(mean±SD; 8 courses)] or absence of pleural or ascitic fluid [I18±3J.J Llhllll' (7 courses)]. 
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Topotecan LIT ratios in plasma were very similar between courses within each patient and 
averaged 40.0±3.89% (drained) and 40.0±6.II% (not drained), respectively. 
Table 2: Summary of topotecan plasma pharmacokinetics in the presence or absence of pleura 
Of ascitic fluid 
Pat Third No. of AVCL CUf Cmax Tlf2 Uf ratio 
no. space curves (ng.h/mL) (L/h/m') (ng/mL) (h) (%) 
pleural 12.9 136 2.06 1.83 44.7 
none 2 14.7,18.3 119,95.5 3.33,6.50 2.17, 1.77 44.8,43.5 
2 pleural 23.3 64.3 2.71 4.53 36.3 
none 2 18.7,17.0 80.0,88.1 2.04,2.30 4.43,5.90 34.6,35.8 
3 ascites 3 22.1±1.92 68.2±5.82 2.43±0.32 4.38±0.36 40.3±2.4 
4 ascites 3 5.80±1.82 I 55±61.2 1.51±0.65 3.00±0.58 39.2±S.3 
none 3 6.28±1.42 148±12.1 1.16±0.15 3.40±0.66 40.5±8.4 
Data were obtained both in the presence and absence of third space fluids in each individual patient treated with lopotccan doses 
and treatment schedules as given in Table 1. The AUe values were c.a!culalcd by compartmental analysis, and data orpatienls 3 
and 4 represent mean values ± SD. Abbreviations: AUCL, area under the topolccan laclone plasma concentration-lime curve; 
ClJf, apparent plasma clearance of topotccan lactone; CIOU, pe.ak plasma concentration of topotccan lactone; TIl?, apparent 
terminal disposition halt:life; LiT ratio, percent of total drug (lactone plus carbo;., .. ylate forms) circulating as lopotecan lactone. 
Pleural and ascitic "uid penetration 
Given the low plasma protein binding oftopotecan [-35%; (II)] and the relatively high total 
protein content in pleural fluid and ascites of the patients (range, 38 to 45 mglmL), no correction 
for protein binding was performed. Topotecan concentrations in pleural fluid and ascites peaked 
at;,6 h after oral dosing, demonstrated a mean lag time of 1.61 h (range, 1.37 to 1.86 h; overall 
mean±SD in plasma, 0.63±0.28 h), and rose slowly to equal that in plasma by -8 h (Figs. I A to 
IC). Topotecan disappearance from pleural fluid [Tw, 11.9 h (II~I)] and ascites [Till, 7.94 h 
(11= 1)] was slower than that frolll plasma. As a result, third space penetration, expressed as the 
ratio of concomitant pleural fluid or ascites and plasma concentration of total topotecan 
depended greatly on the sampling time point, and increased significantly with time in all 
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patients (Figs. ID to IF). Overall, the mean ratio of third space topotecan total drug AVC to that 
in plasma was 0.55 (range, 0.26 to 0.87). The hydrolysis of topotecan to the ring·opened form 
was rapid and LIT AVe ratios were l8.1% and 23.5% in pleural fluid and 29.2% in ascites. 
Measurement of topotecan in ascites from patient 3 indicated that less than I % of the 
administered dose was present in ascites at 6 to 8 h after dosing, indicating lack of a sink effect. 
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Fig. 1: Concentration versus time plots of topotecan expressed as total drug (lactone plus 
carboxylate) in plasma (open circles) and ascites (closed circles, patients 1 and 2) or 
pleural fluid (closed circles, patient 4) and corresponding topotecan third-space 
fluid:plasma concentration ratios in patients I (A and D), 2 (B and E), and 4 (C and F). 
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Toxicity 
Overall, treatment was very well tolerated in the 4 patients. No severe hematological toxicity 
or other organ toxicity was observed following oral topateean administration at these doses. The 
third patient experienced fatigue graded 2 on a 4-point scale (NCI-Common Toxicity Criteria), 
whereas the fourth patient had mild nausea and vomiting. 
DISCUSSION 
This study was performed to explore the influence of pleural and ascitic fluid on the 
pharmacokinetic behavior of topateean in cancer patients. Although the topateean 
administration was preceded by ~isplatin infusion in this study in all patients, important 
pharmacokinetic interactions that may have influenced the generated data are not very likely; (i) 
comparison of the kinetics of topotecan in clinical combination therapy regimens with cispiatin 
to single agent therapy did not reveal an apparent interaction [12J, and (ii) using a randomized 
cross-over design for the administration order, no statistically significant differences in clinical 
pharmacokinetics were observed between sequences of oral topotecan and i. v. cisplatin [9J. 
Topotecan concentrations in pleural fluid and ascites were initially less than in plasma, and 
several hours were required for equilibrium to be attained between these fluids and plasma. The 
limited surface area for topotecan diffusion relative to the volumes of fluid, and the fact that 
pleural fluid and ascites ~re not well stirred, in addition to the hydrophilic nature of the drug 
likely contributed to the slow equilibrium kinetics. Overall, both pleural fluid and ascites 
represented only a small additional compartment for topotecan distribution, particularly in view 
of the already large topotecan steady-state volume of distribution of73-133 L [13]. Nonetheless, 
concentrations equivalent to that in plasma were achieved after 8 hours, and topotecan 
elimination was found to be more slowly from the pleural and peritoneal cavity than from 
plasma. This is in keeping with earlier findings indicating slow peritoneal clearance of to po tee an 
and high peritoneal:piasma concentration ratios of>lO following i.p. drug administration [14, 
15J 
Topotecan has been detected previously in ascites of2 patients treated with a combination of 
i.v. topotecan and oral etoposide [16]. However, the reported ascitic fluid:plasma concentration 
ratios were established by single point measurements at different times after administration. 
Since these concentration ratios were shown in our patients to be by no means constant 
parameters during the dosing interval (Figs. ID to IF), single-point data are clearly ) 
inappropriate to directly compare the extent of penetration by topotecan. Hence, the approach of 
using paired AVe values in third space fluids and plasma, as done in the current study. should 
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be considered the gold standard to report these ratios. Although the described data on topotecan 
accumulation is limited to only 4 patients, our results suggest that oral administration of 
topotecan can produce adequate drug distribution in pleural fluid and ascites at concentrations 
associated with significant antitumor activity in experimental models [7,181. In this context, it is 
of particular interest that topoisomerase I inhibitors were previously shown to be highly S-phase 
specific and that cytotoxicity is a function of the time to drug exposure above a certain threshold 
concentration [19]. The topotecan penetration and subsequent accumulation in the third spaces 
might thus offer a potential therapeutic advantage in that tumor cells in the thoracic and 
peritoneal cavity are exposed to high local drug levels for prolonged time periods. This concept 
has also been described recently for systemic therapy with the structurally-related camptothecin 
derivative, irinotecan (CPT-II), although in contrast to topotecan, concentrations appeared to 
decline in parallel with those in plasma [20]. The reason for this discrepant behavior is 
unknown, but it likely reflects intrinsic differences in physicochemical and/or pharmacokinetic 
properties of both compounds, including differential binding to (plasma) proteins. 
The plasma pharmacokinetics of topotecan revealed a substantial degree of interindividual 
variability, in line with previous observations [9, 21l By comparing topotecan plasma levels in 
the same patient before and after drainage of pleural or ascitic fluid, no differences in rate of 
absorption and elimination became apparent. The lack of increased systemic exposure to 
topotecan in patients with massive third space volumes was further substantiated by the lack of 
excess toxicity. Hence, in contrast to clinical information on irinotecan treatment that suggested 
an increased risk of severe toxicity in patients with large pleural effusions or ascites [20]. there 
was no evidence that the severity of toxicity was different between study courses with and 
without third space volumes in our patients treated with topotecan. 
In conclusion, we have shown that (i) topotecan plasma pharmacokinetics are unaltered in 
patients with third space volumes, (ii) it can be safely administered to patients with large pleural 
effusions or massive ascites, and (iii) there appears to be substantial penetration of topotecan 
into these third spaces that may proof beneficial for local antitumor effects. 
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ABSTRACf 
Background and Pwpose In ;11 vitro studies synergism and sequence dependent effects were 
reported for the combination of topotecan and cisplatin. Recently an oral formulation of topotecan 
became available. This phase I shldy was peJfonned to assess the feasibility of the combination of 
oral topotecan and cisplatin, the phannacokinetic interaction, and sequence dependent effects. 
Panenls and Methods Topotecan was administered orally daily for five days in escalating doses 
and cisplatin at a fixed dose of75 mg/m2 i.v. either before topotecan on day 1 (CT) or after topotecan 
on day 5 (Te) once every 3 weeks. Patients were treated in a randomized cross-over design. 
Results Forty-nine patients entered the study; one patient was not eligible. The CT sequence 
induced significantly more severe myelosuppression than sequence Te, and resulted in MID at a 
topotec.n dose of 1.2S mWm'/dxS. In sequence TC, the MTD was topotecan 2.0 mWm'/dxS. DLT 
consisted of myel os liP pression and diarrhea. Pharmacokinetics oftopotecan and cisplatin were linear 
over the dose range studied, no sequence dependent effects were observed. In addition, topotecan did 
not influence the protein binding of cisplatin and the platinum-DNA adduct formation in peripheral 
leukocytes in either sequence. 
Conchlsion The reconunended dose for phase n studies in patients, comparable with the patients 
studied, is oral topotecan 1.25 mglm2/day x 5 preceded by cisplatin 75 mg/m2 day I once every 3 
weeks, and topotecan 2.0 mg/m2/day followed by the same dose cisplatin on day 5. No 
phamlacokinetic interaction could be discemed. The antitumor efficacy of both schedules should be 
evaluated in a randomized phase n shldy. 
INTRODUCfION 
Topotecan (9-dimethylaminomethyl-1O-hydroxycamptothecin, Hycamtin~ is a water-soluble 
topoisomerase I inhibitor (camptothecin). DNA topoisomemse I is a nuclear enzyme, involved in 
cellular replication and transcription. Topotecan exists in two fonns in a pH dependent dynamic 
balance between the closed lactone ring (active) form and the carboxy acid (inactive) form. By 
fomling a covalent adduct between topoisomerase I and DNA, named the cleavable complex, 
topoisomerase I inhibitors interfere with the process of DNA breakage and resealing during DNA 
synthesis. The stabilized cleavable complex blocks the progress of the replication fork resulting in 
irreversible DNA double-strand breaks leading to cell death [1-3]. Based on their mechanism of 
action, synergy was suspected for the combination of to poi some rase I inhibitors and DNA damaging 
agents such as cisplatin. Preclinical studies confirmed this hypothesis. However, the observed 
interaction seemed to depend on the cell line studied and the schedule of administration of to po tee an 
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and cisplatin used [4-17]. When topotccan was preceded by cisplatin, synergy was increased 
compared to concomitant incubation with both dmgs in the IGROV-l ovarian cancer cell line and the 
MCF7 cell line [5,6J. Also in the clinical setting dmg sequencing seems to be important [17]. 
To date, topotecan has demonstrated prominent activity in several malignancies, most notable in 
ovarian [I8-23J, small cell lung carcinomas [24-26J, aud hematological malignancies [27-30J, in 
which cisplatin is also highly active. Recently, an oral formulation of topotecan became available, 
which is a more convenient method of drug administration. The oral fonnulation has a bioavailability 
of 32-44% [31-33J with moderate intrapatient variability. The maximally tolerated dose for oral 
topotecan, administered for five days every 21 days as a gelatin capsule, has been determined as 2.3 
mglm2/day with myelosuppression, in particular neutropenia, as the dose limiting toxicity (DLT) 
[34]. Non-hematological toxicities were generally mild and not dose limiting, including fatigue, 
anorexia, nausea, vomiting and diarrhea. In ovarian- [35] and small cell lung cancer (36] randomized 
studies suggest the oral fomlUlation is equivalent to the intravenous formulation. 
Against this background, we initiated a phase I study in which patients were treated in a 
randomized cross-over design to determine the maximum tolerated dose of oral topotecan given daily 
for 5 days combined with cisplatin 75 mg/m2.i.v. administered either on day 1 or day 5 every 21 days, 
to describe and quantitate the toxicities o~the combination and to determine whether the sequence of 
topotecan and cispiatin administration has any influence on the observed toxicity or the 
phannacokinetic interaction between the dmgs. 
PATIENTS AND METIIODS 
Patient selection 
Patients with a histologically or cytologically confirmed diagnosis of a malignant solid tumor 
resistant to standard forms of therapy were eligible. Other eligibility criteria included the 
following: age between 18-75 years; Eastern Cooperative Oncology Group (ECOG) performance 
status::;; 2; no previous anticancer therapy for at least 4 weeks (6 weeks for nitrosoureas or 
mitomycin C); no previous therapy with topoisomerase I inhibitors; adequate hematopoietic 
function (absolute neutrophil count (ANC) ;, 1.5 x 10'IL and platelet count;, 100 x 10'1L), renal 
function (creatinine clearance;?: 60 mL/min) and hepatic (total serum bilirubin ~ 1.25 x upper 
normal limit and serum aspartate aminotransferase (ASAT) and alanine aminotransferase 
(ALAT) ~ 2.0 x upper normal limits, in case of liver metastasis serum ASAT and ALAT ~ 3.0 x 
upper normal limits) function. Specific exclusion criteria included the existence of gross ascites 
~nd/or any gastrointestinal condition that would alter absorption or motility. All patients gave 
written informed consent before study entry. 
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Dosage and dose escalation 
Escalating doses of oral topotecan were combined with a fixed dose of cispJatin, 75 mg/m2, 
administered intravenollsly over 3 hours once every 3 weeks. The starting dose of topotecan was 0.75 
mg/m2/day for 5 consecutive days, which is 33% of the recommended dose of oral topotecan, when 
administered as a single agent Dose escalation was based on the prior dose level toxicities. At least 
three patients were treated at -each dose leveL If one of three patients experienced dose limiting 
toxicity (DLT), three additional patients were entered at that dose level. The maximum~tolerated dose 
(MTD) was defined as one dose level below the dose that induced DLTs in 3 out of 6 patients during 
the first course in any sequence, which were defined as NCI·eTC grade 4 neutropenia lasting for five 
days or more, or complicated with fever requiring hospitalization, grade 4 thrombocytopenia and/or 
non-hematological toxicity ;:::.. grade 3 (grade 2 for renal toxicity), excluding nausea. Intrapatient dose 
escalation was not pennitted. Ifa patient encountered DLT, the dose oftopotecan was decreased one 
dose level at re-treatment. The treatment was resumed when the neutrophil count had recovered to ;:::.. 
1.0 x lO'/L and the platelet count to;, 100 x lO'/L. A maximnm of six cycles was administered to 
each individual patient. 
DllIg administration and sequencing 
In the first part of the study, patients were randomly assigned at study entry to one of two 
treatment groups. Six patients were treated at each dose level. 
Group A. In the first treatment course, patients received cis plat in as a 3-hour infusion diluted 
in 250 mL of hypertonic saline [3% (w/v) sodium chloride] on day I, immediately followed by 
the oral administration of topotecan (sequence CT), which was given for five consecutive days 
on an empty stomach, at least 10 minutes before meals. In the second course, the sequence of 
administration of topotecan and cisplatin was reversed, starting with topotecan for 5 days and 
administering cispiatin on day 5, 3-hours after the last oral administration of topotecan at the 
same doses (sequence TC). 
Group B. Patients received the two treatment courses in reversed order. 
The third and following courses were administered using the least toxic sequence, with in the 
third course a 24 hour interval between the administration of cisplatin and topotecan to study the 
pharmacokinetics of both drugs to rule out the possibility of any pharmacokinetic interaction. 
In the second part of the study, after determination of the MTD in the most toxic sequence, 
further dose escalation of topotecan was pursued in the reversed sequence. Patients were then 
enrolled to receive that single sequence with a 24-hour interval between the administration of 
topotecan and cisplatin in the second course only. 
In all patients pre-medication consisted of ondansetron (8 mg Lv.) combined with 
dexamethasone (10 mg i.v.) administered 30 min before the start of the cisplatin infusion. To 
prevent cisplatin-induced renal damage, the administration of cisplatin was preceded by the 
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infusion 00000 mL of a mixture of 5% (w/v) dextrose and 0.9% (w/v) sodium chloride over 4 
hours, and followed by another 3000 mL with the addition of 20 mM potassium chloride and 2 
gIL magnesium sulphate applied over 16 hours. Topotecan capsules containing either 0.25 or 
1.00 mg of the active compound were supplied by SmithKline Beecham Pharmaceuticals 
(Harlow, UK). Cisplatin (Platosin "') was purchased as a powder from Pharmachemie (Haarlem, 
The Netherlands). 
Treatment assessment 
Before therapy a complete medical history was taken and a physical examination was 
performed. A complete blood count (CBe) including WBC and differential, and serum 
biochemistry, which included sodium, potassium, calcium, phosphorus, urea, creatinine, total 
protein, albumin, total bilirubin, alkaline phosphatase, aspartate aminotransferase (ASAT), 
alanine transferase (ALAT), y-glutamyl transferase, glucose and uric acid, were performed, as 
was creatinine clearance. \Veekly evaluations included history, physical examination, toxicity 
assessment according to the eTC criteria, and serum chemistry. eBe was determined twice 
weekly. Tumor evaluation was performed after three courses in the first part and after every two 
courses in the second part of the study according to the World Health Organisation (WHO) 
criteria for response. Duration of response was calculated from the start of treatment. Patients 
were treated for at least three cycles of therapy in the first part and two cycles in the second part 
of the study unless disease progression or unacceptable toxicity was encountered. 
Sample collection fol' pharmacokinetics 
Blood samples for pharruacokinetic analysis were obtained during the first 3 treatment courses 
until the MTD was reached in the most toxic sequence. Hereafter samples were only taken in the first 
2 courses. Blood sampling for topotecan pharmacokinetics was perforrned on the first and fifth day of 
dmg dosing, whereas for cisplatin pharmacokinetics sampling was performed on the day of 
administration (days 1, 5 or 6, dependent on the schedule). At the doses recommended for further 
study, additional topotecan pharmacokinetics were perfonned on day 2 of the first treatment course. 
Blood was withdrawn from a vein in the aml opposite to that used for dmg infusion, and collected in 
4.5-mL glass tubes containing lithium heparin as anticoagulant For analysis of topotecan kinetics, 
samples were obtained at the following time points: prior to dosing, and 0.5, 1, 1.5,2,3,4,6, 8 and 
12 hours after administration oftopotecan. Immediately after sampling, tubes were briefly immersed 
into an ice bath kept at the bedside, and plasma was separated within 10 min by centrifugation at 
3000 x g for 5 min (4'e). Next, 250-J.tL aliquots of the plasma supernatant were added to 2.0-mL 
polypropylene vials (Eppendorf, Hamburg, Gernmny) containing 750-J.tL of ice cold (-20°e) 
methanol. After mixing on a vortex-mixer for 10 s, samples were stored at ~80oe until the day of 
analysis. 
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Blood samples for measurement of cisplatin concentrations were obtained inunediately before 
infusion; at 1, 2, and 3 hours after start of Ole infusion; and 0.5, 1,2,3, and 18 hours after the end of 
the infusion. Sample volumes were 4.5 mL each except at predose and 1 and 18 hours after infusion, 
which were 21 (3x 7) mL each. Immediately after sampling plasma was separated by centrifugation at 
3000 x g for 10 min. Next, 500-f1L aliquots of the plasma supernatant were added to 1.0-mL of ice 
cold (-20°C) ethanol. After mixing on a vortex-mixer for 105, samples were stored at -SO°C until the 
day of analysis. Blood samples to determine the cisplatin DNA-adduct levels were obtained 
immediately before infusion, and I and 18 hours after the end of the infusion. 
Pharmacokinetic assays 
Samples for topotecan kinetics were analyzed by a reversed-phase high-perfommllce liquid 
chromatographic (HPLC) method, as described [37J, that allowed simultaneous detennination of the 
lactone and the hydrolyzed ring-opened carboxylate fanTIs. Prior to drug analysis, samples were 
removed from the freezer and centrifuged for 5 min at 23000 x g (4°C), A volume of 100 f1L was 
transferred to a clean microtube containing 400 f1L phosphate buffer. Of this mixture, a 200-f1L 
volume was used for analysis. The HPLC system consisted of a constaMetric 4100 solvent delivery 
system (LDe Analytical, Riviera Beach, FL), ~ Waters 717Plus autosampler (Bedford, MA), and a 
Jasco FP 920 fluorescence detector (Jasco). Chromatographic separations were achieved at 35°C on a 
Shandon Hypersil BDS colunm (100x3 mm, internal diameter; 3 fVu particle size) from Applied 
Science (Breda, The Netherlands), with a mobile phase composed of 10 mM aqueous potassium 
dihydrogen phosphate containing 22% (v/v) methanol and 0.2% triethylamine, with the pH adjusted 
to 6.0 (orthophosphoric acid). The mobile phase was filtered [0.45-flln Millipore HA filters (Milford, 
MA)] and degassed by ultrasonication. The flow rate was set at 0.7 mL/min, and the column effluent 
was monitored at excitation and emission wavelengths of 381 and 525 nm, respectively with the 
emission band width set at 40 run. Peak detection was performed with the Fisons ChromCard data 
analysis system (Milan, Italy). Drug concentrations in unknown samples were determined by 
interpolation on linear c.alibration CUlVes, constmcted in blank human plasma, by least-squares linear 
regression of peak heights versus lIx. The mean percentage deviation from nominal values (accuracy) 
and precision (within-run and between-mn variability) were always <15%. The lower limit of 
quantitation for both the lactone and carboxylate fonns were 100 pg/mL. 
Non-protein bound and total cisplatin concentrations in plasma were determined by a validated 
analytical procedure based on measurement of platinum atoms by flameless atomic-absorption 
spectrometl)' (AAS) as described [38,39]. For measurement of unbound cisplatin, 500-f1L aliquots of 
plasma were extracted with neat 1000 f1L ice-cold ethanol in a 2-mL polypropylene vial. After a 2-
hour incubation at -20°C, the supernatant was collected by centrifugation at 23,000xg for 5 min 
(40 C), and transferred to a clean vial. A volume of 600 ~ was evaporated to dryness under nitrogen 
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at 60'C, and the residue reconstituted in 200 or 600 ~ water containing 0.2% (v/v) Triton X-IOO 
and 0.06% (w/v) cesium chloride by vigorous mixing. A volume of 20 ~ was eventually injected 
into the AAS. For determination of total cisplatin, a I OO-~ volume of plasma was added to 900 ~ 
water containing 0.2% (v/v) Triton X-IOO and 0.06% (w/v) cesium chloride, followed by vortex-
mixing for 10 s. Of this solution, a volume of 20 J.1L was injected into the AAS. Samples were 
analyzed on a Perkin Elmer Model 4110 ZL spectrometer with Zeeman-background correction using 
peak area signal measurements at a wavelength of265.9 nm and a slid width of 0.7 nm [38,39]. The 
injection temperature was set at 200C. Platinum DNA adduct levels in peripheral leukocytes were 
determined as described [40], with modifications [41]. Following DNA isolation fiom bullY coat 
preparations, samples were digested with DNAse I and zinc chloride and injected into the furnace 
using a 4-times multiple sampling feature of the Perkin Elmer AAS. The cispiatin DNA-adduct levels 
were expressed as picogram platinum per microgranl DNA (pg PtI ~ DNA). 
Pharmacokinetic data analysis 
Individual plasma concentrations of topotecan were fit to a two-compartment model, using the 
software package Siphar v4.0 (SIMED, Creteil, France). The concentration-time profiles were 
obtained after zero-order input, with weighted least-squares analysis applying a weighting factor of 
l/y. The topotecan area under the plasma concentration-time cUlVe (AUC) was detennined for both 
the lactone (AUC(I.) and carboxylate forms (AUC(,) on the basis of the best fitted curves. The 
apparent plasma clearance (CU&L) of topotecan lactone was calculated by dividing the dose 
administered (expressed in fi:ee base equivalents) by the observed AUC. The tenninal disposition 
half-life [Tw(z)] of topotecan was calculated as In2lk, where k is the temlinal elimination rate 
constant (expressed in hoi). The peak plasma concentrations (emax) and the time to peak plasma 
concentration (Tma..x) were detennined graphically from the (obselVed) experimental values. The ratio 
of the systemic exposure of topotecan lactone to total drug (Lff ratio) was defined as 
AUC(l.Y[AUC(L)+AUC(Cl]. 
Kinetic profiles of CDDP were obtained similarly using a two-compartment linear model with 
extended leastMsquares regression analysis as reported earlier [42]. The AUC of cispiatin was 
calculated to the last sampling time point with detectable drug levels (0",) by the linear trapezoid 
method and extended to infinity by addition of O.J!<'mn, where lomn is the slope obtained by log-
linear regression of the final plasma concentration values. 
Statistical considerations 
Phannacokinetic parameters for all compounds are reported as mean values ± S.D. The difference 
in phannacokinetic parameters between sequences was evaluated statistically using a paired Student's 
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Hest. Probability values (two-sided) of less than O.OS were regarded as statistically significant. All 
calculations were perfonned using the statistical packages NCSS version SX (IL. Hintze, Kaysville, 
UT) and STATGRAPHICS Plus version 2.0 (Manugistics Inc., Rockville, MA). 
RESULTS 
Forty-nine patients entered this study between January 1997 and February 1999. Patient 
characteristics are listed in Table 1. One patient was not eligible due to reduced renal function at the 
time of study entry, 1 patient was not assessable for toxicity because of the occurrence of a 
cerebrovascular accident after two days of treatment with topotecan and was taken off study. Forty-
seven patients were assessable for toxicity and 45 patients for response. 
The majority of the patients was either asymptomatic or had only mild symptoms. Nineteen 
patients were female and 28 were male. Seventeen patients had received prior chemotherapy, one line 
only. No patients were pretreated with drugs known to be highly myelosuppressive i.e. carboplatin, 
mitomycin C, nitrosoureas or high dose cyclophosphamide. The most common tumor type was head 
and neck cancer. Dose levels of topotecan studied were 0.7S, 1.0, 1.2S, I.S, 1.7S, 2.0 and 2.3 
mglm2/day, respectively. The total number of assessable courses was 175. The median number of 
courses per patient was 4 (range I ~6). 
Both myelosuppression and diarrhea were the principal DLTs of this regimen. Seven patients 
required dose reductions after experiencing dose~limiting toxicity. Once dose reduction had taken 
place, the courses in these patients were evaluated for toxicity at the lower dose level. 
Hematologic toxicity and dl1lg sequencing 
The severity of the observed hematologic toxicity was clearly dependent on the sequence of 
drug administration. At each dose level studied, both neutropenia and thrombocytopenia were 
more severe when cisplatin administration preceded the administration of topotecan (CT 
sequence) (Table 2 and Figure I) reflected in both a significantly lower nadir and percentage 
decrements in neutrophil and platelet counts in this sequence [P=<O.OOOOl (neutropenia), 
P~<O.OOOOI (thrombocytopenia)]. At the dose level of 1.0 mglm' in the sequence CT, two out 
of six patients experienced neutropenia grade 4 lasting for 5 days or more. By protocol 
definition, these patients were judged as having DLT. At the next dose level combining 
topotecan 1.25 mglm21day with cispiatin 75 mg/m2 in the sequence CT, of the six patients 
treated, one patient experienced neutropenic fever and another patient had neutropenia grade 4 
lasting for more than 5 days in combination with diarrhea grade 3 and vomiting grade 4. Four 
additional patients were treated at this dose level. One of these patients, patient number 10, had 
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DLT because of a neutropenia grade 4 lasting longer than 5 days. Another patient, who formally 
was ineligible due to reduced renal function at study entry, experienced grade 4 neutropenia and 
thrombocytopenia in the second course, and died as a result of the complications of this toxicity. 
Table 1: Patient characteristics 
No. of 
Characteristic Patients 
No. Entered 49 
No. Assessable 47 
Age, years 
Median 57 
Range 28-70 
Sex 
Female 19 
Male 28 
Performance stahlS 
Median 
Range 0-1 
Tumor type 
HeadlNeck II 
(N)SCLC 10 
ACUP 10 
Cervical 3 
Miscellaneous 13 
Previous therapy 
Chemotherapy 9 
Radiation 12 
Chemotherapy and radiation 8 
None 18 
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Table 2: Toxicity (worst per cycle) and drug sequencing 
Topotecan Sequence Nr ptsl Neutropenia Thrombopenia Nausea Vomiting 
2 4 3 4 1 2 3 1 2 3 4 Mglm Iday Cycles 3 
0.75 CT 6/9 0 7 0 0 3 0 0 0 
0.75 TC 7119 0 0 0 0 11 3 0 6 1 0 0 
1.0 CT 7/7 2 3 0 4 2 1 5 0 1 
1.0 TC 7/22 0 0 0 12 5 0 5 13 0 0 
1.25 CT 9117 7 5 4 6 6 1 2 3 0 1 
1.25 TC 9117 0 0 6 5 1 2 5 1 0 
1.5 TC 3113 3 0 0 4 2 0 0 0 0 0 
175 TC 7117 2 3 2 0 4 9 3 9 2 2 2 
2.0 TC 12/36 11 2 2 15 12 3 109 3 2 
2.3 TC 7117 8 3 7 5 3 8 5 0 3 
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a 
a 
4 
7 
4 
2 
4 
8 
2 
Diarrhea 
2 3 4 
a a a 
a a a 
a a a 
0 0 
3 a 
0 0 0 
0 0 0 
0 0 0 
6 2 
o 3 
Fatigue 
1 2 3 
5 2 a 
6 4 a 
0 3 0 
7 2 0 
5 2 a 
7 2 0 
8 a 
3 6 0 
9131 
4 2 
per 
pat. 
116 
017 
217 
217 
4/9 
3/9 
1/3 
317 
7112 
DLT 
per cycle 
I" all 
0/6 119 
0/6 0119 
2/6 217 
0/6 2/22 
3/9 5117 
119 3/17 
0/3 1/13 
2/6 4/17 
4/108/36 
417 417 5/17 
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Pis: patients; DL T: dose limiting toxicit}~ CT: cisplatin 
followed by topotcc.an; TC: cispl.atin preceded by topotec.an. 
Several patients experiencing DLT required dose reductions. 
Once dose reduction had taken place, patients were evaluated 
for toxicity at the lower dose level 
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Since 3 out of 9 (4 out of 10 taking into account the ineligible patient) patients experienced 
DLT no further dose escalation was pursued. The protocol defined MTD as the dose level below 
that level at which 3/6 patients experienced DL T. The dose level combining cisplatin 75 mg/m2 
day 1 with by topotecan 1.25 mg/m2/day day I to 5 is considered the recommended dose for this 
sequence, but only in non- or marginally pretreated patients in good physical condition and 
under strict conditions of control as the patients under study. 
After the detemlination of the recommended dose in the sequence CT, dose escalation of 
topotecan continued in the reversed sequence. At the dose level 1.25 mg/m2 lout of 6 patients 
experienced DLT consisting of neutropenic fever in this sequence. At the dose level 1.5 mg/m2 no 
DLT was observed. One patient had a neutropenia grade 4 lasting for 5 days or more and vomitmg 
grade 3 at dose level 1.75 mg/m2 in the sequence Te. At the dose level combining topotecan 2.0 
mg/m2/day with cisplatin, no DLT occurred in the initial 3 patients. It was decided to escalate the 
dose oftopotecan to the dose recommended for useas a single agent, 2.3 mg/m2/day. Of the first three 
patients, only one patient developed DLT (diarrhea grade 4). However, three of the four additional 
patients treated at this dose level, were considered to have DLT. on the basis of vomiting grade 4 (1 
patient), diarrhea grade 4 (I patient), neutropenia grade 4 lasting for 5 days or more (2 patients) and 
thrombocytopenia grade 4 (I patient). Thus, combining topotecan 2.3 mg!m'/day and cisplatin 75 
mg/m2 was not considered feasible. Seven additional patients were treated at dose JeveI2.0/75 mg/m2. 
Four of these patients developed DLTs~ vomiting grade 4 (2 patients), diarrhea grade 3 or 4 (3 
patients) although manageable with loperamide therapy, neutropenia grade 4 lasting for 5 days or 
more (2 patients), and thrombocytopenia grade 4 (1 patient), resulting in DLT in 4 out of 10 patients. 
Thus, in full accordance to the recommendations for the sequence CT, the recommended dose of 
topotecan is 2.0 mg/m2/day combined with cisplatin 75 mg/m2 for the sequence topotecan followed 
by cisplatin. Since it was felt that these doses are only feasible in non- or minimally pretreated 
patients in good physical condition under strict medical surveillance, it was decided to expand the 
dose level combining topotecan 1.75 mg/m2 to six patients. One of these patients experienced grade 4 
vomiting in the first course. No other DLTs were observed. 
Overall, the hematologic toxicity was relatively mild (Table 2 ). Grade 3 to 4 neutropenia was 
observed in 55 of 175 courses (31 %). It was complicated by neutropenic fever in only 4 patients. 
The onsets of neutropenia and thrombocytopenia were relatively late. The nadir of the 
neutrophils usually occurred around day 19 (range 4-30) after the start of the treatment and 
lasted for median 5 days (range 1-15). Thrombocytopenia was mild, being grade 3-4 in only 8% 
of the cycles. all in conjunction with neutropenia. Despite the limited severity of 
myelosuppression, treatment had to be delayed in 34% of the COl.lrSeS due to prolonged 
myelosuppression. A marked inhibition of erythropoiesis was observed. The percentage of 
patients requiring erythrocyte transfusions was 72%, in 74 of 175 courses. 
64 
Combination of topotecan ami cispiatill 
A 
6.0 P~O.0440 
:if 
0 4.0 
:R P=O.OO.t9 ~ P:O.oo.tS 
a 
~ 2.0 
0.0 
0.75 1.00 1.25 
B 
200 
'" 
P=O.617 
! 150 
2 
'" 100 '""' u
" I 50 
0 
0.75 1.00 1.25 
Topotecan dose (mg/m 2/d) 
Fig. 1: (A) Absolute neutrophil count (ANe) nadirs and (B) topolecan clearance (CLlf(L)) during 
the first and second courses in sequences CT (III) and TC (0). Data are expressed as 
mean (bars) ± SD (error bars). 
Non-hematologic to.A~city 
Gastrointestinal toxicity was mild to moderate (Table 2) and generally comparable to the toxicities 
that result ITom similar single agent doses of topotecan and cisplatin. No sequence dependent effects 
were noted. Nausea grade 2 or 3 was observed in 60 of 175 courses (34%) and vomiting grade 3 or 4 
in 15 of 175 courses (9%). Both were in time related to the administration of cisplatin. Diarrhea grade 
3 or 4 was encountered in 7 cycles (4%) and had a median day of onset on day 8 (range 7-14) and a 
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median duration of 4 days (range 2-10). The diarrhea was self-limiting or resolved after low dose 
loperamide therapy in all but two patients, who were hospitalized for i.v. rehydration. 
Consistent with the profile of cisplatin 75 mg/m2, seventeen patients developed nephrotoxicity 
grade 1, and 4 patients grade 2 after a median of2 cycles (range 1-6). Peripheral neurotoxicity grade 1 
was encountered in 18 patients. Twenty patients had mostly reversible ototoxicity grade 2 (tinnitus) 
and 2 patients ototoxicity grade 3 after receiving median 2 cycles (range 1 -6). One patient at dose 
level 2.3 mg/m2 developed grade 4 bilimbinemia. due to obstmction of a biliary stent. One patient 
with a nasopharyngeal cancer, treated at dose tevel 2.0 mg/m2 developed progressive dyspnoe 
accompanied by fever during the second course. An X-ray of the chest revealed interstitial 
enhancement with a reticulonodular pattem, especially more prominent at the bases. The pulmonary 
function demonstrated reduced lung volumes compatible with restrictive lung disease. Bronchoscopy 
revealed no abnormalities. Despite therapy with antibiotics and low dose corticosteroids, the patient's 
condition worsened and it was decided to perfoml an open lung biopsy. Pathologic examination 
revealed interstitial fibrosis with a marked infiltration with eosinophils, which was considered related 
to topotecan treatment. The patient was treated with high dose corticosteroids resulting in an 
amelioration of the symptoms. 
Other side effects were mucositis (8 % of cycles), alopecia (19 patients grade I, 7 patients grade 
2), and fatigue. 
Anti-tumor activity 
Six patients achieved a partial response. The tumor types included, non-small cell and small cell 
lung cancer, ACUP, renal and pancreatic cancer. The patient with small cell lung cancer was 
pretreated twice with combination chemotherapy consisting of doxombicin, etoposide and 
cyclophosphamide resulting in major responses of 30 and 25 weeks duration, respectively. Her 
response on cisplatin/topotecan chemotherapy lasted 22 weeks. The patient with pancreatic cancer 
was pretreated with 5-fluorouracil in combination with a DPD-inhibitor resulting in a partial response 
for 19 weeks. On therapy with cispiatinftopotecan he achieved a partial response for 26 weeks. The 
patient with renal cancer did not respond to prior therapy with a famesyltransferase inhibitor. His 
response on cisplatin/topotecan lasted 20 weeks. The other 3 patients were not pretreated. The 
duration of their responses was 21 (NSCLC), 30 (ACUP) and 30+ (ACUP) weeks. Twenty-nine 
patients showed disease stabilization with a median duration of20 weeks (range 8-68 weeks). 
Topotecan and cisplatin pharmacokinetics 
The possible effect of drug sequence on the phannacokinetics of topotecan and cisplatin was 
investigated in the first 18 patients, that were randomized in a cross-over design for the administration 
sequence. These patients were all treated at the fixed cisplatin dose of75 mg/m2 and topotecan doses 
of 0.75, 1.0 or 1.25 mg/m2/dx5. Table 3 lists the main pharmacokinetic parameters from a 
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compartmental analysis of the two drugs, with topotecan given at 0.75 mglm2/dx5. The sequence of 
drug administration did not significantly influence the disposition of topotecan lactone, indicating 
mean (±SD) AUC values of 7.52±2.51 and 6.18±1.56 ng.h/mL (F---OJI) using the CT and TC 
sequence, respeclively (Fig. 2). The apparenl clearance (CLI!) of top ole can laclone was clearly dose-
independent in the range of 0.75 to 1.25 mg/m2, similar to single agent data, and not significantly 
different between study courses (107±33.0 (CT) vs 109±53.5 LIhIm' (TC); P~OJ8, paired Student's 
t-tesl) (Fig. I). Similarly, the lactone 10 lotal dmg AUC ratio (Ur ratio) was independent of the 
sequence and averaged 0.36±0.04 (CT) vs OJ3±0.08 (TC). Topotecan pharmacokinelic parameters 
obtained on the fifth administration day were essenttally similar to the data from day 1 (Data not 
shown). In order to nile out a potential effect of the interval time between drug administration, kinetic 
data were obtained from the first 18 patients (3 receiving the CT sequence and another 3 receiving 
the reversed order at each dose level) treated with a topotecan dose of 0.75, 1.0 or 1.25 mg/m'/dxS. 
Data of unpaired analysis in these patients indicated that a change of the interval time to 24 hours had 
no significant influence on any ofthe studied parameters (1'>0.05, Mann-Whitney's U-test; Table 3). 
Table 3: Effect of drug sequence and interval time on the pharmacokinetics of topotecan and 
cisplatin at a topotecan dose of 0.75 mg/m'/dxS and a single fixed cisplalin dose of7S 
, 
mg/m. 
Parameter 3-110111" illieival (II~) 24-hour il1tel1lQ/ (11=6) 
CT(dl) TC (dl) CT (dll2) TC (dI/2) 
Topotecall 
C=,(ng/mL) 2.0S±0.96 1.97±0.SS 3.01±1.85 2.86±1.l0 
AUC(I.) (ng.h/mL) 7.S2±2.S1 6.l8±1.56 9.20±3.4S 9.89±3.09 
CLlf(L) (Lntlm') Ill±34.0 131±38J 96.3±40.8 83.S±2S.2 
ur ratio OJ6±0.04 OJ3±0.08 OJ3±0.03 OJ3±0.02 
Cisplatin 
AUCfu (~g.h/mL) 2.30±1.l7 2.29±0.20 3.24±0.27 3.07±0.51 
CLfu (mLimin) 817±463 747±177 823±52.2 76S±139 
AUCM (~gh/mL) 33J±IO.5 29.6±4.12 46.5±1.26 4SJ±4.08 
~,(pg/~ DNA) 2.91±2J3 1.93±1.28 2.41±0.81 3.20±2.78 
Data are mcan valucs ± S.D. Abbreviations: C",u, peak plasma levcl; AVe, area under the plasma concentration-lime curve; CUf, 
apparent clearance; UT ratio, topotccan lactone to total drug AVe ratio; fu, unbound platinum fraction; tot, total platinum fraction; 
A,.,.u, peak platinum DNA adduct levels in peripherallcukocytcs. 
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The peak plasma levels and the plasma clearance of unbound cisplatin were also independent of the 
drug sequence with a 3-hour or a 24-hour interval time between administration (Table 3). Over the 3 
dose levels studied, the cisplatin clearance was not dependent on the topotecan dose, and averaged 
S17±463 (CT) vs 747±177 mIJmin (TC) (1'=0.19) \Viti. the 3-hour interval time (Fig. 2). Similarly, 
sequence and topotecan dose had no influence on the protein binding of cisplatin (overall mean: 
93.1±2.S%) and on the peak platinum DNA-adduct levels in peripheral blood leukocytes [4.5S±4.12 
(CT) vs 5.72± 4.66 pg PtJ~g DNA (TC) across all 3 dose levels; i'=0.55J. 
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Fig. 2: Plasma concentration-time curves of topotecan lactone (A) and unbound cisplatin (B) 
(closed symbols: sequence CT; open symbols: sequence TC) in 6 patients treated with 
topotecan 0.75mg/m'/day and cisplatin 75 mg/m'. Data represent mean values (symbol) ± 
S.D. (error bars). 
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Table 4: Sunmlary of topotecan phamlacokinetics during the first course as a function of treatment 
cohort. 
Topotecan II Cmax(L) AUC(L) CLlf(L) Ufratio 
(mgim'/dx5) (ngimL) (ng.h/mL) (Uh/m') 
CT sequence 
0.75 6 2.05±0.96 7.52±2.51 111±34.0 036±0.04 
1.00 6 226±0.73 838±1.93 126±28.4 039±0.05 
125 10 4. IO± I. 72 14.5±4.42 99.0±46.0 0.42±0.07 
TC sequence 
0.75 6 1.97±0.55 6.18±1.56 131±383 033±0.08 
1.00 6 3.88±2.43 8.27±4.47 95.8±63.8 035±0.16 
125 6 433±2.43 14.7±5.64 102±483 038±0.05 
1.50 3 6.87±5.74 18.2±6.11 106±29.0 03710.05 
2.00 6 5.92±3.1O 18.4±6.74 131±64.6 038±0.04 
230 7 3.72+1.00 18.4+6.15 145+60.1 0.39+0.07 
Data arc me.an values ± SD. Abbrc\latiOlls: C"""~, peak plasma lcve!; Aue, are.a under the plasma wnccntration·time curve; CUf, apparent 
de-Bronte; ur ratio, topotecan lactone to total drug AUe ratio; II, number of patients studied. 
To further assess the effects of cisplatin administration and dmg sequence on topotecan 
phannacokinetics, all additional patients enrolled in the study had complete sampling performed, 
with the exception of 3 patients treated at the 2.0 mgim'/day topotecan dose and 1 patient (only 
second course missing) at the 2.3 mglm2/day dose. ASlimmary of the topotecan phannacokinetic data 
from the first course is provided in Table 4. In both sequence groups, substantial interpatient 
variability in kinetic parameters was apparent, with more than 2-fold variation in AVe values, 
although mean values were correlated to the administered dose (Speannan's p(rho)~.76; TC 
sequence). There were no significant differences in any of the parameters between the topotecan dose 
levels (1'>0.05, Kruskal-Wallis' test), consistent with a linear and dose-independent behavior of the 
compound. Phannacokinetic parameters between sequences were again not significantly different. 
Parameters between the day of topotecan dosing were not significantly different as indicated by the 
ratio of the topotecan lactone AUC measured on days 1 and 5 (Data not shown), although the mean 
ratios slightly deviated from 1.0 probably as a result of a minor topotecan accumulation during the 
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consecutive treatment days. Pharrnacokinetic data obtained during the second treatment course, again 
with sampling performed on days 1 and 5, were essentially similar to the first course (Not shown). 
The effect of the topotecan dose on the disposition of un bound and total cisplatin in plasma during 
the first treatment course is shown in Table 5. None of the pharmacokinetic parameters between the 
sequences and the various topotecan dose levels was significantly different. 
Table 5: Effect of topotecan dose on the phannacokinetics of cisplatin during the first treatment 
course at a single fixed cispJatin dose of75 mg/m2. 
Topotecan 
(mg/m'/dx 5) 
CT sequence 
0.75 
LOO 
1.25 
TC sequence 
0.75 
LOO 
1.25 
1.50 
175 
2.00 
230 
1/ 
6 
6 
10 
6 
6 
6 
3 
3 
7 
7 
AVO" 
(flIl·h/mL) 
230±L1~ 
2.64±L27 
2.97±L12 
2.71±0.20 
2.87±035 
2.58±0.45 
2.75±0.46 
3.22±0.27 
3.l3±0,s0 
2.58±0.23 
CLfu 
(mUm in) 
817±463 
623±31O 
962±660 
925±177 
833±143 
874±183 
919±174 
722±75 0 
815±87.0 
975±130 
AVC(~ 
(flIl·hlmL) 
333±10.5 
41.5±6.51 
37.9±439 
37.0±4.l2 
35.5±4.45 
4L6±9.79 
32.9±3.54 
47.6±4.28 
371±6.44 
36.l±4.89 
CL~ 
(mUmin) 
88.l±45.l 
58.6±13.5 
563±7.72 
67.5±9.87 
67.3±IL5 
556±14.8 
753±8.06 
48.8±4J6 
69.7±l1.3 
69.8±730 
Data are mean values ± SD. Abbrc\lations: AUC, area under Ihe plasma conccntration·time cum~; CL, deamnoe; fu, unbound platinum 
fraction; tot., total platinum fraction; II, number of patients studied 
At the recommended doses for further clinical studies, viz. 75 mg/m2 cisplatin followed by 1.25 
mg/m'/day topotecan (CT) and 2.0 mg/m'/day topotecan followed by 75 mg/m' cisplatin (TC), 
plasma sampling was also penomled on day 2 to ensure that the topotecan disposition did not alter 
before day 5. Paired analysis showed that all relevant parameters were essentially similar between 
days of drug administration in both sequences (Table 6), although in the (less myelotoxic) TC 
sequence, the topotecan lactone peak plasma level and Aue values were slightly higher on day 2 as 
70 
Combination of topotecall and cisplat;n 
compared to days 1 and s. This is most likely caused by the small number of patients shtdied (n=4 on 
day 2), in combination with large intrapatient and interpatient variability in topotec.an kinetics. 
Table 6: Topotecan and cisplatin pharmacokinetics at the recommended doses during the first 
treatment COurse: (I) 75 mg/m' cisplatin followed by 1.25 mg/m'/dx5 topotecan and (2) 
2.00 mg/m'/dx5 topotecan followed by 75 mg/m' cisplatin. Data are mean values ± S.D. 
(1) CT sequellce (II~I 0) (2) TC sequellce [/l~6 (T) or 7 (C)] 
Parameter day I day 2 day5 day I day 2 day 5 
Topotecan 
Cm~(ng/mL) 4. 1O± 1.72 l31±2.31 3.50±2.25 511±3.50 7.52±3.55 6.16±3.30 
AUC(L) (ngh/mL) 14.5±4A2 138±4.22 14A±4A2 15.9±S.79 246±S.24 22.6±6 10 
Lff ratio OAQ±O.03 OJ9±0.07 OAO±O.08 OJ6±0.02 OJ7±0.04 OA1±0.05 
Cisplalin 
AVCfu (~gh/IIIL) 2.97±1.l2 3.13±O.50 
CLfu (mUmin) 962±660 SI5±S7.0 
AVC .. (~g.h1mL) 37.9±4.39 37.1±6A4 
A,n, (pg/~ DNA) lI2±6.52 2J4±2.67 
Topotocan pharmacokinctic paramctcrs on day 2 were only available from 4 patients. Abbfc\iations: C=", peak plasma le\·e!; AUe. area 
under the plasma concentrntion-time curve; L!f ratio, topotlXan lactonc to total drug AUe ratio; fu, unbound platinum fraction; tot, total 
platinum fraction; CL, clea!ancc; A,>l.~, peak platinum DNA adduct lewis in peripheral1cukoc)1cs 
DISCUSSION 
Both cisplatin and topotecan have broad antitumor activity. Because topoisomerase I inhibitors 
might interfere in the repair of cisplatin induced DNA interstrand cross-links, there has been 
considerable interest in the effects of combining these classes of drugs. Interaction of to poi some rase I 
inhibitors with platin derivatives have been studied in vilro and ill vivo. The combination of 
topotecan and cisplatin was synergistic in teratocarcinoma [10], non-small cell lung cancer 
[5,11,14,17], ovarian cancer [5,9], esophageal cancer [16], breast cancer [5] and melanoma cell lines 
and in a human tumor xenograft of small cell lung cancer [13] and ovarian cancer [9]. In contrast, 
patterns of cross-resistance observed in studies with resistant small cell lung cancer cell lines 
suggested that topoisomerase I inhibitor-cisplatin combinations might be disadvantageous [12]. The 
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cytotoxicity of the combination of to po tee an and cisplatin was also dependent on the schedule used. 
When V79 chinese hamster lung fibroblast were exposed to cisplatin early in the course oftopotecan 
treatment synergy was most prominent [43]. This phenomenon was also confinned in IGROV-l 
ovarian cancer and MCF7 breast cancer cell lines. Incubation of these cells with cisplatin followed by 
topotecan resulted in optimal synergism [5J. However, in other cell lines variations in the scheduling 
of cisplatin and topotecan did not influence the observed interaction [5,I'll The potential importance 
of sequence dependence for the combination of cispiatin and the intravenous fonnulation of 
topotecan in the clinical setting was studied by Rowinsky et at, revealing enhanced 
myelosuppression when cisplatin administration preceded topotecan [17]. Recently. an oral 
fonnulation of topotecan with a bioavailability of 32-44% became available, which is a more 
convenient method of drug administration [31-33J. The reported phase I study was perfonned to 
explore the influence of alternate sequences of oral topotecan in a daily times five schedule and 
cisplatin on the observed side-effects and phannacokinetic behavior of both drugs and to detennine 
the maximum tolerated dose of topotecan in combination with cisplatin 75 mg/m2 once every 3 
weeks in both sequences. 
Both neutropenia and diarrhea were the DLTs of oral topotecan combined with cisplatin in this 
schedule. Other toxicity was usually mild to moderate and consisted of nausea and vomiting, 
mucositis, fatigue, neuro- and nephrotoxicity and alopecia. 
Myelosuppression was significantly more severe when cisplatin preceded topotecan 
administration. This observation is in accordance with the data reported for the combination of the 
intravenous fOffimlation oftopotecan and cisplatin [17]. The onset of the neutropenia was relatively 
late with a median day of onset of the nadir on day 19 (range 4-30). These data are in line \Vitll the 
data reported by Miller et al. [44]. The combination oftopotecan, administered intravenously on day 
1 to 5, with cisplatin on day 1 resulted in a neutrophil nadir around day 12 (range 8-25). Compared to 
the median time to neutrophil nadir of 12 days (range 9-15) for single agent oral topotecan [34J and 
day 9 (range 6-10) [19] for single agent intravenously administered topotecan, the nadir in our study 
\V3S delayed. This resulted in treatment delay due to prolonged myelosuppression in 34% of the 
courses. Despite grade 3 or 4 neutropenia was observed in 31 % of the courses, the incidence of 
neutropenic fever \V3S only 2%. 
The doses in this sequence, cisplatin followed by topotecan, we can recommend for phase II 
studies are oral topotecan 1.25 mglm2(day day 1 to 5 and cisplatin 75 mg/m2, but only in non- or 
minimally pretreated patients in good clinical condition and under strict medical surveillance, 
comparable to the patients treated in this study. In other circumstances dose adjustment of topotecan 
should be considered. In other phase I studies, combining cisplatin 50 mgtm' on day I with i.v. 
topotecan as a 3D-min infusion daily for 5 consecutive days, neutropenia and thrombocytopenia 
constituted the principal toxicities. The reconmlended dose of to po tee an for further trials \YaS 0.75 to 
1.0 mg/m2(day combined with cisplatin 50 mg/m2, accounting for 50·66% of the single agent 
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intravenous dose of topotecan [17,44]. This percentage is similar to our results where the 
recommended dose of oral topotecan in this schedule is 54% of single agent oral topotecan in a daily 
times five schedule [34]. \Ve realize that oral availability of topotecan is not taken into account 
However, the relevance of bioavailability becomes questionable in view of the results of recent 
studies indicating that the oral administration oftopotecan at a dose of 2.3 mg/m2/day is as effective 
as the intravenous administration of topotecan 1.5 mg/m2/day [35, 361 in both ovarian cancer and 
small cell lung cancer. 
For the reversed sequence, the recommended doses are oral topotecan 2.0 mg/m2/day day I to 5 
followed by cisplatin 75 mg/m2. This constitutes a topotecan dose of 87% of the single agent dose. 
However, as indicated, it is reconunended that the use of topotecan and cisplatin at these doses 
should be limited to patients similar to those studied in this trial, i.e., untreated or minimally 
pretreated patients with a good perfonnance status under strict medical surveillance. In all other 
circumstances, topotecan dose reduction is recommended. This sequence of dmg administration was 
also studied for the combination of the intravenous formulation oftopotecan for 5 consecutive days in 
escalating doses and cisplatin 50 mg/m2 in an al~emating schedule with carboplatin, cisplatin, 
teniposide and vincristine in patients with small-cell lung cancer [45]. Preliminary data indicate that it 
is feasible to combine i.v. topotecan [5 mg/m2/day, the recommended dose of single-agent 
topotecan, with cisplatin 50 mg/m2. Thu:s, the observed hematological toxicity is sequence dependent 
both for the intravenous and the oral formulation oftopotecan in combination with cisplatin, resulting 
in a higher dose intensity of topotecan when administered before cisplatin.The observed 
phannacokinetic parameters of the lactone and the carboxylate fonn oftopotecan demonstrated linear 
and dose independent behavior over the total dose range studied and were similar to single agent data 
[46] and also comparable to the data obtained in the schedule with 24 hour interval between the 
administration of topotecan and cisplatin in our study, indicating no apparent phannacokinetic 
interaction between topotecan and cisplatin. The sequence of dmg administration also had no 
influence on the phannacokinetics oftopotecan at the dose levels administered, neither on day I, 2 or 
5. This is in contrast with the reported reduction of the clearance of intravenously administered 
topotecan observed after preceding cispiatin administration [17]. Sequence~dependent differences in 
toxicity and phannacokinetics can be obscured by a large intra-patient variability in AVe. However, 
the intrapatient variability in Ave oftopotecan lactone for oral topotecan expressed as coefficient of 
variation (CV) is 18.5% [34] and is comparable with the intrapatient variability in AVC observed 
after intravenous administration of topotecan (CV is 12.6%) [47]. Since patients were treated in a 
cross-over design, sequence dependent toxicological and pharmacological differences could be 
assessed as accurately as in an rv study. 
Also the ratio of topotecan AUe of lactone to total dmg correspond very well with data of a 
previous study in which oral topotecan was administered as a single agent (34] and did not vary with 
the sequence of dmg administration. 
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The plasma clearance and volume of distribution of unbound cisplatin as well as the AUC up to 
the last measured time point of total cisplatin in plasma indicated no significant influence of 
topotecan on the protein binding and plasma disposition of cispiatin. Preclinical studies indicated that 
the reversal of cisplatin·induced DNA interstrand cross·links was delayed by concomitant incubation 
with a topoisomerase I inhibitor [48·50], without modifying their fonnation. However, in our study 
the values of the maximal platinum DNA·adduct fonnation in peripheral leukocytes and the area 
under the DNA-adduct versus time curve were consistent with single agent data [42J. and were 
independent of the drug sequence. Although the preclinical observations might not be extrapolated to 
the clinical setting, it is possible that the extreme variability in platinum DNA-adduct values would 
not allow any small alteration in adduct formation to be observed even if it was present It is also 
possible that other mechanisms may contribute to the enhanced toxicity observed for the sequence 
CT. In ill vitro studies induction of topoisomerase I [51 J and enhanced topoisomerase I inhibitory 
activity [52] were observed after incubation with cisplatin followed by the administration of a 
topoisomerase I inhibitor. Simultaneous incubation of platinum derivatives and topoisomerase I 
inhibitors resulted in enhanced S-phase arrest in human colon and ovarian cancer cell lines indicative 
of increased topoisomerase I inhibitor-induced cytotoxicity [48,49]. This observation might indicate 
that the synergistic toxicity observed for the combination of topoisomerase I inhibitors and platinum 
derivatives can partly be explained by a modification in cellular response to DNA damage. 
Based on the available data, the importance of the sequence of drug administration and the 
enhanced toxicity observed when cisplatin is followed by topotecan can not simply be extrapolated to 
the antitumor activity of the combination. However, a sequence dependent effect on antitumor 
activity can not he ruled out. Further randomized phase II studies in patients with topotecan sensitive 
tumor types are needed to elucidate the importance of dmg sequencing and possible cytotoxic 
interaction, and the potential relevance of the higher dose intensity of both drugs, that can be 
achieved when the less toxic sequence of drug administration is used. 
In conclusion, the recommended dose for phase II studies in selected patients is oral topotecan 
1.25 mg/m2/day for 5 consecutive days combined with cisplatin 75 mg/m2 on day I. once every 3 
weeks, or topotecan 2.0 mgim'/day day I to 5 followed by the same dose cisplatin on day 5. No 
phannacokinetic interaction could explain the enhanced myelosuppression observed in the sequence 
CT. 
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ABSTRACT 
Anticancer drugs still are dosed based on the body-surface area (BSA) of the individual patient, 
while the BSA is not the main predictor of the clearance for the majority of drugs. The relevance of 
BSA-based dosing has not been evaluated for topotecan yet A retrospective pharmacologic analysis 
was performed of kinetic data from 4 clinical phase I studies in which topotecan was administered 
orally as single agent combined with data from a combination study of topotecan and cisplatin. A 
strong correlation (r=O.91) was found between the area under the plasma concentration time curve of 
the lactone and carboxylate forms of topotecan by plotting 326 data sets obtained from 112 patients 
receiving oral topotecan at dose levels ranging from 0.15 - 2.70 mg/m2, The intra-patient variability, 
studied in 47 patients sanlpled for 3 or more days, for the apparent lactone clearance (CLfF), ranged 
7.4 - 69% (mean 24 ± 13%, median 20%). The inter-patient variabilities in the CLfF, calculated with 
the data of all studied patients, expressed in Uhfm2 and in Lilt were 38% and 42%, respectively. In 
view of the relatively high inter- and intra-patient variabilities in topotecan clearance, in contrast to a 
variability of only 12% in tile BSA of the studied patients, no advantage of BSA-based dosing was 
found over fixed dose regimens. 
INTRODUCTION 
Most anticancer drugs are dosed based on the body-surface area (BSA) of the individual 
patient, with the aim of reducing inter-patient variability of dmg exposure. However, this 
strategy failed for most drugs [I j, except for docetaxel (Taxotere"), where BSA has been shown 
to be a main predictor of the clearance in a pharmacokinetic model [2]. The relevance of this 
concept of BSA-based dosing has not been evaluated for topotecan (Hycamtin®), one of the 
most promising agents that entered clinical practice in the recent years. Topotecan has antitumor 
activity against various human malignancies, and relationships have clinically been found 
between systemic exposure of top ate can and hematological toxicity [reviewed in 3-5], and with 
antitumor activity in preclinical models [6]. The bioavailability of oral topotecan in adult cancer 
patients ranged from 30 - 44% with inter-patient variabilities of26 - 31% [7-9]. However, since 
pharmacokinetic analysis in most patients [1 0-12J has only been carried out for 2 days, a reliable 
estimate of the intra-patient variability of orally administered topotecan has not yet been 
established. The recommended dose for single agent oral topotecan is 2.3 mglm2/day for 5 days 
every 3 weeks. As alternative a fixed dose of 4 mg/day for 5 days every three weeks was 
proposed [10]. However, thusfar studies on oral topotecan were performed by dosing patients 
based on their body-surface area instead of using fixed dose regimens. Since most patients will 
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take their oral medication in an outpatient setting, it is important to keep dosing regimens as 
simple as possible and because of this it would be most practical to use fixed dosing regimens 
[13]. The aim of the present analysis of kinetic data from several phase I studies was to 
investigate, whether dosing of oral topotecan in the treatment of adult cancer patients based on 
body-surface area of individual patients has any advantage over fixed dose regimens. 
PATIENTS AND METHODS 
Patient selection 
The patient selection criteria were fully described elsewhere for the oral phase I studies in 
which topotecan was administered as single agent [3) and for the study in which oral topotecan 
was combined with i.v. cisplatin [14]. In short, patients with a confirmed diagnosis of a 
malignant solid tumor resistant to standard chemotherapy regimens were eligible for these 
studies. Age should be between 18 and ~5 years and performance status, defined by the Eastern 
Cooperative Oncology Group, had to ~e ::; 2. No previous anticancer therapy for at least 4 weeks 
was allowed. Adequate hematopoietic and renal functions were required, patients with mildly 
impaired liver functions (i.e. total serum bilirubin::; 1.25 x upper normal limit, ASAT and 
ALAT::; 2 x upper normal limits and in case of liver metastases::; 3 x upper normal limits) were 
allowed to participate in the described studies. A specific exclusion criterion was the existence 
of any gastrointestinal circumstance, which could alter the absorption of topotecan. All patients 
signed informed consent. 
Treatment schedules in the single agent. phase I studies 
Oral administration, using the i. v. formulation, of single agent topotecan was studied in 4 
phase I studies [3J. The first study involved a twice-daily dosing of topotecan at dose levels of 
0.15 - 0.60 mg/m' for 21 days, repeated every 28 days [3, II]. In the second study, topotecan 
was administered twice-daily for 10 days, every 21 days, at dose levels of 0.50 - 0.80 mg/m' [3, 
12]. In the third study the administration of topotecan was reduced to once a day for 10 days at 
dose levels ranging from 1.00 - 1.60 mg/m' [3, 12J. The final phase 1 study of single agent oral 
topotecan involved a once daily administration for 5 days, also repeated every 21 days, and 
included dose levels ranging from 1.20 - 2.70 mg/m' [3, 10]. In the daily times 5 schedule also 
patients were included who were treated with a fixed dose of 4 mg/day. 
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Tl'eatment schedule in the combination phase I study 
The latter mentioned regimen of oral topotecan, this time at dose levels ranging form 0.75 -
2.30 mg/m2/day for 5 days, using the drug formulated in gelatin capsules, was also studied 
combined with a fixed dose of 75 mg/m2 of i.v. cisplatin [14J. In the present report we also 
included pharmacokinetic-data of patients, treated with oral topotecan daily times 5, at dose 
levels of 1.50 and 1.75 mg/m2 preceded by a 3 h cisplatininfusion at 50 mg/m2 on day I of each 
course in an ongoing study using the same eligibility criteria as previously reported [14]. 
Pharmacokinetic sample collection and analysis 
Blood samples were collected, upto 12 h after dosing [10-12, 14J, in 4.5 ml glass tubes 
containing lithium heparin as anticoagulant and were centrifuged within 10 minutes to separate 
the plasma. Subsequently, the plasma was deproteinized by 4 fold dilution in ice-cold (-20'C) 
methanol, resulting in a stabilized lactone to carboxylate ratio [15], and stored at -80°C upon 
analysis. Simultaneous determination of the lactone and carboxylate form of topotecan was 
performed by a reversed-phase high-performance liquid chromatographic (HPLC) method as 
described [15], with minor modifications for the analysis of drug levels in the combination 
phase I study [14]. 
On the basis of the best fitted curves, two and three compartmental analysis models after 
zero-order input were used for the calculation of the area under the plasma concentration-time 
curves (AVC)o-;rumity of the lactone as well the carboxylate form oftopotecan as described [14J. 
The apparent oral clearance (CLlF) of topotecan lactone was calculated by dividing the dose per 
m
2 by the observed lactone AVC, expressed in Llh/m'. The absolute CLIF, expressed in Llh, 
was calculated by dividing the absolute dose by the AVC of topotecan lactone. 
Statistical analysis 
Linear regression analysis was performed, using the NCSS package (Version 5.X; lL. Hintze, 
East Kaysville, UT, 1992), to test potential relationships between evaluated parameters. One 
way analysis of variance was performed to evaluate statistically significant differences (p<O.05) 
between groups, using the same program. 
RESULTS 
In the 4 phase I shldies on single agent oral topotecan 56 patients were evaluable for 
phanmacokinetic analysis for a total of 114 kinetic days (table 1). The majority of evaluable days 
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Table 1: Evaluable phannacokinetic days in the 4 single agent phase I studies of orally administered 
topotecan. 
Dose twice once No. total number of evaluable kinetic courses 
(mg/m2) daily daily ofpts day I day 4 day 8 day21 total 
0.15 21 days 2 2 3 
0.30 21 days 3 3 3 6 
040 21 days 2 3 2 2 7 
0.50 21 days 4 4 4 8 
0.60 21 days 3 3 3 6 
0.50 10 days 1 1 2 
0.60 10 days 4 3 4 7 
0.70 10 days 4 4 4 8 
0.80 10 days 
1.00 10 days 3 3 3 6 
140 10 days 3 3 3 6 
1.60 10 days 4 4 4 8 
1.20 5 days 3 3 3 6 
1.80 5 days 3 3 3 6 
2.30 5 days 6 6 6 12 
2.70 5 days 4 4 4 8 
1.25 • 10 days 2 
4.00 • 5 days 6 6 6 12 
total b 56 57 22 33 2 114 
a; Fixed dose 
b: One patient in thc h'lce daily 0.40 mgfm1 was also sampled during course 2 and onc patient in the once 
daily lAO mg/m1 was also sampled during a course \\lth a fixed dose of 1.25 mg 
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were obtained in the phase I trial studying the combination of oral topateean and i. v. cisplatin, in 
which 56 patients were sampled for a total of 228 days (table 2). 
By plotting 326 data sets (95% of total) of kinetic days for which both the lactone and the 
carboxylate Ave could be assessed, a strong linear relationship was found between the Aues of 
the pharmacologic active lactone form of topateean and its inactive ringMopened carboxylate 
form (AUCcarbo:"1o(ale = 1.62 + 1.57*AUCiactone, r=0.91, fig 1). For further estimation ofintecM and 
intra-patient variabilities and their implication for BSA dosage regimens, pharmacokinetic 
parameters of the lactone form were used in this analysis. 
Table 2: Evaluable phannacokinetic days in the phase I study in which oral topateean 
was combined with Lv. cisplatin. 
Dose No Total number of evaluable kinetic days 
(mg/m2) of Cldl Cld2 Cld5 C2dl C2d5 C3dl C3d5 C6dl C6d2 C6d5 Total 
pts 
0.75 6 6 6 6 6 6 6 36 
1.00 6 6 6 6 6 6 6 36 
1.25 II 10 4 II 5 5 4 4 2 2 48 
1.50 9 9 5 8 3 3 I 31 
I. 75 10 10 6 9 3 3 31 
2.00 8 6 3 7 4 4 24 
2.30 7 7 7 4 4 22 
Total 56" 54 18 54 31 31 16 16 3 3 2 228 
" 
1 patient received 2.30 (Course I) and 2.00 mgfm2 (Course 2) 
Inter and intra-patient variability 
Since the majority of the patients in the single agent oral phase I studies were sampled for 
pharmacokinetic analysis only for 2 days during 1 cycle, the intra-patient pharmacokinetic 
parameter variabilities for topotecan lactone were studied using the data obtained in the 
topotecan/cisplatin combination phase I study, in which pharmacokinetic sampling was 
performed during several cycles. As already reported, there was no pharmacokinetic interaction 
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between oral topotecan and i.v. cisplatin [14J. In view of this, all kinetic days (with and without 
cisplatin) were used for the present analysis. The intra-patient variability in AVC and CLIF of 
topotecan lactone \~as calculated as the standard deviation divided by the average, only using 
data of the 47 patients which at least had 3 evaluable kinetic courses of the AUC of topotecan 
lactone. The averaged intra-patient variability in the lactone AUC across all dose-levels was 24 
± 13% (median 20%, range 7.6 - 61%). The averaged intra-patient variability in the CLlF, 
expressed in Llhlm' and in Llh, was 24 ± 13% (median 20%, range 7.4 - 69%). 
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Fig 1: Relationship between the AVCs of the lactone and carboxylate form of topotecan in 326 
evaluable data sets 
The inter-patient variability in CLIF, expressed in L/h/m2 as well as in L/h, was calculated 
using the data of all the patients, by using the averaged apparent CLIF of all kinetic days of each 
patient as single value. The averaged apparent CLIF was 103 ± 39.0 Llhlm' (CV~38%, n~107, 
fig 2a), with no significant difference (p~0.074) in the CLiF over the 19 studied dose-levels. 
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The averaged apparent CLIF, studied over 27 different individual dosages, was 194 ± 80.4 Llh 
(CV~42%, n~107, fig 2b) or 195 ± 81.1 Llh (CV~42%, F114, fig 2b), by inclusion of the 
patients treated with a fixed dose. 
300 
250 
200 
150 
100 
50 
A 
o 0 
03> 
! g 
00 
o 'b 
o 0, 
8 
, 
~ g ~o 0 0 
eJlo8S>~ 
8 i 08 ~ 
Q:> 00 g 8 
o 
§ 
! 
o 
o 
o 
o 
0+---.--.---.--,,--,--, 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 
Dose (mglm') 
600 
B 
o 
500 
400 
300 
o 
200 , 
100 o 
0.00 l.00 2.00 3.00 4.00 5.00 6.00 
Dose (mg) 
Fig 2: Plot of dose/rn' (A) and absolule dose (B) and the averaged apparent CLIF (patients with 
a fixed dose are indicated by triangles). 
In addition, no alteration in topotecan lactone kinetics was found (p~0.30) after multiple (up 
to 6) courses (fig 3), using the data of patients treated in the combination phase I study, in which 
patients were samples for multiple courses. 
BSA as determinant fol' dose calculations 
As shown in fig 2 and 3, the apparent CLIF was constant over the studied dose-ranges and 
courses. In fig 4 the BSA is plotted versus absolute apparent CLIF in Llh (mean ± S.D.), 
calculated with the actual dose given to each individual patient. A poor positive relationship was 
found between BSA and the average apparent CLiF (CLIF ~ 52.4 + 75.I*BSA, [='0.29), with 
large variabilities in the apparent CLfF across all studied BSA values in the 47 patients with 3 or 
more pharmacologically evaluable courses. 
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Fig 3: Apparent CLIF during multiple courses and days. 
DISCUSSION 
Dosing of most cytotoxic ag~nts is commonly based on the BSA of patients, intending to 
reduce inter-patient pharmacokinetic variabilities of a compound. This, in turn, is based on an 
assumed relationship between the clearance of a compound and the BSA of the individual 
patient [I, 13]. However, calculation of the exact clearance oftopotecan is not feasible since the 
compound has a reversible conversion from the lactone to the carboxylate form. Moreover, 
accurate dosing of oral topotecan based on BSA is also not feasible, since for oral use the drug is 
now only available as gelatin capsules containing 1.0 and 0.25 mg respectively, resulting in the 
necessity of rounding of the absolute dose to the nearest quartile mg. Since excretion by the 
kidneys is a major route of elimination of topotecan [reviewed in 4] and alterations in the 
pharmacokinetic parameters for topotecan have only been described in patients with a renal 
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dysfunction, i.e. creatinine clearance < 60 mLlmin [16], in the set of studies we performed an 
altered topotecan clearance was not expected. The apparent CLfF of oral topotecan, in patients 
with a normal renal function, is highly dependent on the absorption of the lactone form from the 
gastrointestinal tract. 
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Fig 4: Body-surface area (BSA) versus absolute apparent CLIF expressed in Llh (mean ± S.D.). 
The oral bioavailability of topotecan in adult cancer patients for drinking of the i. v. solution 
ranged from 30 ± 7.7% [7] to 44% [9] and was found to be 42 ± 13% for the drug formulated in 
gelatin capsules [8]. In these clinical studies inter-patient variabilities in the oral availability in 
adults ranged from 26 - 31 % (7, 8], which is not dissimilar to the inter-patient variability of 38 
86 
Oral topotecall amI BSA-adjusted dosing 
and 42% for the apparent CLIF expressed in Llh/m2 and in Llh, respectively, in our studies. 
Since the inter-patient variability was calculated with the averaged apparent CLIF of topotecan 
lactone, using the data of patients which were studied up to 6 times, this variability might even 
be underestimated. 
Only limited information was available on the intra-patient variability of orally administered 
topotecan in adult cancer patients. Gerrits et al. [3] reported intra-patient variabilities in AVC of 
topoteean lactone of25 ± 31% (n~22) and 35 ± 25% (n~IO) in clinical phase I studies in which 
topotecan was administered either once daily times 5 or 10 respectively, and of 97 ± 70% 
(n~IO) and 60 ± 51% (n~13) in twice daily times 10 and 21 schedules, respectively. Since 
samples were only collected for pharmacokinetic analysis on 2 treatment days during one cycle, 
an accurate estimation of the intra-patient variability was not possible. In this present analysis 
we assessed the intra-patient variability using data of 47 patients, who were sampled on 3 - 6 
days each, resulting in an average intra-patient variability of the lactone AVC of 24 ± 13% 
(median 20%) with a range of7.6 - 61%. 
The broad range in the intra-patient variability in lactone AUC after oral administration of 
topotecan is probably related to the fact the carboxylate form is poorly absorbed from the small 
intestine, while the lipophilic pharmacologic active lactone form of topotecan is able to pass the 
membranes of the small intestine [4]. Since the pH in the small intestine ranges from pH 5 - 7 
and the rate of interconversion between the lactone and carboxylate form of topotecan is pH 
dependent, the amount of topotecan which is available for absorption is related to a fluctuation 
in the pH. 
\Ve did not find saturation of the absorption, tissue distribution or elimination of orally 
administered topotecan over the studied dose-range of 0.15 - 2.70 mg/m2 apparent from a lack in 
significant difference in the observed CLIF over the dose range studied. Also administration of 
multiple (up to 6) courses of orally administered topotecan did not alter the apparent topotecan 
lactone CLIF. 
The inter-patient variability in the topotecan CLIF of 38 and 42%, expressed in L/h/m2 and 
Llh respectively, is much larger than the 12% inter-patient variability in BSA of our patients 
(average BSA 1.9 ± 0.22 m', n~107). In view of the intra-patient variability of24 ± 13% in the 
apparent lactone CLIF, with individual variabilities upto 69%, the inter-patient variability in the 
bioavailability of 26 - 31 % and the poor relationship between the BSA and the average apparent 
CLIF, we feel that there is no scientific rationale for BSA-based dosing of orally administered 
topotecan in adult patients. This confirms our previous observation of similar pharmacokinetics 
after oral administration of either 2.3 mg/m2 oftopotecan or a fixed dose of4 mg [10], which 
was already suggesting that fixed-dose regimens could be applied. 
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In conclusion, in view of the relatively high intra~ and inter-patient variabilities in the AUe 
and CLIF of topotecan lactone and the relatively small range in observed BSA, oral topotecan 
can be added to the list of agents where BSA-adjusted dosing does not appear definitely better 
[I]. We recommend a fixed dose regimen for future use in clinical trials, which is more 
convenient for the oncologist and the pharmacist, is more cost-effective and last but not least, a 
fixed dose regimen is less cumbersome for the patients. Further randomized clinical studies in a 
large population are needed to fully explore the advantages of fixed dose regimens of orally 
administered topotecan, in which simultaneously the need for potential dosage adjustments at 
extreme BSA values have to be investigated. 
A careful study of inter-patient variability of topotecan AUC in patients of the same BSA, 
renal and hepatic function, to Jook at the effects of factors as age, gender, protein binding, and 
inherited or acquired metabolic function in addition to expression of the MDR~l P~glycoprotein 
and BCRP drug~transporting proteins [17] in intestinal tissues as an explanation for this 
variability, is currently being conducted. 
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ABSTRACT 
Backgroulld Genderwdependent differences in the clinical pharmacokinetic behavior of various 
drugs have been documented previollsly. Most commonly, these difterences are associated with 
differences in body composition, renal elimination, drug absorption Of hepatic metabolism. 
Genderwdependent differences in the pharmacokinetics of topotecan (Hycamtin®) have not yet 
been described. 
Patients alld methods Pharmacokinetic data of the lactone and carboxylate forms of topateean 
were derived from clinical studies in which topotecan was administered either orally or 
intravenollsly to a total of 55 males and 37 females. 
Results A significant difference (P=O.0082) of38% was found between the apparent clearance of 
topotecan lactone after oral administration in males (237± I 05 Llh) and females (163±62.S Llh). 
\"hen adjusted for body~surface area, this difference remained significant (P=O.031). Similarly, 
differences were noted in the percentage of topotecan in the lactone form (37.1±5.32% versus 
41.7±6.SI%, P~0.0076). Statistical analysis revealed that individual hematocrit values, which 
were consistently lower in females (P<O.023), were a significant predictor of the apparent 
topotecan lactone clearance. This was confirmed experimentally in in vitro incubation studies in 
whole blood using artificially altered hematocrit values and in blood samples from both male 
and female volunteers. 
Conclusion Topotecan is thus subject to significant gender~dependent differences in 
pharmacokinetics that arise as a result of a physiological difference in hematocrit values between 
males and females. This finding may have significant implications for the interpretation of the 
relationships between pharmacokinetics and pharmacodynamic outcome of topotecan treatment, 
and may provide a basis for the development and refinement of future clinical protocols. 
INTRODUCTION 
Topotecan (I-Iycamtin®, fig I), a water-soluble semisynthetic analogue of the topoisomerase I 
inhibitor camptothecin, is one of the most promising new anticancer agents. Single agent 
topotecan, administered intravenously (i.v.), has demonstrated antitumor activity against various 
solid tumors in adult cancer patients, including metastatic ovarian and small cell lung cancer. 
Most responses were achieved using a daily times 5 schedule in which topotecan was 
administered as a 30-min infusion [reviewed in 1]. Since daily i.v. administration of to po tee an 
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Fig. 1: Chemical structures of the lactone (A) and carboxylate (B) forms of topotecan and its 
known human metabolites. 
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for 5 days, repeated every 21 days, is inconvenient for patients, an oral formulation of topotecan 
has been developed with a bioavailability of 42 ± 13% {2]. Different administration schedules of 
oral topotecan have been evaluated in clinical studies, including once daily times 5 and 10 and 
twice daily times 10 and 21 administrations, from which the once daily times 5 schedule was 
recommended for future clinical studies [reviewed in 3]. The need for further clinical 
development of the oral topateean formulation became even more important in view of recent 
findings that the oral formulation has similar efficacy as coinpared to the i.v. formulation, while 
less hematological toxicity was observed [4,5]. 
The pharmacokinetic profile of topateean is quite complex since it can undergo a 
spontaneous pH-dependent interconversion between a pharmacologic active lactone form and an 
inactive carboxylate form (fig 1). Gender-dependent differences in pharmacokinetic behavior 
have been described for a wide variety of compounds over the last few decades. Most 
commonly, these have been shown to be associated with differences in body composition, renal 
elimination, drug absorption or hepatic function [reviewed in 6]. In this report, we describe 
gender-dependent differences in topotecan pharmacokinetics after both oral and i.v. 
administration, and present in vitro studies to provide a formal explanation of this phenomenon. 
PATIENTS Ai'lD METHODS 
Patient selection criteria 
All patients included in the studies had a histologically or cytologically confinned diagnosis of a 
malignant solid tumor, refractory to standard therapy or for which no recognized therapy was 
available. The patients participated in either a phase I study, in which oral topotecan was combined 
with i.v. cisplatin [7], or a phase II study of single agent topotecan administered as a 21-day 
continuous i.v. infusion [8]. The eligibility criteria, treatment plans and detailed clinical profiles have 
been fully described elsewhere [7,8]. 
DllIg administration 
SmithKline Beecham Phamlaceuticals (Harlow, UK) supplied capsules containing either 0.25 or 
1.0 mg oftopotecan lactone and a lyophilized vial preparation containing 5 mg of to po tee an lactone. 
Orally admiuistered topotecan was studied at dose levels of O. 75, 1.00, 1.25, 1.50, 1.75, 2.00 or 2.30 
mg/m2/day for 5 days, repeated every 3 weeks, in combination with a fixed dose of 75 mg/m2 
cisplatin by a 3 h innis ion, in 49 patients [7]. A total of 10 patients, treated Witll oral topotecan daily 
times 5, at dose levels of 1.50 or 1.75 mg/m2, preceded by i.v. cisplatin at a dose of 50 mg/m2 on day 
1 of each course, was also included in this study. In the i.v. phase II study, topotecan was 
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administered as a 21-days continuous infusion at dose levels of 0.50 and 0.60 mglm2/day at an 
infusion rate of6 mLl24 h, using ambulatory pumps, repeated every 28 days [8J. 
Blood sample collection and analysis 
Blood samples were collected in 4.5-mL glass tubes containing lithium heparin as anticoagulant. 
Following oral administration, samples were obtained prior to dosing, and 0.5, I, 1.5,2,3,4,6,8 and 
12 h after dosing on day I [7]. Similarly, in the i.v. trial blood was withdrawn prior to infusion, and at 
steady state on day 8 after start of dosing [8]. The blood samples were centrifuged intnlediately at the 
site of the patient to separate the plasma. The plasma samples were directly deproteinized by 4-fold 
dilution in ice-cold (-20'C) methanol, resulting in a stabilized lactone to carboxylate ratio [9J, and 
stored at -80°C upon analysis. Simultaneous detennination of the lactone and carboxylate foml of 
topotecan was perfom1ed by a reversed-phase high-perfonnance liquid chromatographic method as 
described [9J. 
Pharmacokinetic analysis 
In the present pharmacokinetic analysis we used the pharmacokinetic data of day 1 of course 
I in the oral phase I study [7J and of day 8 in the continuous infusion phase II study [8]. The area 
under the plasma concentration-time curve (AUC) of total topotecan, i.e. lactone plus 
carboxylate, and the topotecan lactone and carboxylate forms in the oral phase I study were 
calculated by noncompartmental and two or three compartmental analysis models after zero-
order input. The apparent clearance oftopotecan lactone and the clearance of total topotecan in 
the oral phase I study were calculated by dividing the dose in mg/m2 or the absolute dose in mg 
by the observed AVC and were expressed in L/h/m2 and Llh, respectively. \Vhile in the i.v. 
study, the clearances were calculated by dividing the rate of infusion divided by the steady-state 
plasma concentration. The apparent terminal disposition half-life of topotecan lactone and 
carboxylate were calculated as In2/k, in which k represents the rate constant of the terminal 
disposition phase. The lactone to total ratio in the oral phase I study was defined as the 
AVCrl AVCT, while the times to reach the maximum concentration for topotecan lactone and 
carboxylate were determined graphically. The lactone to total concentration ratio in the 21-days 
continuous infusion study was calculated as the concentration of the lactone form divided by the 
concentration of total topotecan. 
In Vitl"O experiments 
From 5 male volunteers a volume of 12 ml heparinized blood was collected, from which 6 
mL was centrifuged for 5 min at 2000g to separate plasma and blood cells. The plasma 
supernatants, combined with the buffy-coat, and the remaining red blood cell fractions were 
collected. Fractions of the whole blood, the red blood cells and the plasma were combined to 
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create different hematocrit values in blood of the same individual, ranging between 0.20 and 
0.60 LIL. A volume of 1 mL of these samples was incubated simultaneously with 5 ng/mL of 
topotecan lactone and 5 ng/mL of topotecan carboxylate for 15 minutes at 37°C to study the 
impact of the hematocrit on the lactone to total concentration ratio in the plasma compartment. 
The blood samples were further processed as described above for the blood samples of the 
patients. The remaining fractions were used for the determination of hematocrit values. To 
confirm the gender-related difference in the topotecan pharmacokinetics, I mL of normal 
heparinized whole blood of 5 female and 5 male volunteers was incubated with 5 nglmL of 
topotecan lactone and carboxylate and further processed as described above. 
Statistical analysis 
All parameters are reported as mean values ± SD. Two-tailed unpaired Student's t-tests were 
performed to evaluate statistically significant differences (P<O.05) in phannacokinetic and 
biochemical parameters between males and females, using the NeSS package (Version 5.x; J.L. 
Hintze, East Kaysville, UT, 1992). Linear regression analysis was performed to test potential 
relationships between parameters, using the same program. 
RESULTS 
Clinical pharmacokinetics 
A total of 54 patients (36 male and 18 females) enrolled in the oral phase I study was 
evaluated for pharmacokinetic analysis during day I of course 1. Since cisplatin has no effect on 
the pharmacokinetics of topotecan [7], courses without and in combination with i.v. 
administered cispiatin were used for the determination of gender-dependent differences in 
topotecan pharmacokinetics. The pharmacokinetic and biochemical characteristics of the 
evaluable patients are listed in table 1. The apparent clearance of topotecan lactone was 
significantly 1.4-fold faster in males as compared to females (p~O.0082), while after correction 
for the body-surface area the apparent clearance of the lactone form was remained significantly 
1.3-fold faster in males (p=O.031). Interestingly, no significant differences were observed in the 
clearance of total topotecan. The lactone to total ratio of the Aue was significantly 1.3-fold 
higher in females (P~O.0076) and a significant correlation (FO.35, P~O.0086) was found 
between the lactone to total AUe ratio and the apparent clearance of topotecan lactone (fig 2a). 
Linear regression analysis was performed between, respectively, the significantly different 
biochemical characteristics body-surface area and hematocrit and the apparent clearance of 
topotecan, expressed in LIh as well as in L/h/m2. A significant relationship was found between 
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Table 1: Pharmacokinetic and biochemical characteristics 
Oral phase I study 
LIT (%) 
CLIFL (Llh) 
CLIFL (Llh/m ') 
CLIFT (Llh) 
CLIfT (Llhfm ') 
TmaxL (h) 
TY,L(h) 
BSA (m') 
Ht (LIL) 
CLcreat (mL/min) 
Albumin (gIL) 
Total protein (gIL) 
Males 
37.1 ± 5.32 (n~36) 
237 ± \05 (n~36) 
123 ± 53.3 (n~36) 
85.0 ± 33.3 (n~36) 
44.7 ± 17.9 (n~36) 
1.63 ± 1.25 (n~36) 
3.65 ± 1.05 (n~36) 
1.96 ± 0.204 (n~36) 
0.39 ±0.037 (n~30) 
89 ± 20 (n~21) 
41 ± 4.0 (n~34) 
76 ± 5.3 (n~34) 
21-Days continuolls intravenous infusion 
LIT (%) 
CLL (L/h) 
CLL (Llh/m') 
CLT (Llh) 
CLT (L/h/m') 
BSA (m') 
Ht (L/L) 
CLcr<!at (mL/min) 
Albumin (giL) 
Total protein (giL) 
29.6± 6.67 (n~18) 
73.9 ± 27.8 (n~19) 
37.5 ± 14.3 (n~19) 
21.3 ± 5.78 (n~18) 
lOA ± 3.88 (n~18) 
1.98±0.139(n~19) 
0.37 ±0.038 (n~12) 
98 ± 16 (n~9) 
43 ± 4.0 (n~12) 
70 ± 8.9 (n~12) 
Females 
41.7 ± 6.51 (n~18) 
163 ±62.5 (n~18) 
92.4 ± 33.3 (n~18) 
69.1 ±29.9(n~18) 
38.5 ± 14.6 (n~18) 
1.92 ± 1.60 (n~18) 
3A7±0.722 (FI8) 
1.77±0.204 (n~18) 
0.36±0.041 (n~16) 
80 ± 19 (n~IO) 
41 ±2.9(n~15) 
75 ± 4.8 (n~15) 
34.1 ± 5.70 (n~19) 
59.9 ± 13.6 (n~19) 
34.3 ± 8.14 (n~19) 
20.0±3.85 (n~19) 
11.5 ± 2.56 (n~19) 
1.76 ± 0.164 (n~19) 
0.34 ± 0.028 (n~16) 
87± 22 (n~14) 
41 ± 6.1 (n~16) 
71 ± 16 (n~16) 
p 
0.0076 
0.0082 
0.031 
NS 
NS 
NS 
NS 
0.0003 
0.015 
NS 
NS 
NS 
0.034 
NS 
NS 
NS 
NS 
0.0001 
0.023 
NS 
NS 
NS 
IlT (%) = lactone to total ratio, CUF and CL = (apparent) clearance of topotecan laclone and total, Tmax = lime 10 reach the 
maximal plasma concentration oftopotecan lactone and carbo~1'late, T\tl = leoninal half life oflopolecan laclone and carbo~)'late, 
BSA = body-surface area,Ht = hematocrit, CI"""t = creatinine clearance, NS = no significant diftcrcnce. 
the body-smtace area and the absolute apparent clearance expressed in Llh (P~O.013), while no 
significant relationship was found after correction of the apparent clearance for the body-surface 
area, In contrast, the relationship between hematocrit and the absolute as well the corrected 
apparent clearance was significantly correlated (p~0.040 and P~0.030 respectively). In the 
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continuous i.v. phase 1I study. 38 patients (19 males and 19 females) had evaluable topotecan 
pharmacokinetics on day 8 of course I, with a 1.2-fold higher lactone to total concentration in 
females (table I). As in the oral study, a significant correlation (FO.61, P<O.OOOI) between the 
lactone to total concentration and the apparent clearance of topotecan lactone was found (fig 
2b). 
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Fig. 2: Relationship between the lactone to total ratios and the apparent topotecan lactone clearance 
in patients treated with oral topotecan (A) or i.v. topotecan (B). Male patients are indicated 
by open circles and females by closed circles. 
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In vitro studies 
We sought- to define an in vitro model that would explain the differences between males and 
females in topotecan pharmacokinetics. In the expedments with the whole blood samples of the 
healthy male volunteers, with artificially altered hematocrit values, a strong significant correlation 
(r=0.98, P<O.OOOl) was found between the hematocrit value and the lactone to total concentrations 
after a 15-min incubation at 37'C with 5 ng/mL of both topotecan lactone and carboxylate (fig 3). By 
comparing normal heparinized whole blood samples of 5 male and 5 female volunteers, a significant 
difference (p~0.0015) in the hematocrit value was found, with mean values of 0.44 ± 0.014 LIL for 
males and 0.39 ± 0.019 LIL for females. After a 15-min incubation at 37'C with 5 ng/mL of 
topotecan lactone and carboxylate, the lactone to total concentration ratio in the plasma compartment 
was significantly higher (P<O.OOOI) in females as compared to males, with respective values of27.8 ± 
0.41 % and 25.2 ± 0.36 %. In addition, the change in the lactone to total concentration ratio was 
accompanied by a significantly (p=O.OlO) higher exposure of the lactone foml in the plasma 
compartment of the blood samples of the female volunteers, with mean concentrations of 3.41 ± 
0.103 and 3.22 ± 0.074 ng/mL for the blood samples obtained from the female and male volunteers. 
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Fig. 3: Relationship between the hematocrit (Ht) and the lactone to total concentration ratio in 
plasma. Each symbol represents the created hematocrit value versus the lactone to total ratio 
in the plasma of 1 healthy volunteer. 
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DISCUSSION 
In the present study, we have demonstrated for the first time that topotecan clearance is 
significantly slower in females as compared to males. These data complement previous 
knowledge of the clinical pharmacology of topotecan, and may have important clinical 
implications for its optimal use. Previous studies have revealed that major factors responsible for 
gender-dependent pharmacokinetics are related to differences in body composition, renal 
elimination, drug absorption and hepatic function [reviewed in 6). Indeed, a significant 
difference in the body-surface area between male and female patients was found in the present 
study. However, the apparent clearance of topotecan lactone after oral administration was still 
l.3-fold higher in male patients as compared to female patients after correction for body-surface 
area, indicating that body-surface area was not the major predictor for the gender-dependent 
clearance of topotecan lactone. Likewise, no significant linear relationship was found between 
body-surface area and the apparent clearance of topotecan lactone after correction of the 
apparent clearance for body-surface area. 
Pharmacokinetic studies performed during previous clinical trials of topotecan have 
consistently failed to recognize the discrepant drug disposition in males and females. This is 
most likely caused by the fact that in most studies only a limited number of patients was 
sampled or combined measurement of topotecan lactone plus carboxylate was performed. 
Recently, gender-dependent differences in topotecan pharmacokinetics were not found in a 
population of children and adults in the range of 3 weeks to 22 years of age. [10]. This is 
probably related to the fact that no gender differences in hematocrit values are reported in 
children under the age of 12 years and only marginal differences were observed between the 12 
and 18 years [II]. 
Topotecan is mainly eliminated by the kidneys, with 40% (range 26-80%) of the dose 
excreted in the urine as parent compound within 24 It after a 30-min Lv. infusion [reviewed in 
I]. One of the known metabolic pathways of topotecan is the loss of the methyl moiety linked to 
the nitrogen in the core structure of to po tee an by the cytochrome P450 enzyme system, resulting 
in N-desmethyl topotecan (fig 1). Concentrations of this metabolite in plasma and urine were 
very low; after a 30-min Lv. infusion, peak plasma concentrations of N-desmethyl topotecan 
accounted for less than 1% of the maximal total drug concentration, and in urine only 1 to 4% of 
the delivered dose was excreted as N-desmethyl topotecan [12]. Recently, a new metabolic 
conjugation pathway has been described [13], resulting in the formation of topotecan-O-
glucuronide and N-desmethyl topotecan-O-glucuronide (fig 1). Since relatively low amounts of 
these metabolites were excreted in the urine, with maximal concentrations of 10 and 3.5%, 
respectively, in comparison with urinary concentrations of the parent compound, coupled with 
the fact that altered topotecan clearance only has been described in patients with severely-
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impaired renal function [14], gender-dependent differences in the known metabolic pathways of 
topotecan are unlikely to occur. However, minor gender-related differences in renal clearance 
could be expected, since the glomerular filtration rate of the kidneys is related to the body-
weight, and thus higher topotecan clearance in males could be due to their higher body-weight 
[reviewed in 6]. Nevertheless, as described above, the apparent clearance of topotecan lactone 
was significantly higher in males, even after correction for the body-surface area (i.e. body-
weight), while no significant difference was found for the clearance of total topotecan. 
Differences in intestinal drug absorption between males and females after oral administration 
have been reported and shown to be possibly related to a slower gastric emptying rate in 
females, different levels of gut enzymes and differences in the hepatic first-pass effect. In the 
present analysis, however, differences in the gastric emptying rate are less likely, since the time 
to reach the maximum concentration of topotecan lactone after oral administration did not differ 
significantly. Moreover, previously we did not find differences in the oral bioavailability of the 
i.v. dosing solution between males and females oftopotecan lactone, with bioavailabilities of31 
± 8.4 % (n~7) and 30 ± 7.5% (n~5) for males and females, respectively [data compiled from 15]. 
Gender-related differences caused by different levels of liver and gut enzymes are not expected 
since metabolism is a minor route of elimination of to po tee .an. As described above, low amounts of 
the known metabolites of topotecan were detected in urine and plasma of patients. Like\vise, in a 
phase I and phannacologic study in patients with impaired hepatic function, similar topotecan 
phannacokinetics were observed in patients with and without liver injury [16], also suggesting a 
minor role ofliver enzymes in the overall elimination oftopotecan. 
A significant relationship was found following linear regression analysis of body-surface area 
versus the absolute apparent clearance of topotecan lactone, while after correction for body-surface 
area this relationship did not remain statistically significant. However, significant relationships were 
noted between the hematocrit and the absolute apparent clearance of topotecan lactone, as well as the 
apparent clearance corrected for body-surface area, indicating that hematocrit was a significant 
predictor for the apparent clearance of topotec.an lactone. 
To further evaluate the role of hematocrit in topotecan phannacokinetics as a potentially important 
contributing factor to the observed gender-dependency, variolls additional in vitro studies were 
perfonned. Hematocrit values in healthy humans are known to be different in males and females, with 
respectively values of 0.44 ± 0.02 LIL and 0.39 ± 0.02 LIL [17]. FurthemlOre, erythrocytes are known 
to be carriers for a variety of endogenous compounds and drugs, including topotecan [18-20]. Drugs 
and endogenous compounds in the plasma compartment are in equilibrium between plasma proteins 
and plasma water, i.e. in a bound and unbound [omt The plasma \Yater is the central compartment, 
from which the unbound dmg is able to move across -cell membranes, including those of red blood 
cells. Topotecan has a plasma protein binding of approximately 35% [21], and hence 65% of the drug 
in principle is directly available for cellular uptake. To demonstrate the relationship between 
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hematocrit value and the lactone to total concentration ratio in plasma, whole blood of 5 male 
volunteers, with artificially altered hematocrit values, was incubated with topotecan lactone and 
carboxylate. The hematocrit appeared to be a principle predictor of the resulting topotccan lactone to 
total concentration ratio in the plasma compartment, with higher ratios at lower hematocrit values. 
This phenomenon was confinned by in vitro incubation of topotecan in whole blood of males and 
females, showing significantly higher lactone to total topotecan concentrations in females as 
compared to males. The higher lactone to total topateenn ratios in blood with lower hematocrit values 
is most likely caused by the fuct that the carboxylate fonn, which is charged, is not able to pass cell 
membranes and thus remains in the plasma compartment [22]. Hence, the absolute amount of the 
carboxylate fonn in the plasma compartment in the in vitro experiments is independent of the 
hematocrit value, resulting in lower carboxylate concentrations in blood samples with lower 
hematocrit values. In addition, we found significantly higher topotecan lactone concentrations in the 
plasma compartment of the blood samples of the female volunteers. This phenomenon is consistent 
with the in vivo finding of lower topotecan lactone clearance in females, as a result of higher 
exposure of the lactone form in females compared to males. 
In conclusion, we have shown that topatecan is subject to significant gender-dependent 
differences in pharmacokinetic behavior that result from a physiologic difference in hematocrit 
values between males and females. This finding ~ay have implications for interpretation of the 
relationship between pharmacokinetic parameters and pharmacodynamic outcome of topatecan 
treatment. A potential gender-dependent relationship between the pharmacokinetics and 
pharmacodynamics has to be investigated in a study using single agent topotecan at a fixed dose. 
Eventually, pharmacologic data generated in this investigation and the recognition of the 
gender-dependency in topotecan pharmacokinetics may provide a basis for the development and 
refinement of clinical protocols allowing more rational and selective treatment with topotecan. 
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ABSTRACT 
Background A recent clinical study with cisplatin-topotecan chemotherapy has shown that the 
maximum tolerated dose was cisplatin 75 mg/m2 on day 1 followed by oral topateean 1.25 
mglm2/day for 5 days [10]. Since preclinical studies have shown a relationship between 
topotecan exposure and anti tumour response, we tried to increase the topateean dose when 
given with a reduced fixed dose of cis pia tin 50 mg/m2. 
Patients and Methods A total of 12 patients were treated with oral topotecan administered daily 
for 5 consecutive days in escalating doses starting at 1.50 mglm2/day and cisplatin was given as 
a 3-h infusion before topotecan. Serial plasma samples were obtained from all patients for 
pharmacokinetic analysis of the lactone and carboxylate forms of topotecan and unbound and 
total cisplatin. 
Results Dose-limiting toxicity, consisting of thrombocytopenia, neutropenia andlor diarrhea, 
was encountered at the second dose level (topotecan 1.75 mg/m2/day, cisplatin 50 mglm\ 
Hematological pharmacodynamics indicated a delayed onset of neutropenia with this 
combination as compared to single agent dat~. The apparent clearance of topotecan was 
independent of dose, with mean values of I09±65.8 and 715±14.4 L/hlm' (P~0.27) at the 1.50 
and 1.75 mglm'/day doses, respecti~elY. The topotecan dose did not affect any of the cisplatin 
phannacokinetic parameters (P;:::O.l 0), suggesting lack of a kinetic interaction. 
Conclusion The maximum-tolerated dose of this combination is cisplatin 50 mg/m2 on day 1 
immediately followed by oral topotecan 1.50 mglm'/day for 5 days. A 33% reduction in 
cisplatin dose allowed only a 20% dose increase in oral topotecan. These results indicate that 
the studied regimen has no advantage as compared to the combination with cisplatin 75 mg/m2. 
INTRODUCTION 
Topotecan [(S)-9-dimethylaminomethyl-IO-hydroxycamptothecin, Hycamtin®J is a water-
soluble semi-synthetic derivative of camptothecin, an inhibitor of the nuclear enzyme 
topoisomerase I known to interfere with the process of DNA breakage and resealing, resulting in 
irreversible DNA-single strand breaks and ultimately in cell death [IJ. Since cisplatin is a DNA 
damaging agent, synergy was hypothesised for the combination with topotecan. This synergism 
was demonstrated in in vitro studies in various -cancer cell lines [2). III vitro studies indicated 
that topoisomerase I inhibitors delayed the reversal of cispiatin induced DNA interstrand cross 
links without modifying their formation, as a possible mechanism for the observed synergism. 
Also, simultaneous treatment prolonged the DNA and RNA synthesis inhibition induced by 
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either drug alone [3,4J. When observed, synergy seemed to be dependent on the sequence of 
administration and cytotoxicity increased when topotecan administration was preceded by 
cisplatin [5]. Driven by these promising ill vitro data and by the clinical knowledge that 
topoisomerase I inhibitors and cispJatin have different toxicity profiJes and share a broad 
spectrum of antitumour activity, several phase I studies combining Lv. topotecan and cisplatin 
were initiated [6-9]. All studies showed that a considerable dose reduction of i.v. topotecan was 
required as compared to t~e single agent dose, and that cisplatin given before topotecan 
produced a greater incidence of severe neutropenia in the studies in which the sequence 
dependent effects were studied [6,10]. 
Based on ill vitro observations showing more pronounced anti tumour efficacy with protracted 
exposure of to poi some rase I inhibitors at low concentration, several clinical studies on low dose 
continuous infusion of topotecan were performed [11-14]. Since oral delivery is a more 
convenient method for prolonged drug administration, and preferred by patients [15,16], an oral 
formulation of topotecan was devel~ped. Topotecan, supplied in gelatin capsules, has an 
absolute bioavailability of 42±13% [17]. The maximally tolerated dose for oral topotecan, 
administered for 5 days every 21 days as a single agent was defined as 2.3 mg/m'/day, with 
myelosuppression (in particular neutropenia) as the dose limiting toxicity [18]. Two randomised 
studies on single agent topotecan suggested that the oral formulation is equipotent to the 
intravenous formulation in patients with ovarian- and small cell lung cancer, whilst associated 
with less grade 3 and 4 neutropenia [19,20]. Recently, a phase I study combining oral topotecan 
(T) given for 5 days every 3 weeks with cisplatin (C) at 75 mg/m' on day I (sequence CT) or day 
5 (sequence TC) was completed [10]. In congruency with the results of the study by Rowinsky 
with i.v. topotecan [6J, the maximum tolerated dose (MTD) for topotecan in the CT sequence of 
, . , 
1.25 mg/m Iday x 5 was considerably lower than that for the alternate sequence (2.00 mg/m Iday 
x 5). Cisplatin was not observed to have an effect on the pharmacokinetics oftopotecan[lO]. 
Finally, topotecan systemic exposure was directly associated with anti tumour activity in ill 
vivo studies [21]. Given this apparent relationship between topotecan systemic exposure and 
clinical response, we tried to increase the topotecan dose in the combination cisplatin-oral 
topotecan by using a lower cisplatin dose. We performed a phase I study in patients with solid 
tumours with oral topotecan preceded by a fixed dose ofi.v. cisplatin at 50 mgtn? 
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PATIENTS AND METIIODS 
Patient selection 
Patients with a histologically or cytologically confirmed diagnosis of a malignant solid 
tumour refractory to standard forms of therapy. or for whom no better option than cisplatin~ 
topotecan was available, were eligible. Other eligibility criteria included the following: age 
between 18·75 years; Eastern Cooperative Oncology Group performance status::; 2; no previous 
anticancer therapy for at least 4 weeks (6 weeks for nitrosoureas or mitomycin C); no previous 
therapy with topoisomerase I inhibitors; and adequate hematopoietic (absolute neutrophil count 
(ANC) " 1.5 x 1O'lL and platelet count" I 00 x lO'IL), renal (creatinine clearance" 60 mLimin) 
and hepatic (total serum bilirubin:; 1.25 x upper normal limit and serum ASAT and ALAT:; 2.0 
x upper normal limits, in case of liver metastasis: semm ASAT and ALAT::; 3.0 x upper normal 
limits) function. Specific exclusion criteria included the existence of gross ascites andlor any 
gastrointestinal condition that would alter drug absorption. The study protocol was approved by 
the institutional ethics board. All patients gave written informed consent before study entry. 
Dosage and dose escalation 
Escalating doses of oral topotecan were administered on day 1 M5, every 21 days preceded by a 
fixed dose of 50 mg/m2 cisplatin administered intravenously over 3Mh given on day 1. The 
starting dose oftopotecan was 1.50 mg/m2/day, which is 120% of the recommended dose for the 
combination with cisplatin at 75 mg/m2 given day 1 in the same drug sequence [10]. Dose 
escalation was based on the prior dose level toxicities. At least 3 patients were treated at each 
dose level. If I of 3 patients experienced dose limiting toxicity (DLT), 3 additional patients were 
entered at that dose level. The maximulTIMtolerated dose (MTD) was defined as one dose level 
below the dose that induced DLTs in 3 out of 6 patients during the first course. DLTs were 
defined as NCI-CTC version 1994 grade 4 neutropenia lasting for 5 days or more, or 
complicated with fever requiring hospitalisation, grade 4 thrombocytopenia andlor 11011-
hematological toxicity;:: grade 3 (grade 2 for renal toxicity), excluding nausea. Intrapatient dose 
escalation was not permitted. If a patient encountered DLT, the dose of topotecal1 was decreased 
one dose level at retreatment. The treatment was resumed when the neutrophil count had 
recovered to ;:: 1.0 x 109/L and the platelet cOllnt to ;:: 100 x 1091L. A maximum of 6 cycles was 
administered to each patient. 
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Dl1Jg administration 
All patients received cisplatin as a 3-h infusion diluted in 250 mL of hypertonic saline [3% 
(w/v) sodium chloride] on day I, immediately followed by the oral administration oftopotecan, 
which was given for five consecutive days on an empty stomach, at least 10 min before meals. 
Pre-medication consisted of ondansetron (8 mg i.v.) combined with dexamethasone (10 mg 
i.v.) administered 30 min before the start of the cisplatin infusion. The administration of 
cisplatin was preceded by infusion of I L of a mixture of 5% (w/v) dextrose and 0.9% (w/v) 
sodium chloride over 4 h, and followed by another 3 L with the addition of 20 mM potassium 
chloride and 2 gil magnesium sulphate applied over 16 h. Topotecan capsules containing either 
0.25 or 1.00 mg of the active compound were supplied by SmithKline Beecham 
Pharmaceuticals (Harlow, UK). Cispiatin (platosin) was purchased as a powder from 
Pharmachemie (Haarlem, The Netherlands). 
Treatment assessment and phal'macokinetic data analysis 
Treatment assessment and blood sampling was performed as described in the previous study [10]. 
Blood samples for phannacokinetic analysis were taken at the following time points: for cisplatin 
before infusion; at I, 2, and 3 h after start o(the infusion; and at 0.5, ( 2, 3, 4, and 18 h after tile end 
of the infusion, and for topotecan prior to dosing; and at 0.5, I, 1.5,2,3,4,6,8 and 12 hours after 
administration of top ate can. 
Samples for topotecan kinetics were analysed by a validated reversed-phase high-perfonnance 
liquid chromatographic method, that allowed simultaneous detennination of the lactone and the 
hydrolysed ring-opened carboxylate fomls, as described [22] with minor modifications [10]. Non-
protein bound and total cisplatin concentrations in plasma were detennined by a validated analytical 
procedure based on measurement of platinum atoms by flameless atomic-absorption spectrometry 
[23]. 
Individual plasma concentrations of top ate can were fit to a one- or two-compartment model, using 
the sofhvare package Siphar v4.0 (SIMED, Creteil, France). The concentration-time profiles were 
obtained after zero-order input, with weighted least-squares analysis applying a weighting factor of 
lIy. Standard noncompartmental analysis of these data \vas also conducted. The topotecan area under 
the plasma concentration-time curve (AUCO-lNF) was determined for both the lactone (AUC(L» and 
carboxylate forms (AUC(C). The apparent plasma clearance (CUftL» of topotecan lactone was 
calculated by dividing the dose administered by the observed AUe. The temlinal disposition half-life 
[Tw(z)] of to po tee an was calculated as In21k, where k is the rate constant of the terminal disposition 
phase (expressed in h-l). The peak plasma concentrations (C",,-,) and the time to peak plasma 
concentration (TII11.x) were detemlined graphically from the (observed) experimental values. The ratio 
of the systemic exposure of topotecan lactone to total drug (Lff ratio) \vas defined as 
~UC(L![AUC(L)+AUCtC)]. 
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Model dependent pharmacokinetic analysis of CDOP was conducted similarJy using a two-
compartment linear model with extended least-squares regression analysis as rcported earlier 
[10]. The noncompartmental analysis was also conducted in the same fashion, and AUCO·INFS of 
unbound and total cisplatin were calculated to the last sampling time point with detectable dmg 
levels (Cl~t) by the linear trapezoid method and extended to infinity by addition of CiuJk,,=, 
where kterrn is the slope obtained by log-linear regression of the final plasma concentration 
values. 
Table 1: Patients characteristics 
Characteristic 
Age, years 
Median 
Range 
Sex 
Female 
Male 
Performance status 
Median 
Range 
Tumour type 
Carcinoma of unknown primary 
Mesothelioma 
Non-small cell lung cancer 
HeadlNeck 
HeadlNeck+NSCLC 
Cervical 
Colon 
Previous therapy 
Chemotherapy 
Radiation 
Chemotherapy and radiation 
None 
56 
38-74 
I 
0-2 
108 
No. of patients 
4 
8 
4 
2 
2 
I 
2 
I 
3 
6 
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Statistical considerations 
Phamlacokinetic parameters for all compounds are reported as mean values ± S.D. The difference in 
phannacokinetic parameters was evaluated statistically using a Student's t~test and a Friedman's two~ 
way analysis of variance test. Probability values (two-sided) of less than 0.05 were regarded as 
statistically significant All calculations were perfomled using the statistical package NCSS version 
5.x (JL Hintze, Kaysville, UT, 1992). 
RESULTS 
Twelve patients (8 males, 4 females) entered this study between March and September 1999. 
Patient characteristics are listed in Table 1. All patients were eligible, II patients were 
assessable for toxicity (I patient died due to a suspected pulmonary embolism on day II) and 10 
patients were assessable for response (I patient stopped treatment after one course at her own 
request and refused CT -evaluation). The majority of patients had mild symptoms. Fifty percent 
of patients, equally distributed over both dose levels, had received prior chemo- and/or 
radiotherapy_ Overall, all patients were un- or minimally pretreated and in good clinical 
condition. The patient population was thus comparable to the 'highly selected' group of patients 
at the recommended dose level of topotecan 1.25 mg/m2/day on day 1-5 in combination with 
cisplatin 75 mg/m 2 on day I in our previous study [10). Dose levels oftopotecan studied were 
1.50 and 1.75 mg/m2/day. The total number of assessable courses was 43, with a median number 
of courses per patient of 4 (range 1-6). 
Gastrointestinal toxicity and myelosuppression were the principle DLTs of this regimen. 
Three patients, treated at dose level 1.75, required dose reductions after experiencing DLT, and 
I patient even had a second dose reduction to 1.25 mg/m2/day. 
Hematological toxicity 
Hematological toxicity observed during all courses is shown in Table 2a. Neutropenia was 
the main hematological toxicity. The percentage of courses associated with grade 3 or 4 
neutropenia (no DLTs) and grade 3 or 4 thrombocytopenia at the topotecan dose level of 1.50 
mg/m2 was respectively, 36% and 9%, and 32% for grade 1 or 2 thrombocytopenia. At the next 
dose level of topotecan 1.75 mg/m2, grade 3 or 4 neutropenia occurred in 50% of courses, 
associated with grade 3 or 4 thrombocytopenia in 11 % of courses. Grade I or 2 
thrombocytopenia was observed in 22% of courses. At this dose level, 2 patients were judged as 
having experienced DLT: I had grade 4 neutropenia lasting for more than 5 days and 1 had 
neutropenic fever and grade 4 thrombocytopenia. The patients who had their topotecan dose 
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reduced due to hematological toxicity had a much higher incidence of grade 3-4 hematological 
toxicity in subsequent courses compared to patients who were initially treated at a lower dose 
level. All of these patients had had prior chemo- and/or radiotherapy. The percentage decrease in 
leukocyte, neutrophil and platelet count during the first course in 10 patients (l patient was 
inassessable for toxicity and I patient did not have all blood samples taken exactly according to 
the protocol) is shown in Table 2b. The median day of onset of neutropenia during the first 
course was relatively late (day 18, range 14-21) as compared to topateean single agent data, in 
contrary to thrombocytopenia nadir which occurred after an interval similar to the one of single 
agent nadir (day 14, range 12-18). An example of hematological pharmacodynamic-time profiles 
from 2 patients receiving topotecan at either 1.50 or 1.75 mg/m2/day x 5 is shown in Fig 1. 
Table 2a: Hematological toxicity (worst per cycle) 
Topotecan No. of Neutropenra Thrombocytopenia 
2 
mglm /day pts/cycles 3 4 3 4 
1.50 6116 2 0 0 
1.75 6118 3 6 
1.50 3/6 0 5 0 2 
(after dose reduction) 
1.25 113 0 3 2 
(after dose reduction) 
Table 2b: Absolute hematological toxicity during course I 
Topotecan No NadirWBC Nadir ANC Nadir platelets 
2 
mglm /day pts day % decrease day % decrease day %decrease 
1.50 5 18±3 74±16 19±2 84±ll 15±3 62±20 
1.75 5 15±1 83±13 16±2 93±10 13±1 83±6.9 
Abbreviations: WBC, while blood cell count; ANC, absolute neutrophil eount 
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Overall, at the recommended dose of topotecan 1.50 mg/m2 on day 1~5, hematological 
toxicity was acceptable with 4 chemo- andlor radiotherapy pretreated patients experiencing 
neutropenia grade 4 for less than 5 days and grade 3-4 thrombocytopenia in only 2 of the 22 
courses. Three patients with grade 2 anemia received blood transfusions. Only I course had to 
be delayed at this dose level for hematological reasons. Patients starting at the second dose level 
oftopotecan 1.75 mg/m2 and requiring dose reduction due to hematological toxicity were prone 
to have hematological toxicity at the lower dose levels. These patients accounted for 63% of all 
grade 3 or 4 neutropenia's at this dose level, and for all grade 3 or 4 thrombocytopenia's. 
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Fig 1: An example of hematological pharmacodynamic~time profiles from 2 patients receiving 
topotecan at either 1.50 (open circles) or 1.75 (closed circles) mg/m'/day x 5. 
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Non-hematological toxicity 
Fatigue and gastrointestinal toxicity were the most frequently reported non-hematological 
side-effects (data shown in Table 3). One patient treated with topotecan 1.50 mg/m2 experienced 
grade 3 diarrhea in the first course, which was considered DLT as defined according to the 
protocol. The diarrhea occurred on day 7 and resolved within one day with loperamide 
treatment, therefore topateean dose was not reduced. The patient had no diarrhea in the second 
course. On the next dose level of to po tee an at 1.75 mg/m2, 3 out of6 patients experienced DLT, 
1 had grade 3 mucositis and vomiting, 1 had grade 3 diarrhea and was treated with loperamide 
from day 14-16 (this patient also had grade 4 neutropenia lasting for more than 5 days), and 1 
had diarrhea grade 3 on day 12 (and neutropenic fever). One extensively pretreated patient with 
progressive metastatic colon cancer died 11 days after the first administration of cisplatin and 
topotecan, presumably due to a pulmonary embolism, which was not considered related to the 
treatment. Since the patient died at home, the clinical diagnosis was not confirmed by additional 
investigations. 
Other side effects were alopecia (grade 1 or 2 in 50% of patients) and peripheral 
neurotoxicity (grade 1 or 2 in 16% patients). No nephrotoxicity other than grade 1 was 
encountered. 
Overall, non-hematological toxicity at the recommended dose level was infrequent. Other 
than the patient described with grade 3 diarrhea on day 7, who had grade 3 nausea in the second 
course, no toxicity graded> 2 was observed. 
Table3: Non-hematologia!l toxicity (worst per cycle) 
Topotecan No. Nausea Vomiting Diarrhea Fatigue 
2 ptslcycles 2 3 1 2 3 1 2 3 1 2 3 mg/m Iday 1 
1.50 6116 5 2 2 0 0 9 0 0 
1.75 6/18 6 4 2 5 3 2 6 2 0 
1.50 3/6 2 0 0 0 0 0 0 0 0 
(after dose reduction) 
1.25 1/3 0 0 0 0 0 0 0 0 0 0 0 
(after dose reduction) 
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AntitumoUl' activity 
One patient with a mesothelioma achieved a partial response, which is currently still ongoing 
after course 6. Another patient with pulmonary metastases of a head and neck tumour and a 
simultaneous secondary primary non-small cell lung cancer also achieved a partial response, 
which was not confirmed since she had radiotherapy for consolidation of the response. Six 
patients showed disease stabilisation. Two patients were not evaluable for response, including 
the one patient that presumably died due to a pulmonary embolism. 
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Fig 2: Average plasma concentration-time curves of (A) topotecan lactone and (B) unbound 
cisplatin (CDDP) in 6 patients on day I at the recommended dose level of topotecan at 
2 1.50 mglm , 
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Topott:can and cisplatin pharmacokinetics 
Pharmacokinetic analysis was performed on data obtained from II out of 12 patients III 
course I and in 1 patient also in course 6. Table 4 and 5 list the main pharmacokinetic 
parameters of the two drugs with topateean given at L50 or 1.75 mglm2/day x 5 in combination 
with a fixed dose of cisplatin 50 mg/m2 day every 3 weeks. The average plasma concentration-
time curves of to po tee an lactone and unbound cisplatin on day 1 at the recommended dose level 
of to po tee an at 1.50 mg/m2 are presented in Fig 2. 
Table 4: Summary of to po tee an lactone pharmacokinetics of course 1 day 1 
(data present mean values ± SD) 
Cm" (ng/mL) 
Tm" (h) 
AVC (ng.h/mL) 
CLlf(Llh/m') 
ty,t,) (h) 
LIT ratio 
, 
Topotecan (mg/m /day) 
1.50 (F6) 1.75 (n~5) 
3.42 ± 1.36 5.08 ± 3.52 
2.61 ± 2.12 2.59 ± 2.14 
17.0 ± 6.83 24.6 ± 4.68 
109± 65.8 73.5 ± 14.4 
3.53 ± 1.18 3.23 ± 1.24 
0.38 ± 0.034 0.42 ± 0.058 
p 
0.31 
0.99 
0.065 
0.27 
0.69 
0.19 
Abbreviations: C",u, peak plasma leyel; T mu, time to maximum concentration; AUC, area under the plasma concentratio-time 
curve; cJ)r, apparent clearance; t%(L), half-life of the terminal disposition phase; LIT ratio, topotcc-8n lactone to total drug AUC 
ratio_ 
The apparent clearance (CLlt) of the pharmacologically active topotecan lactone and the 
lactone to total dmg, AVe ratio (LIT ratio) were not dependent on dose and were similar to 
previous reported values obtained from studies where topotecan was administered as a single 
agent [18J. The interpatient variability in AVC was 40% at 1.50 mg/m' and 19% at 1.75 mg/m'-
The apparent clearance of topotecan (Cllt) on days I, 2 and 5 averaged 93.1±5I.0 (FII), 
8I.0±30.8 (n~9) and 76.7±14.4 Llh/m' (n~9), and were not significantly different (P ~ 0.20, 
Friedman's two way analysis of variance test), suggesting that topotecan does not accumulate 
following multiple dosing (Fig 3). All data were consistent with a dose-independent and linear 
behavior of topotecan. 
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Table 5: Summary of ciplatin pharmacokinetics of course 1 
(data present mean values ± SD) 
Topotecan (mg/m'/day) 
1.50 (n~6) 1.75 (n~5) 
Cisplatin total 
Cm" (~lg/mL) 1.87±0.197 1.93 ± 0.318 
AUC (~g.h/mL) 25.2± 3.55 23.2±4.86 
CL (mLimin) 65.3 ± 11.5 72.1 ± 24.5 
tl/'e,) (h) 58.4 ± 32.2 34.6± 16.5 
Cisplatin unbound 
Cm" (~lglmL) 0.55 ± 0.087 0.62±0.13 
AUC (~lg.h/mL) 1.35 ± 0.271 1.51 ± 0.305 
CL(mLimin) 1221 ± 192.9 1068 ± 184.9 
me,) (h) 0.77 ± 0.29 0.52 ± 0.11 
p 
0.71 
0.45 
0.56 
0.17 
0.31 
0.38 
0.21 
0.10 
ema~, peak plasma level; AUe, area under the plasma concenlralion·lime curve; CL, clearance; tv,,(l), half· life of the 
terminal disposition phase. 
The effect of the topotecan dose on the pharmacokinetics of total and unbound cisplatin in 
plasma during the first treatment course is shown in Table 5. Cisplatin clearance was not 
effected by concomitant administration of topotecan dose, with mean values of 65.3 and 72.1 
mL/min when given in combination with 1.50 and 1.75 mglm2/day oftopotecan, respectively. 
Pliarmacokinetic data for topotecan and cisplatin obtained during the sixth treatment course 
in one patient were similar to the first course, indicating no alteration in topotecan and cisplatin 
pharmacokinetics, topotecan CLif on 3 separate days was 159±65.4 nglh/m' and 168±14.0 
nglh/m2, during the first and sixth course, respectively. Overall, pharmacokinetics of both 
compounds were dose independent and similar to single agent data [18]. 
DISCUSSION 
The combination of i.v. cisplatin and oral topotecan is attractive given their broad anti~ 
tumour activity, preclinical synergism, their different toxicity profiles and patient's preference of 
oral chemotherapy (when at least equally effective). In all phase I studies combining cisplatin 
and topotecan, the topotecan dose at MTD was considerately reduced as compared to single 
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agent topateean regimens. Since preclinical studies suggest existence of a topotecan systemic 
exposure-response relationship. and while clinical studies in topotecan-sensitive tumour types 
still have to confirm this issue, we tried to increase the topotecan dose by decreasing the 
cispiatin dose to 50 mg!nt Although cisplatin at this dose is effective in combination regimens 
in non-small-cell lung cancer [24] and ovarian cancer [25J, a reduced cisplatin dose is 
considered to be related with a loss of response and survival in, for example, ovarian cancer 
[26]. 
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Fig. 3: The apparent clearance (CLI!) of to po tee an lactone obtained on the first, second and fifth 
administration day in the first course of respectively 11, 9 and 9 patie'fits treated with 
cisplatin 50 mg/m' on day I and topotecan 1.50 or 1.75 mg/m'/d on days 1-5. Data 
represent mean values (bars) ± standard deviation (error bars). 
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In the present phase I study both myelosuppression and gastrointestinal toxicity were dose 
limiting in 3 out of 6 patients treated with topotecan at 1.75 mg/m2 administered on day 1-5 
every 3 weeks, preceded by Lv. cisplatin 50 mg/m2 on day 1. Other toxicities such as 
nephrotoxicity, neurotoxicity, fatigue and alopecia were mild and infrequent. All patients who 
were treated at the 1.75 dose level and had their topotecan dose reduced due to dose limiting 
toxicity, had prior chemo- and/or radiotherapy. and experienced significant hematological 
toxicity at the lower dose levels, while the 6 patients who were initially treated at the 
recommended dose level of topotecan 1.50 mg/m2 experienced less toxicity. Despite the late 
onset of the neutrophil nadir, compared to single agent data, only one course was delayed at the 
l.50 mg/m2 dose level. No other important toxicity was encountered at this dose level, except 
for one patient experiencing grade 3 diarrhea for one day only and grade 3 nausea. 
The observed pharmacokinetic parameters of the lactone and the carboxylate form of 
topotecan demonstrated linear and dose independent behavior over the total dose range studied 
and were similar to data obtained from studies oftopotecan administered orally as a single agent. 
Furthermore, topotecan dose had no influence on"the unbound fraction of cisplatin, as suggested 
previously [I OJ. 
In conclusion, the MTD of lopotecan is 1.50 mg/m' on day 1-5, preceded by cisplalin 50 
mg/m2 on day 1. This regimen seems to have no advantage as compared to our previous 
recommended schedule of topotecan 1.25 mg/m2, preceded by cisplatin 75 mg/m2 in a similar 
patient population [10], since the dose reduction of 33% of cisplatin only allows a minor dose 
escalation oftopotecan. 
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ABSTRACT 
Two sensitive reversed-phase high-performance liquid chromatographic fluorescence 
methods, with simple sample handling at the site of the patient, are described for the 
determination of the lactone and lactone plus carboxylate forms of 9-al11inocamptothecin (9-
AC). For 9-AC lactone, the sample preparation was a liquid-liquid extraction with acetonitrile-
Il-bulylchloride (1:4, v/v), whereas the sample preparation for 9-AC total (lactone plus 
carboxylate) was a simple deproteinization with 5% perchloric acid-methanol (1:1, v/v), which 
results in the conversion of the carboxylate into the lactone form. The lower limits of 
quanti tat ion were 50 pg/ml and 100 pg/ml for 9-AC lactone and 9-AC total, respectively. The 
within-run precisions at four tested concentrations were :::;6.3% for 9-AC lactone and :::;5.3% for 
9-AC total. The between-run precisions were s;.8.9% and :::;:5.6%, respectively. The assays were 
developed to enable pharmacological analysis of9-AC in a bioavailability and oral Phase I study 
in patients with solid tumors. 
INTRODUCTION 
20(S)-Camptothecin (CPT; NSC 94600) (fig. 1) is a cytotoxic plant alkaloid, that was first 
extracted from the wood and bark of the oriental tree Camptotheca aCliminata, Decaisne 
(Nyssaceae) [1,2). In spite of promising antitumor activity ill vitro and in animal tumor models, 
severe toxicity, including diarrhea and dose-limiting myelosuppression precluded further 
clinical testing (reviewed in [3]). After the identification of DNA topoisomerase I as the 
molecular target of CPT [4,5), interest in new structure development was accelerated, with 
various derivatives of CPT (semi)synthesized to enhance the aqueous solubility. Two 
compounds of this type, viz. topotecan and irinotecan are currently undergoing clinical 
evaluation and have shown impressive antitumor activity [6]. Another derivative that is not 
soluble in water, 9-amino-20(S)-camptothecin (9-AC; NSC 603071; fig. 1) was recently also 
introduced into clinical trials because of its unprecedented antitumor activity against solid tumor 
xenografts [7,8J. 
Pharmacokinetic studies of the camptothecins, including 9-AC, are complicated by a 
chemical, pH-dependent instability of the lactone ring (fig. I) [9J, generating an open-ring 
carboxylate, which is over lOOO-fold less active as an inhibitor of DNA topoisomerase I [10). 
The importance of this nonenzymatic hydrolysis reaction of the lactone moiety in the 
pharmacology and toxicology of 9-AC is largely unknown. To address this question, 
development of analytical methodologies enabling the quantitation of both forms are required. 
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Various authors recently described assays for the determination of 9-AC lactone andlor total 
drug levels (lactone plus carboxylate; 9-AC total) applicable to plasma samples obtained from 
patients [11-13]. Major drawbacks of these procedures are the necessity for immediate analysis 
by high-performance liquid chromatography (HPLC), postcolumn acidification andlor laborious 
solid-phase extraction techniques. 
We now describe novel assays for the analysis of 9-AC lactone and 9-AC total in human 
plasma, which only require a one-step solvent extraction for sample clean-up prior to reversed-
phase HPLC with fluorescence detection. The presented methods have been thoroughly 
validated in terms of accuracy and precision, and are now successfully implemented- in studies 
on the pharmacology of9-AC in patients with solid tumors. 
pH 
Lactone Conn Carboxylate Conn 
Fig. 1: Chemical structures and pH-dependent interconversion of the lactone and carboxylate 
forms of9-AC (R~NH2) and CPT (R~H). 
EXPERIMENTAL 
Chemicals and reagents 
9-AC (lot #93L07A, containing the base with a purity of 100%) and CPT (lot #93K05A, 
containing the base with a purity of 100%) were obtained from Pharmacia Inc. (New Mexico, 
USA). Methanol, acetonitrile (both HPLC-grade), dimethyl sulfoxide (DMSO) and 11-
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butylchloride (both analytical grade) were purchased from Rathburn (Walkerburn, Scotland). 
Perchloric acid (70-72%, vlv; analytical grade) was obtained from Baker (Deventer, The 
Netherlands). The water was filtered and deionized with a Milli-Q-UF system (lvlilford, USA) 
and was used in all aqueous solutions. DmgMfree human plasma originated from healthy donors 
and was delivered by the Central Laboratory of the Blood Transfusion Service (Amsterdam, The 
Netherlands). 
Stock solutions and standards 
Separate stock solutions of9-AC and CPT were made by dissolving 10.0 mg of9-AC or CPT 
in 10.00 ml of DMSO. A vc:>Iume of 5.00 ml of these solutions was accurately transferred to 50 
Illl volumetric flasks and diluted to the mark with DMSO, resulting in solutions containing 
100,000 ngfml of9-AC or CPT, respectively. Working solutions of9-AC lactone were prepared 
daily by serial dilution in a mixture of methanol-water-perchloric acid (500:500:1, vlvlv) from 
the primary stock solution. Similarly, working solutions of 9-AC total were made in methanol-
water (1: 1, v/v). Spiked plasma samples used as calibrations standards were prepared daily by 
addition of 50 J..l1 of the working solutions to 950 III of drug-free human plasma, resulting in 
calibration standards of 50, 100,500, JOOO, 1500 and 2000 pgfml for 9-AC lactone and of 100, 
200, 1000, 5000, 10000, 15000 pgfml for 9-AC total. 
Four pools of quality control (QC) samples were prepared in human plasma in the 
concentrations of 250, 900,1600 and 150000 pgfml for 9-AC lactone and of 500,7500,12500 
and 250000 pgfml for 9-AC total. The QC samples containing the highest concentrations were 
used as diluted control and/or for low volume injection. To minimize differences in the 
composition between clinical and QC samples, also the carboxylate form of 9-AC was added to 
the QC samples of 9-AC lactone. The 9-AC carboxylate was spiked at the same concentrations 
as 9-AC lactone and was prepared by adding 9-AC in methanol-water (1:1, v/v) to plasma, 
followed by incubation at 37°C for 20 hrs. 
Sample preparation for the lactone form of9-AC 
To 1000 ~I of human plasma a volume of 100 ~I of 2.5 ngfml of CPT in methanol-water-
perchloric acid (500:500:1, vlvlv) and 0.8 g ofNaCI were added in a glass tube supplied with 
PTFE-covered screw caps. For the extraction, 7.5 ml of acetonitrile-n-butylchloride (I :4, v/v) 
was added and the sample was vortex-mixed for 5 min, which resulted in the formation of a gel. 
Subsequently, the sample was centrifuged for 2 min at 4000 x g at ambient temperature. The 
sample was shaken once to break the gel and centrifuged for 5 min at 4000 x g. The supernatant 
was collected in a glass tube containing 50 ~tl of DMSO and evaporated at 50aC under a gentle 
stream of nitrogen, until a residue of approximately 50 jll was left over. To the residue, 50 l.tI of 
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methanol and I 50 ~I of perchloric acid-water (1 :500, vlv) was added. The sample was 
transferred to a low volume insert of glass, and a volume of ISO jll was injected into the HPLC 
system. 
Sample p .. eparation fo .. total 9-AC 
A volume of 250 ~I of 5% perchloric acid-methanol (I: I, vlv) was added to 250 ~I of human 
plasma in 1.5 ml polypropylene-microcentrifuge tubes, followed by vortex-mixing for 10 min. 
Subsequently, the sample was centrifuged for 5 min at 24,000 x g at ambient temperature. The 
clear supernatant was transferred to a low volume insert of glass and 200 jll were injected into 
the HPLC system. 
Chromatographic system 
The HPLC system consisted ofa constaMetric 3200 pump from LDC Analytical, a subsidiary 
of Thermo Instruments Systems Inc. (Riviera Beach, USA). The samples were injected by a 
Waters 717plus autosampler (division of Millipore, Milford, USA). A fluoriMonitor 4100 
fluorescence detector from LDC Analytical was used for the detection. Chromatographic 
separations were achieved on a Inertsil ODS-80A column (150 ' 4.6 mm ID, 5~m particle size) 
from GL Science Inc. (Tokyo, Japan), protected by a Lichrospher 100 RP-18 endcapped guard 
column (4 ' 4 mm ID, 5 ~m particle size) obtained from Merck (Darmstadt, Germany). 
For the assay of the lactone form of 9-AC in plasma, the mobile phase was a mixture of 
methanol-water (40:60, vlv). The pH was adjusted to 2.20 by addition of perchloric acid. The 
mobile phase for the assay of9-AC total in plasma was composed of methanol-water (32.5:67.5, 
v/v), with the pH adjusted to 2.10 using perchloric acid. The mobile phases were degassed by 
ultrasonication and were delivered at a flow rate set at 1.00 ml/min for both assays. The column 
was maintained at 40°C, also for both assays, using a model SpH99 column oven (Spark 
Holland, MeppeJ, The Netherlands), and the eluents were monitored at an excitation wavelength 
of370 nm and an emission wavelength of 450 nm, with a bandwidth of 40 nm. 
Calibmtion 
Acquisition and integration of chromatographic data was performed with the Chrom-Card 
data analysis system (Fisons, Milan, Italy) running on an IC\\' workstation. Calibration curves 
were made by linear regression analysis of peak heights versus l/concentration using the 
software package Lotus 2.4 (Lotus Development Corporations, New York, NY, USA). 
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Validation 
For the validation of the assays of 9-AC lactone and 9-AC total in plasma, the six-points 
calibration curves were processed in duplicate and analyzed on four occasions with the lower 
limit of quanti tat ion (LLQ) and the QC samples in quintuplicate. For the determination of the 
LLQ, plasma samples of five independent individuals were taken and spiked to contain 50 pg/ml 
for 9-AC lactone and 100 pg/ml for 9-AC total. For the concentration accepted as the LLQ, the 
percent deviation of at least 80% of the samples assayed should be .:5:20%. The average within-
run and between-nm precision (expressed as the coefficient of variation (%CV) for each 
concentration, excluding the LLQ, should be " 15% and should be " 20% for the LLQ. The 
average accuracy (%) for each concentration, including the LLQ, should be within 85-115% of 
the nomuinal values. 
The absolute recoveries were calculated on the basis of the concentrations of the calibration 
curves. For 9-AC lactone the peak heights of processed plasma samples were compared with the 
peak heights of two samples with a concentration equivalent to 1000 pg/ml 9-AC and 250 pg/ml 
CPT in plasma extracts with 100% recovery. For this purpose, 50 ~I of 20 ng/ml of 9-AC and 
100 ~I of 2.5 ng/ml of CPT in methanol-water-perchloric acid (500:500:1, v/v/v) were 
evaporated in a tube containing 50 III ofDM~O, and were dissolved as plasma extracts. For 9-
AC total, the peak heights of processed pla~ma samples were compared with the peak heights of 
two samples with a concentration equal to 5000 pglml of9-AC in plasma extracts with 100% 
recovery; 25 ~I of 100 ng/ml of9-AC in methanol-water (1:1, v/v) was added to 975 III blank 
plasma extract. 
The stability of 9-AC total was tested by incubation of the four QC samples at 37°C for 20 
hours and during 3 freeze-thaw cycles. At the freeze-thaw cycles the QC samples were put at 
room temperature for 1 hour before freezing again. The stability of9-AC lactone was only tested 
during three quick freeze-thaw cycles. The samples were thawed quickly in cold water and 
restored at -80°C within 5 to 10 min. The long term stability of 9-AC total and 9-AC lactone at -
80°C was also tested at the concentrations of the QC samples. 
The following potentially co-administered drugs were tested for interference with the 
analytical methods: Paracetamol at a concentration of 0.50 mglml; aiizapride, codeine, 
dompeddon, morphine and ranitidine at a concentration of 0.1 a mg/ml; and dexamethason and 
metoclopramide at concentrations of 0.05 and 0.01 mg/ml, respectively. 
Human experiments 
To demonstrate the applicability of the analytical methods, blood samples from a patient 
were collected at 0, 20 and 40 min, and at I, 1.5,2,3,5, 11,24,28,31,35,48,52 and 55 hrs 
after oral administration of 2.7 mg of 9-AC. Immediately after sampling, the blood was 
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centrifuged, at the site of the patient, for 5 minutes at 3000 x g at 4°C. The plasma was collected 
and directly placed on dry-ice at -20°C. Within a few hours the samples were stored at -80°C. 
A II B II 
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Fig. 2: Chromatograms of a blank human plasma sample containing 250 pglml of CPT, used as 
internal standard (Aj, and a human plasma sample containing 171 pglml of9-AC and 250 
pglml of CPT (Bj in the assay for 9-AC lactone. Peaks I and II correspond to 9-AC and 
CPT, respectively. 
RESULTS AND DISCUSSION 
Calibration curves of the lactone and total (lactone plus carboxylate) forms of 9-AC in human 
plasma were linear in the range of 50 to 2000 pglml and 100 to 15000 pglml, respectively. The 
regression correlation coefficients were ;:::0.992 for 9-AC lactone and ;;::0.997 for 9-AC total, by 
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using weighted (l/concentration) linear least~squares regression analysis to prevent domination 
of the highest concentrations. Intercept values of the standard curves for both 9~AC lactone and 
9~AC total were not significantly different from zerO by Student's I-test (P>0.05). The retention 
times of9-AC and CPT in the assay of the lactone form were 7.5 and 22 min (fig. 2), while the 
retention time of 9~AC in the assay of 9~AC total was 12.5 min (fig. 3), with overall 
chromatographic run times of 30 and 20 min, respectively. The selectivity for the analytes is 
shown by the sharp resolution of the peaks and no significant interfering peaks for both assays in 
blank plasma samples from five independent donors. All the tested potentially co~administered 
drugs did not give interfering peaks for 9-AC and CPT in the assay for 9-AC lactone, and for 9-
AC in the assay for the 9-AC total. 
Table 1: The mean accuracy, the mean within~run precision and the between-nm precision of the 
QC samples (n~5) in human plasma of9-AC lactone. 
QC-sample accuracy (%) precision (%) 
(pgiml) (mean) within~run (mean) between~run 
250 101.6 1.0 3.5 
900 91.5 2.4 2.9 
1600 90.3 1.7 5.2 
150000 98.9 4.1 8.9 
The LLQ for 9-AC in the assays for the lactone and total form were 50 and 100 pglml, 
respectively. The lower value of the LLQ for the determination of the lactone was a 
consequence of concentration of the sample as compared to dilution of the sample in the assay 
for 9~AC total. The extraction recoveries of 9-AC and CPT in the assay for 9~AC lactone were 
78.2 ± 7.98% and 92.4 ± 7.96%, and the recovery for 9-AC in the total assay was found to be 
89.6 ± 6.87%. In both assays, extraction recoveries were independent of the spiked 
concentration. The within~run precisions of the LLQ samples of 9~AC lactone and 9~AC total 
were ~4.2% and :::;10.2%, respectively. The range of accuracy for 9~AC lactone was 95.6% to 
112.0%. For 9~AC total, the accuracy ranged from 95.2% to 107.6%. The average accuracy in 
both assays showed values ranging within 10% of the nominal values (Tables 1 and 2). The 
average within~run and between~run precisions for 9~AC lactone and 9~AC total in human 
plasma varied upto 5.5% and 8.6%, respectively (Tables 1 and 2). 
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9-AC total was found to be stable for 20 hours at 37'C, and during three freeze-thaw cycles. 
However, 9-AC lactone was not stable during three quick freeze-thaw cycles; there was a loss of 
the amount of 9-AC lactone of approximately 10% in comparison with the mean of a set of QC 
samples analyzed at the same time. This instability necessitates quick freezing of the samples 
after blood sampling in order to stabilize the ratio between 9-AC lactone and 9-AC carboxylate. 
9-AC total and lactone forms were stable for at least 4 months when stored at -80°C (data not 
shown). 
A B I 
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Retention time (min) 
Fig. 3: Chromatograms of a blank human plasma sample (A), and a IO-fold dilute human plasma 
sample containing 89 264 PWml of9-AC (8) in the assay for 9-AC total. The peak labeled I 
corresponds to 9-AC 
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Table 2: The mean accuracy. the mean within-mn precision and the between-run precision of the 
QC samples (n~5) in human plasma of9-AC total. 
QC-sample accuracy (%) precision (%) 
(pg/ml) (mean) within-run (mean) between-nm 
500 102.6 2.5 3.6 
7500 103.1 1.4 5.6 
12500 103.5 1.5 5.0 
250000 98.4 2.4 2.2 
100000 
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Fig. 4: Plasma concentration-time curves of9-AC lactone (triangles) and 9-AC total (circles) in 
a patient after oral administration of 2.7 mg of 9-AC. The dotted line indicates the lower 
limit of quantitation for 9-AC lactone. Both curves were fitted to a two-compartment 
model using the MWlPharm software package (Medi-Ware Graningen, Netherlands). 
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Plasma collected ITom a patient prior to the drug administration did not reveal the presence of 
endogenous peaks. Concentrations of 9-AC lactone could be readily estimated from protein-free 
extracts, whereas acidification of plasma samples, re-converting the carboxylate into the 
corresponding lactone, enabled detemlination of 9-AC total. The plasma concentration-time curves 
of9-AC lactone and 9-AC total fonns ofa patient treated orally with 2.7 mg of9-AC, are given in fig. 
4. The data indicate that the LLQ's of 50 and 100 pglml for 9-AC lactone and 9-AC total, 
respectively, are sufficient for monitoring dmg-plasma levels in samples obtained from patients 
treated at low ora I doses. 
In conclusion, two sensitive, selective, accurate and reproducible isocratic reversed-phase 
HPLC methods have been developed for the analysis of9-AC lactone and 9-AC total in human 
plasma. The sample pretreatment procedures are based on single solvent extractions, thereby 
eliminating the need of laborious solid-phase extraction techniques [12,13]. Compared to 
previously described assays for 9-AC, our new methods provide equivalent to superior 
sensitivity with LLQ's of 50 pglml for 9-AC lactone and 100 pglml for 9-AC total (lactone plus 
carboxylate). The methodologies described permit the analysis of patient samples, and will be 
implemented in future investigations on the clinical pharmacology of9-AC administered at low 
(oral) doses. 
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ABSTRACT 
9-Amino-20(S)-camptothecin (9-AC) is a water-insoluble topoisomerase-I inhibitor with evident 
schedule-dependent antitumor activity in preclinical studies. The pharmacokinetic behavior of 9-AC 
given as a bolus Lv. infusion (1.0 mg/m2 over 5 min) was recently characterized in 12 patients in a 
bioavalability study. Remarkable rebound concentrations of 9-AC total drug (i.e. lactone pIlls 
carboxylate fenTIs) were observed at about 2-3 hours after dosing. In vitro experiments indicated that 
this phenomenon was associated with a substantial uptake of 9-AC lactone by erythrocytes 
immediately after dosing, and its subsequent release followed by accumulation of 9-AC carboxylate 
in the plasma compartment mediated by a pH-dependent hydrolysis of the lactone foml, which is 
unable to diffuse across cell membranes. The preferential binding of 9-AC carboxylate to human 
semm albumin shifts the equilibrium between the lactone and carboxylate fonns of 9-AC to the 
phannacological inactive carboxylate fonn. 
INTRODUCTION 
9-Amino-20(SJ-camptothecin (9-AC, NSC 603071) is a semisynthetic derivative of the naturally 
occurring plant alkaloid camptothecin that does not produce hemorrhagic cystitis associated with the 
parent compound [1]. The mechanism of action of9-AC is based on inhibition of to poi some rase-I, an 
intranuclear enzyme which relaxes supercoiled DNA by creating single strand DNA breaks which are 
subsequently religated [2J. In preclinical studies, 9-AC demonstrated significant activity, (including 
cures) in mice xenografted with human carcinomas resistant to common antineoplastic agents [3]. 
These animal studies further demonstrated that dmg efficacy is critically dependent on the duration of 
exposure, frequency of administration and plasma levels of the drug. On the basis of these data, 
severnl clinical trials have been perfonned with the dmg administered using various continuous i.v. 
infusion schedules [4-9]. Currently, there is considerable interest to explore alternative routes and 
schedules of9-AC administration, e.g. oral [1O-12J or daily i.v. bolus administration [13J, to facilitate 
the development of more prolonged dosing that may be required to optimize antitumor activity. 
Phannacokinetic studies with camptothecin analogues, including 9-AC, were previously shown to 
be complicated by a chemical, pH-dependent instability of the terulinal a-hydroxy-o-Iactone ring 
(Fig. I), generating a ring-opened carboxylate, which is over IOOO-fold less active as an inhibitor of 
topoisomerase-I [14]. The clinical pharmacokinetics of9-AC has been studied extensively in patients 
receiving the drug by i.v. infusion over 24 or 72 hours [4,5,7,9,15]. These studies showed that only 
about 10% of the total plasma 9-AC circulated in the active lactone fonn, which is considerably 
lower than that reported for topotecan [16J and the irinotecan metabolite SN-38 [17]. It has been 
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suggested, that this is related to differential affinity of the carboxylate fonns of camptothecins for 
human serum albumin, causing a shift in the equilibrium hydrolysis within the systemic circulation 
[I8J. 
Recently, we reported the phannacokinetics of 9-AC lactone and carboxylate after bolus i.v. 
administration in 12 cancer patients participating in a bioavailability study [19]. In the present work, 
we evaluate the kinetic profile of the total 9-AC concentration, revealing a new feature of 9-AC 
disposition in hUmans, which is characterized by a significant rebound peak in the plasma profile. 
The role of erythrocytes and senlln proteins in the kinetic profile of total 9-AC is described in this 
report. 
NIl, NH, 
pll OH 
0-
Lactone form Carboxylate form 
Fig. 1: Chemical structures and pH-dependent interconversion of the lactone and carboxylate fonns 
of9-aminocamptothecin. 
MATERIALS AND METHODS 
Chemicals and reagents 
Pure reference standards of 9-AC (batch: 93L07 A) and camptothecin (batch: 93K05A were 
provided by Phannacia & Upjohn (Milan, Italy). Perchloric acid was obtained from Baker (Deventer, 
The Netherlands) as a 70% (v/v) aqueous solution. Human and murine serum albumin were 
purchased as essentially fatty acid free lyophilized powders from Sigma Chemicals Co. (St. Louis, 
MO, USA). All other reagents were of analytical grade or higher, and originated from Rathburn 
(Walkerbum, UK). Samples of human plasma and whole blood were obtained from healthy 
volunteers. HPLC grade water was prepared in-house using the Milli-Q UF Plus system from 
Millipore (Bedford, MA USA). 
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Clinical pharmacokinetics 
The pharrnacokinetic profiles of Ute lactone and carboxylate forms of 9-AC after bolus i.v. 
administration were previously described by Sparreboom et al [19]. Briefly. 12 patients enrolled in a 
bioavalability study in which they received the lactone form as a single Lv. bolus of 1.0 mg/m2. 
Quantitative detemlination of the lactone and total drug concentrations were performed in serial 
plasma samples obtained uptD 55 h after dosing using a reversed-phase HPLC method as described 
earlier by Loos et al [20]. 
III vitro stability of9-AC 
The rate of hydrolysis of9-AC lactone was monitored in PBS, 4% (w/v) solutions of human and 
murine serum albumin in saline, and in heparinized human whole blood. All matrices were incubated 
in triplicate with 1.0 ~giml of9-AC lactone at 37'C, and 250-Ill santples were taken at 0, 0.5, 1,2,4, 
7.5, and 24 h after start of the incubation. The samples were diluted 25 to SO-fold in a pool of drug-
free human plasma and analyzed for the intact 9-AC lactone and 9-AC total fomts by HPLC as 
described by Loos et al. [20]. 
In a separate series of experiments, extracellular 9-AC total concentration-time profiles were 
monitored in samples of human whole blood, erythrocyte-rich PBS, a leukocyte bullY coat 
suspension, and platelet-rich plasma. Platelet-rich plasma with vel)' little contamination from 
erythrocytes and leukocytes was prepared by centrifugation at 200xg for 20 min at room temperature 
[21]. Kinetic nms were initiated by addition of 9-AC lactone at 37°C to provide an initial 
concentration of 100 ng/mI. AJiquots were withdrawn periodically, processed to cell free samples by 
centrifugation at IS,OOOxg for 2 min (4'C), and analyzed by HPLC as described above. 
Accumulation of9-AC in cell cultures. 
The human ovarian and colon carcinoma cell lines IGROV-I and WIDR, and the non-malignant 
African green monkey kidney cell line VERO were cultured in Dulbecco's modified Eagle's Medium 
(DMEM; GibcoBRL, Life Teclmologies S.V, Breda, The NeUteriands), supplemented with 10% of 
heat-inactivated fetal calf semm (Hycione, Logan, UT), 10 ruM of sodium carbonate, 2 ruM of L-
glutamine, 100 Vlml of penicillin and 100 Ilgiml of streptomycin (Life Technologies) in a humidified 
atmosphere of5% C02 at 37°C. AJI cell lines were grown to 80 to 90% confluence in 6-well culture 
plates (Greiner, Alphen aid Rijn, The Netherlands), and incubated in triplicate with 1.0 Ilgiml of9-
AC lactone or 9-AC carboxylate for 10 min. The cells were washed rapidly three times with ice-cold 
saline, and harvested by scraping in sao ~ of water. An aliquot of2S0 ~I was used for determination 
of9-AC total drug concentrations by HPLC, and 1 0 ~I were used for the determination of the total 
protein content by a modification oflhe Bradford dye-binding method [22]. 
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RESULTS 
Clinical pharmacokinetics 
As described earlier [I9J, the plasma concentration-time profiles of the lactone and carboxylate 
fonns of9-AC were remarkably similar for the 12 patients studied, with a very short initial half-life 
time orthe lactonefonn of approximately 6.5 min. The overall estimated lactone to total drug ratio in 
plasma was 9.1±3.4%, indicating a rapid and substantial conversion to the carboxylate species. 
Evaluation of the plasma profile of total 9-AC (i.e. lactone plus carboxylate) revealed a very 
pronounced secondary peak in all 12 patients, with a maximum of the total occurring at 2-3 hours 
after dmg administration (Fig. 2). 
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Fig, 2: Representative plasma concentration-time profile of9-AC lactone (0), carboxylate (0) and 
total drug (i.e. lactone plus carboxylate fonns;"') in a single patient after i.v. drug 
administration of 1.0 mg/m2 
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In vitro studies 
In order to gain insight into the pharmacologic mechanisms involved in this rebound peak 
phenomenon, various ill vitro stability studies of 9~AC were perfonned. Equilibrium distribution 
ratios for accumulation of9-AC into erythrocytes were found to change dramatically with time for 9-
AC lactone concentrations in the therapeutically relevant range of 0.1 to 1.0 J.lglml (Fig. 3). 
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Fig. 3: Extracellular concentration·time profiles of 9·AC lactone lactone (0) and 9·AC total drug 
(A) following incubation of9·AC lactone at 100 nglml in human whole blood. The closed 
circle on the ordinate indicates the initial 9-AC total extracellular concentration estimate, 
based on a hematocrit of 0.45. 
Under the same experimental conditions, there \vas no substantial drug accumulation in human 
platelets or peripheral leukocytes that may have affected the kinetic behavior of 9-AC (total drug) in 
human plasma (data not shown). Measurement of extracellular 9~AC total drug following incubation 
of 9~AC lactone in human whole blood demonstrated a rapid fall in concentration, caused by drug 
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accumulation in erythrocytes, followed by a continuous rise until an apparent steady state was 
established at approximately 2-3 hours (Fig. 3), similar to that observed in our patients. At steady-
state, the 9-AC (total drug) plasma to erythrocyte concentration ratio was estimated to be about 100: I. 
This result can be understood by considering that tile large fraction of9-AC lactone taken up initially 
into erythrocytes (-25-30%) will redistribute to the plasma water, followed by dissociation of the 
lactone moiety due to the physiologic pH and the presence of serum proteins (Table I). Under ill 
vilro conditions in PBS, 1O.7±0.4% of9-AC was in the lactone form at equilibrium. The addition of 
human serum albumin, however, was found to further shift the lactone to carboxylate equilibrium 
dramatically in favor of the latter due to a higher affinity of the carboxylate fonn, with less than 1 % of 
total drug remaining as lactone. In whole blood, 0.8±O.2% of 9-AC was in the lactone foml at 
equilibrium, which is not significantly different from human serum albumin solution and human 
plasma The fact that only the intact lactone foml of9-AC can diffuse across cell membranes further 
contributed to the subsequent accumulation of the carboxylate species (Table 2). Drug accumulation 
in the various cell lines tested after incubation with the carboxylate fonn was only approximately 5% 
in comparison with the accumulation during exposure to the lactone fonn. However, the cellular 
accumulation is seriously influenced by the lactone-carboxylate interconversion during incubation, as 
only 3.5±O.l5% (mean±SD) of extracellular carboxylate is converted into lactone after 10 min at 
37"C, compared to 38.2±2.07% of lactone into carboxylate. 
Table 1: Stability of9-AC lactone at equilibrium in various mediaa 
Matrix 
Phosphate buffered saline 
Human serum albumin 
Murine serum albumin 
Human whole blood 
Human plasma 
tIl2
b 
(min) 
25.8±0.31 
37.9±1.9 
244±17.5 
23.6±O.4S 
12.2±D.72 
%as lactone 
at equilibrium 
1O.7±0.42 
0.63±0.10 
35.0±6.2 
O.SI±O.21 
l.3±O.50 
pH 
7.4 
7.0 
7.0 
7.4 
7.4 
a: All matrices were incubated in triplicate \\ilh 1.0 Ilgfml of9·AC lactone at 37~C, \\ith serial samples taken upto 24 h. 
b: Abbreviation: 1If1. half·life. 
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Table 2: Cellulair accumulation of9-AC lactone and 9-AC carboxylate in various celilinesa 
CeHline 
IGROV-I 
VERO 
W!DR 
9-AC lactone 
(ngiml protein) 
29.9 ± 1.97 
22.3 ± 1.65 
32.S± 1.08 
9-AC carboxylate ClLb 
(ngiml protein) (%) 
1.5 ± 0.24 5.1 
1.2 ± 0.30 SA 
1.8 ± 0.10 5.5 
a: All cell lines were incubated in triplicate with 1.0 Jlgfml of9-AC lactone or 9·AC carbox)'lalc for 10 min at 37~C. 
b: Carbox)'latc to lactone concentration ratio 
DISCUSSION 
Recently we have described the pharmacokinetics of9-AC in a cohort of patients that received the 
drug by bolus i.v. administration [19]. The lactone hydrolysis was rapid with greater than 90% 
conversion to the phamlacoiogically inactive, ring-opened carboxylate form within 3 hours following 
a 5-min infusion, which is similar to earlier findings [5,15]. The pharmacokinetic profile of 9-AC 
total dnlg (this report) was characterized by the presence of a major secondary peak, and was shown 
to be caused by an unusual mechanism involving initial uptake of 9-AC lactone in erythrocytes, 
followed by the progressive accumulation of the carboxylate fonn of the drug in plasma. 
Phamlacokinetic studies perfonned during clinical trials of 9-AC administered as a continuous i.v. 
infusion have consistently failed to recognize this behavior [4,5,7,9,15]. This can be explained by the 
fact that the frequency of sampling during the first several hours after infusion was not only less 
intensive, but the steady state levels of total drug at the maximum tolerated dose were more than 10-
fold lower than the peak levels in the present report. 
The rate of uptake of9-AC lactone by erythrocytes ill vitro was too rapid to be reliably estimated, 
with an initial uptake half-life in the order of 30 s or less from phosphate buffered saline (to a 
hematocrit of ~0.45) or human whole blood. This indicates that the rate of exchange between red 
cells and plasma water is sufficiently rapid to be effectively instantaneous on the time scale of 
disposition of 9-AC. However, the rate of 9-AC lactone uptake in vivo is clearly influenced by the 
extensive binding of 9-AC carboxylate to proteins, principally serum albumin, causing a gradual 
depletion of dmg available for cellular distribution. Thus, the apparent contmdiction between the 
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high plasma to blood cell concentration ratio of9-AC total dmg and tlle high initial accumulation of 
the lactone fonn into erythrocytes is due to a compensating effect of protein binding of the 
carboxylate fonn following hydrolysis of the a-hydroxy-8-lactone function, thereby trapping the drug 
in the plasma compartment. The net effect is presumably that early after drug dosing, erythrocytes act 
as a depot from which the plasma 9-AC lactone is supplied, followed by accumulation of the 9-AC 
carboxylate in plasma. \Vhile we did not test this hypothesis directly, our ill vivo data would appear to 
support this notion. In particular, our finding that 9-AC carboxylate did not diffuse across cell 
membranes is consistent with the significantly reduced volume of distribution for this species in ~ur 
patients [19}, and suggests a preferential cellular uptake of the lactone accompanied by accelerating 
predominance of the carboxylate in plasma. 
Previous studies indicated that this unusual disposition feature may not be unique for 9-AC, as this 
rebound phenomenon has also been described for the related compound, irinotecan. The initial 
observation of this behavior was described by Rivory et al. [17], and similar data have been generated 
from numerous patients treated with irinotecan, although the authors sunnized that it might be related 
to enterohepatic recirculation [23-25]. However, the observation of rebound concentrations of 
irinotecan and its metabolite SN-38 are not as distinct as those seen with 9-AC in the present study, 
and are apparently only observed with the drug administered to patients using short i.v. infusion 
schedules (i.e. :0:;;30 min). This is probably because drug concentrations will often not be significant at 
low plasma concentrations to ascertain the secondary peak, and it is only as the plasma concentration 
increases locally, e.g. following an i.v. bolus injection, that erythrocytes carry a physiologically 
relevant load [26]. In case of SN-38, the situation is also complicated by the occurrence of 
enterohepatic cycling following biliary secretion of the hydrophilic CI0-glucuronic acid conjugate, 
which is hydrolyzed by bacterial p-glucuronidase in the intestines [27]. Another possible explanation 
for the discrepancy between camptothecins in the rebound phenomenon may come from the 
differences in protein binding of the lactone and carboxylate species for the different camptothecins. 
It has been described previously that the binding affinity of both drug fonus for human semm 
albumin is an important detenninant in the marked differences in the lactone to carboxylate ratios 
between drugs [18]. For 9-AC and the parent drug camptothecin, serum protein binding of the 
carboxylate fonn is highly favored over the closed ring foml, and an equilibrium favoring the 
carboxylate fornl is rapidly established. In case of 9-AC, this is probably the main reason for the 
extremely low lactone to total drug AUC ratio (i.e. <10%). For topotecan, irinotecan and SN-38 these 
ratios are 36%, 38% and 53%, respectively [16,17]. Therefore, it is reasonable to assume that similar 
effects will be less pronounced in case of topotecan and irinotecan. The absence of the secondary 
peak in the 9-AC total plasma profile in rodents [28] most likely also relates to differences in lactone 
to carboxylate ratios compared to humans; at equilibrium, the amount of 9-AC remaining in the 
lactone fonn in human plasma is IJO±0.50%, whereas in mouse plasma or murine serum albumin 
solution, approximately 35% is present as the lactone form (Table 1). 
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In conclusion, we have shown that a major rebound peak in the plasma profile of 9-AC arises as 
the result of a balance between extensive erythrocyte uptake of the lactone foml and extensive serum 
protein binding of the carboxylate fonn within the systemic circulation, resulting in a shift in 
equilibrium over time. These data support the idea that 9-AC is an exceptionally dynamic drug in 
biological systems, with its pharmacokinetic profile influenced strongly by hydrolytic processes as 
well as by differential cellular distribution and protein binding of the lactone and carboxylate fomls. 
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ABSTRACT 
Objective To study the pharmacokinetics and pharmacodynamics of the novel topoisomerase I 
inhibitor and antitumor agent, 9-amino-20(S)-camptothecin (9-AC), in patients with solid 
tumors after repeated oral dosing. 
Methods Thirty-two cancer patients received oral 9-AC formulated in capsules with polyethylene 
glycol-IOOO as excipient at doses that ranged from 0.25 to 1.5 mgfm'/day. Serial plasma and saliva 
samples were obtained on days 1 and 6 or 8 of the first cycle and analyzed fur the lactone and 
carboxylate forms of9-AC by HPLC. 
Results 9-AC demonstrated linear and dose-independent phannacokinetics, with extremely small 
intrapatient kinetic variability (coefficient of variation: <10%). However, interpatient variability in 
plasma pharmacokinetics was large (coefficient of variation: 99%). The relative extent oflactone to 
carboxylate intcrconversion was large (>90%), and predictable from individual pretreatment semm 
albumin values (p=O.0099). The 9-AC concentration ratio in plasma and saliva was strongly patient 
dependent, and highly variable around a mean value of 1.4 , suggesting that saliva is an unreliable 
matrix for kinetic monitoring. The area under the curve of the lactone fonn of9-AC was significantly 
correlated with the dose-limiting hematological toxicity (p<0.001). 
Conclusion Our data indicate that the large interindividual phannacodynamic variability in response 
to 9-AC is mainly caused by a variability in kinetic characteristics, suggesting that a kinetic-dynamic 
guided study design is warranted in future clinic.al investigations. 
INTRODUCTION 
In the early 1 970s, camptothecin, a plant alkaloid extract from the bark and wood of the Chinese 
tree Camplotheca aCllmil1ala, was demonstrated to possess antineoplastic activity [l]. Analogs of 
camptothecin belong to a family of anticancer agents with a unique mechanism of action, which is 
based on reversible inhibition of DNA topoisomerase 1[2,3). 
Despite the cytotoxicity of the compound further development was halted because of a number of 
severe and unpredictable side-effects observed in early clinical trials [4-6]. The subsequent search for 
less toxic analogs of camptothecin resulted in the discovery of irinotecan, topotecan, 9-amino-20(S)-
camptothecin (9-AC), 9-nitrocamptotllecin, DX-8951f and GIl47211. The first two of these, 
irinotecan and topotecan, were recently registered for the treatment of colorectal and ovarian cancer, 
respectively. 
In aqueous solutions, camptothecins are unstable and undergo a rapid, pH-dependent, non-
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enzymatic hydrolysis of the tenninal lactone ring to fonn the more water-soluble, ring-opened 
carboxylate fonn (Fig. I) [7]. The presence of the intact tenninal lactone ring is tllOught to be 
essential for the topoisomerase I inhibition [8]. The closed lactone ring predominates at acidic pH, 
whereas in human plasma, the equilibrium between these two species greatly favors fonnation of the 
carboxylate fonn, partly because of the physiologic pH and the preferentially binding of this fonn to 
albumin [9, I 0]. The ratio of the lactone fonn to the total dmg concentmtion at steady state in plasma 
is different for each camptothecin analog, which might have important phannacokinetic and 
phannacodynamic implications. 
In preclinical studies 9-AC demonstrated activity against human colon, breast, prostate, non-small 
cell lung cancer and melanoma xenografts 11-14]. Preclinical ill vivo data suggested that duration of 
exposure to 9-AC lactone above a certain threshold concentration (10 nM) and frequency of 
administration were essential for antitumor activity [15,16]. 
Based on its preclinical activity, 9-AC appeared to merit evaluation as an antineoplastic agent To 
mimic the preclinical studies, initial Phase I studies using the intravenous fonnulation of 9-AC 
focused on schedules with prolonged infusion duration of 24-120 hr [17-2lJ, or a continuous 
infusion for 21 days every 4 weeks [22]. Phannacokinetic data obtained during these studies showed 
marked interpatient variability. Steady state plasma concentrations of 9-AC lactone greater than 10 
nM were achieved only in the Phase I study of the 24-itour infusion of 9-AC at the dose 
recommended for further Phase II studies (i.e. 1.65 m&,m'). When 9-AC was administered as a 72-hr 
infhsion once every 2 or 3 weeks, the maximal tolerated dose was 35-54.2 ~lglnbhr. The dose 
limiting toxicity consisted of neutropenia in combination with thrombocytopenia and correlated to 
the steady state 9-AC lactone concentration. 
NI!, 
pH 
Lactone form 
NH, 
OH 
0-
H3CH2C/- OH 0 
Carboxylate form 
Fig. 1: Chemical structures and pH-dependent interconversion of the lactone and carboxylate fomls 
of9-aminocamptothecin. 
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Recently, we reported that 9~AC demonstrated rapid absorption in humans after oral delivery with 
an overall bioavailability of approximately 50% [23]. In the present report, we present a 
comprehensive analysis ofthe plasma phannacokinetics of the lactone and carboxylate forms of9~AC 
in cancer patients receiving the dmg orally over a wide range of dose levels, with special focus on 
phannacokinetic·phannacodynamic characteristics. In order to· assess the clinical usefulness of 
salivary monitoring of 9~AC for kinetic modeling, paired plasma and coinciding unstimulated saliva 
samples were collected in a limited number of patients. 
MATERIALS AND METHODS 
Patient population 
The patients, from whom -phamlacokinetic curves were obtained, participated in an oral 
bioavailability study of 9-AC andlor in a Phase I trial of oral 9-AC administered daily for 7-14 
consecutive days every 3 weeks. Treatment plans and detailed clinical profiles have been 
documented elsewhere [23]. Eligibility criteria included a histologically or cytologically confirmed 
diagnosis of a solid malignant tumor not amenable to established forms of treatment All patients had 
an adequate hematopoietic (absolute peripheral granocyte count ;:::2.0 x 109/L and platelet count ;:::100 
x 109 IL), hepatic (bilimbin within nonnal limits. and semm aspartate aminotransferase, alanine 
aminotransferase and alkaline phosphatase.::;2.5 times nonnallimit) and renal (semm creatinine <133 
liM) function. Other eligibility criteria included the following: age between 18 and 75 years; Eastern 
Cooperative Oncology Group perfonnance status $:2; estimated life expectancy ;:::12 weeks~ no 
previous anticancer therapy for at least 4 weeks (6 weeks for nitrosoureas or mitomycins); no 
previous therapy with other camptothecins and/or intensive ablative regimens. Specific exclusion 
criteria included significant gastrointestinal dysfunction that could alter absorption or motility, and 
chronic treatment with corticosteroids. Concomitant administration of H2~antagonists, antacids, 
proton~pump inhibitors and non~steroidal anti~inflanlmatory dmgs were avoided. All patients gave 
written infoffiled consent before study entry. 
Treatment plan and dose escalation 
The oral fonnulation of 9-AC was supplied by Pharmacia & Upjohn (Nerviano, Italy) as hard 
gelatin capsules that contained 0.10, 0.25 or I mg of the active drug and polyethylene glycol-1000 
(pEGIOOO) as excipient [23], and were stored at room temperature. 
A detailed description of the preparation and rationale for composition of the formulation has been 
described earlier [23J. Patients received 9-AC orally \Vitll 150-200 mL of water at dose levels of 0.25, 
0.40,0.60,0.84, 1.0 or l.l mg/m'/day for 7 or 14 consecutive days, or as a single dose of 1.5 mg/m2 
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Intrapatient dose escalation in the phase I trial was not permitted. Weekly evaluation of the patients 
included a clinical history, physical examination, toxicity assessment according to common toxicity 
criteria (eTC), and semm chemistry. A complete blood cell count with differentiation was 
determined twice weekly. 
Sample collection and d11lg analysis 
Serial blood samples were collected in heparinized tubes ITom an indwelling venous catheter at 0, 
0.33,0.67, I, 1.5,2,3, 5,7.5, II and 24 hours after administration on days I and 6 or 8 of the first 
treatment course. In a limited number of patients, unstimulated saliva samples were obtained at 
coinciding time points. In one patient with a malignant pleural effusion additional pleural fluid 
sampling was perfoffiled to assess the influence of the pleural effusion on the plasma 
phamlacokinetics. Immediately after sampling, aliquots of plasma (separated at 4°C), pleural fluid 
and saliva were frozen at -80°C, and analyzed later for 9-AC lactone and 9-AC total dmg (i.e. lactone 
pillS carboxylate) with use of a validated reversed-phase high-performance liquid chromatographic 
method as described previously [24]. Dmg concentrations in patient plasma samples were calculated 
using interpolation of the corresponding regression analysis. Specimens with dmg levels exceeding 
the upper range of the calibration curve were reanalyzed upon appropriate dilution with drug-free 
plasma. Saliva and pleural fluid sanlples were diluted 4-fold in drug-free plasma and analyzed with 
use of the same analytical assay, with minor modifications. The lower limits of detection of the assays 
were 0.05 ng/mL in plasma and 0.4 ng/mL in pleural fluid and saliva. 
Data analysis 
Plasma-concentration data were analyzed by both non-compartmental and compartmental analysis 
using the Siphar version 4.0 software package (SIMED, Cr"teil, France). The model-independent 
pharmacokinetic parameters included the maximum plasma concentration (Cnu.x) and the time to 
reach the peak concentration (tnu.x). Initial parameter estimates were obtained by an automated peeling 
algorithm based on the Powell method to three compartments, which yielded the best statistical fit as 
detennined by Akaike's information criterion and the F·test. The AVe values were calculated based 
on the best fitted curve, as were the disposition half·lives (fin). The apparent absorption rate constant 
(1<,) was obtained through numerical point-area deconvolution. Relationships between the AVC and 
phannacodynamic outcome were evaluated with (log-)linear and (non-)sigmoidal-maximum effect 
modeling using Siphar and NCSS version 5.0 (DrJerry Hintze, East KayesviIle, UT)Within 
individual patients, myelosuppression was described as the continuous variable, consisting of 
percentage decrease in white blood ceIl count (WBC), absolute neutrophil count (ANC) and platelet 
count (PLT). The relative hematological toxicity was defined as : % decrease = {pretherapy value-
nadir value)l(pretherapy value)*1 00. Only the first course of each patient was taken into consideration 
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to avoid potentially confounding bias due to cumulative toxicity. All data were fitted to a sigmoidal 
maximum effect (E""x) model based on the modified Hill equation, as follows: 
E~Eo+Enu,*[(KP~/(KP(+KP5o~]. In this equation, Eo is the minimum reduction possible, fixed at a 
value of 0, Ema.x is the maximum response, fixed at 100, KP is the pharmacokinetic parameter of 
interest, KP50 the value of the pharmacokinetic parameter predicted to result in half of the maximum 
response, and y is the Hill constant describing the sigmoidicity of the curve. Models were evaluated 
for goodness of fit by minimisation of sums of the squared residuals and by reduction of the estimated 
coeffkient of variation for fitted parameters. Significance of the relationships were assessed by 
constnlction of contingency tables with subsequent l analysis. 
Table 1: Patient characteristics 
Characteristic 
No. entered 
No. assessable for toxicity 
Age, years 
Sex 
Median 
Range 
Female 
Male 
Perfonnance status 
Median 
Range 
Tumor type 
Colorectal 
Ovarian 
Sarcoma 
Mesothelioma 
Lung (non-small cell) 
Miscellaneous 
Previous treatment 
Chemotherapy 
Radiation 
Chemotherapy and radiation 
None 
No. of patients 
32 
30 
59 
29-74 
14 
16 
I 
0-2 
14 
5 
2 
2 
2 
5 
16 
2 
10 
2 
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RESULTS 
Demographic characteristics of all 32 patients who had blood sampling for phamlacokinetic 
analysis are shown in Table 1 Ten patients completed the oral bioavailability study and subsequently 
participated in the phase I and phannacokinetic study of oral 9-AC. Hence, phannacokinetic data 
were obtained in 42 courses. Plasma phannacokinetics could not be determined in 1 course on day I 
and in 2 courses on day 8 as a result of limited sample availability or significant chromatographic 
interference in the drug assay by an unknown compound. Twenty-seven patients were assessable for 
phamlacodynamic analysis and 30 patients were assessable for toxicity. 
r--. 
100 
'§ 
M 
10 1=1 
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0 
.-1;j 1 ~ 1/ ~ V 
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Time (h) 
Fig. 2: Representative concentration-time profiles of 9-AC lactone (circles) and 9-AC total 
(triangles) in plasma and in saliva (rectangle) measured on day 1 (open symbols) and day 8 
(closed symbols) of the first treatment course in a single patient following oral administration 
of 9-AC at a dose level of 0.84 mglm'/day in a daily-times fourteen schedule. All 
pharmacokinetic curves were fitted to a tri·exponential equation assuming a three-
compartment modal for the distribution and elimination of the drug. 
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The plasma concentration-time profiles of9-AC lactone and 9-AC carboxylate were similar for all 
patients studied, with representative examples shown in Fig. 2. The phannacokinetics of both species 
of 9-AC could be best described with a three-compartment model. The kinetic parameters obtained 
by means of this model are presented in Tables II and ID. The absorption of 9-AC lactone after oral 
administration was rapid with a lag time of 0.29±0.07 hr (mean ± SD; 11=11), maximum peak drug 
levels at 0.99±O.l2 hr, and a mean absorption rate constant of 3.03±O.90 III In the first plasma 
samples the ring-opened carboxylate fonn of 9-AC was already detectable. Maximal plasma 
concentrations of9-AC carboxylate were reached at 2AI±O.64 hr after dosing. Eventually, the 9-AC 
carboxylate accounted for 91.1±2.l1% of 9-AC total dnlg concentrations, indicating a clear 
predominant conversion of lactone to carboxylate. Elimination of 9-AC from the central plasma 
compartment was characterized by a decay in an apparent tri-exponential manner based on 
conventional compartment modeling using weighed least-squares analysis with a weighting factor of 
I/Y. The mean values for the linear segments of 9-AC lactone were lin (a): 0.26 hr (range, 0.13-0.38 
hr), tln(p): 0.78 hr (range, 0.54-1.13 hr) and lin(y): 7A7 hr (rauge, 3.66-12.6 hr). No significant 
quantitative differences were observed between the decay kinetics of 9-AC lactone and 9-AC 
carboxylate. 
Table 2: Model-dependent pharmacokinetics of9-AClac after oral drug administration of9-AC. 
Dose (mg/m2/day) 0.25 OAO 0.60 0.84 
11 6 3 4 6 
k, (1/h) ND ND ND ND 
tl" (h) 0.33±0.13 0.32±0.05 038±0.14 0.28±0.05 
tm" (h) 1.06±0.35 0.79±0.15 0.94±0.11 0.98±0.27 
Cm" (ng/mL) 2.09±0.82 7.94±739 3.43±0.60 4.6l±1.51 
tV2(a) (h) 0.25±0.20 O.13±O.ll 0.23±0.07 0.24±0.1l 
t",(P) (h) 0.68±OAO 0.82±033 0.54±0.20 0.73±033 
tV2(Y) (h) 5.22±4.22 8.65±1.25 3.66±0.55 103±6.77 
AUCo.~ day I (ng.h/mL) 6.88±4.76 16.2±14.5 8.15±0.76 12.9±3.97 
AUCo.~ day 8 (ng.h/mL) 9.48±3.85 17.4±15.5 8.69±0.70 1l.7±2.98 
intra %CY of AUC 731 731 4.44 9.74 
inter %CY of AUC 69.2 89.5 89.2 30.7 
% of9-ACtota! AVC 7.18±2.33 12.9±4.20 8.76±3.49 6.98±1.72 
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The kinetic data and recorded AUe values for the following days of administration were similar to 
those achieved the first day in the same patient (Tables 2 and 3). Hence, the resulting intrapatient 
variability in AUC and peak drug levels, expressed as the coefficient of variation, was extremely 
small and averaged 8.67% for 9-AC lactone and 10.9% for 9-AC carboxylate. The interpatient 
variability in the observed phannacokinetics, however, was large, with coemcients of variation in 
AVC values as high as 89.S% for 9-AC lactone and 99.0% for 9-AC alrboxylate. 
Over the total dose range studied, 9-AC lactone and 9-AC total demonstrated ·Iinear and dose-
independent pham13cokinetics (Figs. 3A and B, respectively). No significant relationship was 
observed between the AVCs of 9-AC total and that of the pharmacologically active species, 9-AC 
lactone (not shown). The interpatient variation in the equilibrium ratio of 9-AC lactone and 9-AC 
carboxylate could be explained in part by a individual differences in pretreatment serum albumin 
levels, for which a significant correlation with the AVC ratio of9-AC lactone and 9-AC alrboxylate 
could be demonstrated (1=0.471, jFO.0099). This finding clearly indicates that separate monitoring 
of 9-AC lactone and 9-AC carboxylate concentrations is mandatory to relate drug levels to 
phannacodynamic outcome in patients treated with oraI9-AC. 
1.0 1.1 I.S 
7 3 12 
ND ND 3.03±0.90 
0.29±0.OS O.17±0.13 0.24±0.13 
0.99±0.29 1.00±0.01 1.17±0.33 
11.0±7.46 12.2±6.9S 6.82±2.98 
0.24±0.09 0.36±0.07 0.38±0.21 
0.76±0.SI 0.82±0.16 1.13±0.S9 
S.10±2.68 6.76±2.26 12.6±4.20 
31.2±19.1 49.3±29.7 31.9±14.3 
31.2±27.0 48.S±23.8 ND 
4.96 6.48 ND AbbreViations: II, number of patients; k., absorption rate 
61.1 60.3 44.S constant; 'hi, lag lime; b, lime 10 peak plasma levels; c'" .... ~, maximum plasma I.:onccntrations; tIl2(i), half-life of 
10.2±4.94 8.67±3.22 7.30±3.22 the Hh disposition phase; AUC, area under the plasma 
concentration Wrslis time curve; CV, coet11cicnt of 
variation. 
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Table 3: Model-dependent pharmacokinetics of9-ACm after oral dmg administration of9-AC. 
Dose (mg/m'/day) 0.25 0040 0.60 0.84 
II 6 3 4 6 
11,. (h) 0.41±0.20 0.34±0.04 O.39±0.13 0.31±0.02 
tmax (h) 2.60±1.l9 2.20±0.601.6 3±0.23 2.01±0.49 
Cm" (ng/mL) 9.43±3.50 11.8±5.76 14.5±6.93 15.2±4.88 
hl2(u) (h) 0.55±0.50 0.40±0.30 0.20±0.20 0.18±0.26 
tll2(P) (h) I. 78±0.67 1.l2±0.44 1.00±O.69 1.07±0.55 
tw(y) (h) 7.50±3.96 6.59±2.82 4.98±1.74 9.61±3.73 
AUCo.~ day I (ng.hlmL) 90.8±48.2 89.0±49,4 102±45.1 I 74±39,4 
AUCo·oo day 8 (ng.h!mL) 177±127 137±105 83.9±34.1 162±36.3 
intra %CY of AUC 13.9 27.7 1.63 8.52 
inter %CY of AUC 53.1 55.5 44.3 22.6 
% of9-ACtola! AUe 92.8±2.33 87.1±4.20 9L2±3.49 93.0±1.72 
Salivary dmg monitoring was evaluated as an option for determining the AVe of 9-AC lactone. 
The 9-AC lactone concentration ratio in plasma and unstimulated saliva was strongly patient-
dependent and highly variable around a mean value of -1.4, suggesting that saliva is an unreliable 
matrix for phannacokinetic analysis of this dmg (Fig. 2). 
To determine the impact of a pleural effusion on the phannacokinetics of 9-AC, plasma and 
pleural effusion samples were obtained for dmg analysis in a single patient with a malignant pleural 
effusion. The mean pleura versus plasma concentration ratio of9-AC lactone was 4.95%±2.32 (mean 
± SD; range, O.7~6.8%).These data indicate that pleural effusion does not constitute a major 
pharmacokinetic compartment for this dmg. 
The phamlacokinetic data obtained from 27 patients were plotted against the percentage decrease 
in white blood cell cOllnt (WEC). platelet cOllnt (PLT) and absolute neutrophil COllnt (ANC). at nadir 
relative to the pretreatm~nt value. Four different models, based on linear, log~linear, maximum effect 
(Enn,). and sigmoidal Enn, fitting. were compared for their ability to describe the data. Using 
sigmoidal Enu." modeling of the phannacokinetic and hematological toxicity data significant 
correlations between the AUC of 9-AC lactone and the percentage decrease in WEC (1=0.86; 
p<O.OO I ; Fig. 4A). percentage decrease in PLT (1=0.83; p<O. 00 I; Fig. 48) and percentage decrease in 
ANC (/=0.66; p<O.OOl; Fig. 4C) could be demonstrated. In addition. the worst observed 
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myelotoxicity grade according to conmlon toxicity criteria (CTC) in the entire patient population 
correlated with the AVC of9-AC lactone (1=0.93; 1'<0.001; not shown). The development of any 
myelotoxicity grade 2 or worse was associated with an AVC of9-AC lactone ~17.3 ng*h1mL, using 
the Hill equation and data shown in Fig. 3B. Phammcokineticlphannacodynamic relationships based 
on (log-)Iinear and non-sigmoidal Emax models were less predictive, as were models based on 9-AC 
carboxylate or 9-AC total (not shown). 
DISCUSSION 
Topoisomerase I inhibitors are of great clinical interest because of their unique mode of action, 
their important antitumor activity and the high expression of the enzyme in various human tumor 
types. 9-AC, a semisynthetic analog of camptothecin revealed a broad antitumor activity in preclinical 
studies. Initial Phase I studies focused on schedules \-vith prolonged infusion duration. In order to 
facilitate the prolonged drug administration, an oral fOffilUlation was developed. 9-AC can be 
administered orally as a colloid dispersion (CD) or as gelatine capsules in PEGIOOO. In dogs the 
mean oral bioavailability of the CD fonnulation was 13% (range, 4.5-26%), as compared to 10% of 
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Fig. 3: Absolute dose of9-AC plotted versus AVC of9-AC lactone (A) and 9-AC total (B). 
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represent the fitting of the data to a sigmoidal maximum-effect model. 
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the PEG 1 000. Both fOffimlations retained their antihunor activity after oral administration. Recently 
the phase I study on the oral administration of the CD fonnulation of9~AC, 5 days per week, every 2 
weeks was completed [25J. Diarrhea was the dose limiting toxicity at a dose level of 0.2 mWm'. 
PEG! 000 9~AC was previously shown to demonstrate rapid intestinal absorption in patients after oral 
delivery, with an overall bioavailability (F) of 48.6±17.6%. This compares fuvorable to other 
camptothecin analogs, including topotecan (F~30.0%) [26J, 7-(4-methyl-piperazinomethylene)-
1O,II-ethylenedioxy-20(S)-camptothecin (GIl 472 1 I; F~II.3%) [27], and irinotecan (F~12-21%) 
[28]. The tenminal half-life (tl>2) of9-AC was shown to be 12.6±4.20 hr, which is substantially longer 
than that of to po tee an (range, 2.35-5.91 hr) [26J and GII47211 (range, 6.85±3.13 hour) [27]. Another 
difference between topoisomerase I inhibitors constitutes the AUC ratio of the active lactone and the 
total dmg of the parent dmg. The conversion of9-AC lactone into the ring-opened species in plasma 
could be demonstrated from the first sample acquired (i.e. at 0.33 hr). At equilibrium, the 9-AC 
carboxylate accounted for 91.1±2.11 % of9-AC total dmg concentrations This compares unfavorable 
to the percentages present in the ring~opened form at equilibrium observed in patients for topotecan 
(-50%) [26J, GIl 472 1 1 (-60%) [27J, and irinotecan and its active metabolite SN-38 (-65% and 
-35%, respectively) [29]. These figures underscore the important differences in phannacokinetics 
between camptothecin analogs. 
Our results of the Phase 1 study with oral 9-AC capsules indicated that the drug could be 
administered in a 14-day schedule repeated every 3 weeks with tolerable and manageable toxicity 
[30]. The dose~limiting toxicities were a combination of tiuombocytopenia pIllS neutropenia 
complicated by fever and diarrhea occurring at a dose level of 1.1 mglm2/day. Other side effects were 
mild to moderate (CTC grade 1 to 2) and consisted of nausea, vomiting, alopecia, mucositis and 
fatigue. Although 9-AC demonstrated a linear pham13cokinetic behavior over the entire dose range 
studied, we observed that the AUC of 9~AC lactone was a better indicator for the observed 
hematological toxicity than the dose. The intrapatient variability in AUC and peak dmg levels was 
extremely small and averaged less than 10% for 9-AC lactone. However, the interpatient variability in 
the concentrations of 9-AC at each of the sample-time points as well as in the AUe was large, with 
values for the coefficient of variation as high as 99%. In this study, the high variability in lactone to 
carboxylate interconversion was significantly related to individual differences in pretreatment semm 
albumin levels. Although our results need to be confirmed in a larger number of patients. they tend to 
indicate that higher protein levels will result in a more profound binding of 9~AC carboxylate, 
thereby further diminishing the effective concentration of the active species of the dmg. In ali, these 
data indicate that classical dmg dosing based on body-surface area alone is unlikely to be effective in 
minimizing interpatient differences in systemic exposure to oral 9-AC. 
The phannacokinetics of 9~Ae were clearly related to the phammcodynamic outcome, (i.e. 
hematological toxicity). The sigmoidal Enux model was found most appropriate to fit the kinetic data 
to the observed myelosuppression. The best correlation was obtained with the AUe of9-AC lactone, 
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the exposure to the active drug. Considering this phannacokinetic-pharmacodynamic relationship, a 
target AUC for 9-AC lactone can be defined according to the grade of toxicity that is considered to be 
acceptable in future studies. If hematological toxicity graded 2 or less is defined as acceptable, then 
the target AVC of9-AC lactone is 17.3 ng*h/mL, using the Hill equation and data shown in Fig 3A. 
For phannacokinetic and phannacodynamic analysis frequent blood sampling is inevitable. In 
order to evaluate salivary drug monitoring of9-AC as an altemative to drug monitoring in plasma, the 
concentrations and AUC of9-AC total and lactone were measured in unstimulated saliva samples in 
5 patients during this study. The 9-AC concentration ratio in plasma and unstimulated saliva proved 
to be strongly patient-dependent and highly variable, suggesting that saliva is an unreliable matrix for 
phamlacokinetic analysis of 9-AC. Similar results were obtained recently for pharmacokinetic 
analysis of CPT-I I and SN-38 in saliva demonstrating large interpatient variability in plasma/saliva 
ratios (31). 
Recently, we developed a limited-sampling model for reliable and accurate prediction of the 
systemic exposure to 9-AC after oral drug administration, using only one time blood sample taken at 
3 hr after drug dosing [32). In order to further diminish the interpatient variability in drug exposure in 
future studies, a pharmacokinetic guided approach may be considered. After oral administration of an 
appropriate starting dose of9-AC (i.e. I mg/m2), the 9-AC lactone plasma concentration can then be 
measured at 3 hr after dmg dosing. Using the limited-sampling model and the linear-regression 
relationship between drug dose and AVC (Fig. 3), the optimal dose leading to the target AVC, 
detennined according to the toxicity considered acceptable, can be calculated. 
This procedure may prove valuable in reducing interpatient variation in exposure to 9-AC, and 
will enable us to optimize the treatment for any given patient by combining maximally achievable 
doses with tolerable toxicity during treatment. This strategy seems to be interesting both in further 
phase II studies using the 14 day administration schedule and in Phase I studies with different 
schedules of administration. 
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ABSTRACT 
Lurtotecan (GI147211; LRT) is a semisynthetic and water-soluble analogue of the topoisomerase I 
inhibitor camptothecin. To determine whether the therapeutic efficacy of LRT in patients could be 
improved, the dmg was encapsulated in iiposomes (NX 211; Gilead Sciences). In order to allow 
accurate description of the pltamlacokinetic behavior of NX 211 in cancer patients, we have 
developed sensitive RP·HPLC assays with fluorescence detection 0.;:x=378 nm; J..em=420 nm) for the 
determination of total LRT levels in human plasma and urine. Sample pretreatment involved 
deproteinization with 10% (w/v) aqueous perchloric acid-acetonitrile (2:1, v/v), and chromatographic 
separations were achieved on an Inertsil-ODS 80A analytical column. The lower limit of quantitation 
(LLQ) was established at 1.00 nglml in plasma (200-~1 sample) and at 100 nglml in urine (200 ,tl of 
40-fold diluted sample). The within-nm and between-nm precisions were <7.5%. LRT 
concentrations in urine <100 nglml were detemlined by a modified procedure comprising a single 
solvent extraction with n-butanol-diethyl ether (3:4, v/v). In this assay, the fluorescence signal ofLRT 
was increased 14-fold prior to detection by post-column exposure to UV light (254 nm) in a 
photochemical reaction unit The LLQ of this assay was 0.500 nglml (lSO-,t! sample) and the within-
nm and between-nm precisions were <1 0%, 
INTRODUCTION 
Lurtotecan (7-( 4-methylpiperazinomethylene)-1 O,II-ethylenedioxy-20(SJ-camptothecin; also 
known as GII472Il;LRT) (Fig. I) is a novel semisynthetic analogue of camp to thee in, a cytotoxic 
plant alkaloid that was first extracted from the wood and bark of the oriental tree, Camptotheca 
aCllmillala [1]. The mechanism of action of camptothecin derivatives is based on stabilization of the 
cleavable complex fonned by the intranuclear enzyme topoisomerase I and DNA, and on induction of 
single-stranded DNA breaks [2]. LRT has previously been shown to have significant activity in both 
in vitro cytotoxicity assays and ill vivo tumor model systems [3-5}, and was recently introduced into 
clinical trials [6-8]. 
Clinical phannacokinetic studies of camptothecin derivatives, including LRT, are complicated by 
a chemical, pH-dependent instability of the a-hydroxy-&-Iactone moiety in the core stmcture of the 
compounds, generating a ring-opened carboxylate foml, This lactone functionality undergoes rapid 
hydrolysis in aqueous solution under physiological conditions, i.e. at pH 7 or above, and results in a 
virtually complete loss of biological activity [9]. In recent years, considerable effort has been put in 
the development of altemative formulations that would allow prolonged systemic 
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Fig. 1: Chemical structure oflurtotecan (LRT). 
exposure to the phannacologically active dmg foml. One of these approaches is the incorporation of 
the lactone forms of camptothecins in Iiposomal particles. Indeed, recent preclinical studies indicated 
that Iiposomal encapsulation of the topoisomerase I inhibitors topotecan [1O,11}, camptothecin 
[12,131 and irinotecan [14,15] proved to be very eft:1cient against lactone ring opening, increased 
antitumor activity in experimental tumor models and dramatically enhanced tissue distribution and 
the systemic availability. Efficacy studies perfoffiled in nude mice bearing human colon and head and 
neck tumor xenografts have also indicated improved therapeutic efficacy for a new liposomal 
fonnulation ofLRT (NX 211; Gilead Sciences) as compared to nonliposomal LRT [16]. 
Based on these favorable results, we recently started a project to study the safety profile and 
clinical pharmacokinetics ofNX 211 in patients with advanced solid tumors. In the context of this 
study, we have now developed sensitive RP·HPLC methods with fluorescence detection using a 
sample c1ean·up procedure that dismpts the liposomes, thus ~nabling determination of total dmg 
levels in plasma and urine samples following 1\"'X 211 administration. The methods have been 
validated in terms of sensitivity, accuracy and precision [17], and have been used in a 
phannacokinetic experiment in a patient to investigate their applicability ill vivo. 
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EXPERIMENTAL 
Chemicals and reagents 
LRT dihydrochloride monohydrate (lot: U20441164/1, containing 78.11% of the free base) and 
NX 211 (liposomal LRT, lot: 181801F, containing 0.49 mg LRT as free base/ml) were delivered by 
Gilead Sciences (San Dimas, CA, USA). The internal standard (IS) 6,7-dimethoxy-4-methylcoumarin 
(lot 79F3652) was obtained from Sigma (St. Louis, MO, USA). Dimethyl sulfoxide (DMSO), diethyl 
ether, n-butanol, methanol and acetonitrile were purchased from Rathburn (\Valkcrbum, UK). 
Perchloric acid (70-72%, viv, in water), neat acetic acid and sodium hydroxide were supplied by 
Baker (Deventer, The Netherlands). Ammonium acetate was delivered by Roth (Karlsruhe, Gemmny) 
and sodium chloride by Merck (Dannstadt, Gemlany). All water used in the study was filtered and 
deionized with a Milli-Q-UF system (Millipore, Milford, MA, USA). Drug-free human plasma for the 
construction of calibration curves and quality control (QC) samples originated from the Central 
Laboratory of the Blood Transfusion Service (Amsterdam, The Netherlands). 
Stock solutions 
Stock solutions of LRT were made in triplicate by dissolving X mg LRT in (X x 0.7811) ml 
DMSO, resulting in a solution containing 1.00 mgiml LRT (free base). The working stock solution of 
LRT, containing 0.100 mgiml free base, was prepared by a 10-fold dilution of the stock solution in 
DMSO. A stock solution of the IS at a concentration of I mgiml was prepared by dissolving 50 mg 
IS in 50 ml DMSO. 
Standards fol' total LRT in plasma and urine 
Spiked plasma samples used as calibration standards were prepared daily in duplicate by addition 
of 10 ,II of serial dilutions in methanol-water (l:l,v/v) from the working solution ofLRT to 240 ,t! of 
drug-free human plasma. This resulted in calibration standards of 1.00, 2.50, 5.00, 10.0,25.0,50.0 
and 100 ngiml LRT (free base) in plasma. Four pools of QC samples for LRT were prepared in 
human plasma at concentrations of 4.00, 20.0, 75.0 and 750 ngiml, by addition of the appropriate 
volume of the LRT working solution or dilutions in 10 mM aqueous sodium hydroxide-methanol 
(I :1, v/v) (to shift the equilibrium to the carboxylate fonn) to human plasma. The QC containing 750 
ngiml LRT was used to investigate the suitability of small-volume (20 ~I) injections. Lower limit of 
quantitation (LLQ) samples in plasma were prepared daily in separate blank plasma samples obtained 
from 5 healthy volunteers at a concentration of LOa ng/ml. To minimize a potential difference with 
clinical samples, 2 pools of recovery control (RC) samples containing 20.0 and 750 ngiml NX 211 
were also prepared by addition of an aliquot of the NX 211 stock solution (in phosphate-buffered 
saline) to human plasma. Two pools ofQC samples were prepared in human urine at concentrations 
of 250 and 2500 ngiml, which were diluted 40-fold in blank human plasma prior to extraction. The 
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LLQ samples for urine were prepared daily at a spiked concentration of 100 ng/ml in quintuplicate 
using 5 different drug-free urine samples. 
Standards of LRT in the sensitive urine assay 
Calibration standards in urine were also prepared daily in duplicate by addition of I 0 ~t1 of serial 
dilutions ofLRT in methanol-water (1:1, v/v) to 240 ~t1 blank human urine, at final concentrations of 
the free base of 0.500, l.OO, 2.50, 5.00 and 10.0 nglml. Three pools ofQC samples were prepared at 
concentrations of 1.25, 7.50 and 250 nglml by addition of appropriate volumes of a dilution of the 
LRT working stock solution [in 10 ruM aqueous sodium hydroxide-methanol (1:1, v/v)]. The QC 
sample containing 250 nglml, identical to that used for the assay of total LRT in plasma and urine, 
was diluted 10·fold in blank urine before extraction, and \YaS further used to show the applicability of 
low volume injections (I 0 ~I). The LLQ samples were prepared daily at a concentration of 0.500 
ng/ml, again in quintuplicate using 5 different drug-free urine samples. 
HPLC instrumentation and conditions 
The HPLC systems consisted of constaMetric 3200 and 4100 solvent delivery systems (LDC 
Analytical, Riviera Beach, FL, USA), Waters 717plus autosampling devices (Milford, MA, USA), a 
Beam Boost photochemical reaction unit supplied with a coil of25 m and an internal diameter of OJ 
mm (lCT-ASS-Chem, Bad Homburg, Germany), and Jasco 821-FP and FP-920 fluorescence 
detectors (lasco Benelux B.Y., Maarssen, The Netherlands). Separations were achieved on a 
stainless-steel analytical column (lsOx4.6 1llIl1 internal diameter) packed with Inertsil ODS-80A 
material (5 ~Im particle size), delivered by Alltech Applied Science (Breda, The Netherlands). The 
mobile phase was identical in both assays and was composed of 1.0 M aqueous ammonium acetate 
(PH 5.5)-water-acetonitrile (10:72.5:17.5, v/v/v) with the pH adjusted to 5.5 (acetic acid). The 
analytical columns were maintained at 60°C using a model SpH99 colunID oven (Spark Holland, 
Meppe!, The Netherlands). A detailed composition of the various HPLC systems used for the two 
assays is provided in Table I. Peak recording and integration were perfoffiled with the Chrom~Card 
data analysis system (Fisons, Milan, Italy). All calibration curves were fitted by weighted (lIx) least-
squares linear regression analysis using the peak height ratios ofLRT and the IS versus the nominal 
concentrations of the standards. 
Sample treatment fol' total LRT in plasma and urine 
Samples were prepared by addition of 100 Irl IS solution [100 nglml in 10% perchloric acid-
acetonitrile (2: I, v/v)] to 200 ~I human plasma, or 40-fold diluted urine in plasma, in a 1.5-011 
polypropylene vial (Eppendorf, Hamburg, Gennany). Samples were mixed vigorously for 30 min on 
a multi~tube vortex mixer, followed by centrifugation at 23,000xg (5 min) at ambient temperature. A 
250-JlI volume of the clear supernatant \YaS transferred to a low volume glass insert, from which 200 
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~I (or 20 It! in case of QC and RC samples containing 750 ng/ml LRT and NX 211, respectively) 
were injected into the HPLC system. 
Table 1: Composition of the two HPLC systems. 
Equipment 
Pump 4100 
Pump 3200 
Autosampler 717p 
Column oven SpH99 
Column ODS-80A 
Beam Boost 
Detector FP-920 
Detector 821-FP 
Sensitive urine 
Flow-rate: 0.75 ml/min 
" 
T'=60'C 
Lamp: A~254 nm 
Coil: 25 m; ID: 0.3 mm 
Ae\=378 run 
A~~20nm 
Em band: 40 nm 
Sample treatment for LRT in the sensitive urine assay 
Total plasma/urine 
Flow-rate: 1.25 ltd/min 
Aex=378 nm 
~~20nm 
Em band: 30 nm 
A I OO-~I volume ofIS solution (50 ng/ml in 25 mM aqueous ammonium acetate, pH 3.0) was 
added to a 12-ml glass tube supplied with a PIFE-covered screw cap containing 150 ~II urine. After 
incubation for 30 min at room temperature, 0.8 g solid sodium chloride was added, followed by 
extraction with 2 ml n-butanol-diethyl ether (3:4, v/v) by vigorous vortex mixing for 5 min. 
Subsequently, the sample was centrifuged at 4000xg (5 min), followed by collection of I ml upper 
organic layer, which was evaporated to dryness under a gentle stream of nitrogen at 70°C for a period 
of 45 min. The dried residue was redissolved in 150 JtI 2S mM aqueous ammonium acetate (PH 3.0) 
and transferred to a glass insert. A volume of 50 ~I (or 10 It! for the QC sample containing 250 ng/ml 
LRT) was injected into the HPLC system. 
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Validation 
Yalidation runs ofLRT in plasma and mine and ofLRT in the sensitive mine assay included a set 
of calibration samples assayed in duplicate, and LLQ and QC samples in quintuplicate, and was 
perfomled on 4 separate occasions. Precisions were calculated by one· way analysis of variance 
(ANDY A) for each test concentration, using the mn-day as the classification variable. The accuracy 
of at least 80% of the samples assayed at each concentration should be in the range of 80 to 120%. 
The within-nm (WRP) and between·run precisions (BRP) should be <20% at the concentration of 
the LLQ and <15% at the concentrations ofthe QC samples and the average accuracy (ACC) should 
be within 85·115% for each concentration. including the LLQ. 
The extraction recoveries ofLRT and the IS in the assay for total LRT in plasma and urine were 
calculated by comparing peak heights obtained from a sample containing 25.0 nglml LRT in 
phosphate-buffered saline that was extracted (as described for plasma), to those obtained in extracted 
QC samples prepared in the biological matrix. The extraction recoveries in the sensitive urine assay 
were calculated by comparing observed peak heights of the processed urine samples of the calibration 
curves to peak heights obtained from spiked samples containing 1.00 nglml LRT and 10.0 nglml IS 
in 25 nu\1 aqueous ammonium acetate (pH 3.0). 
The stability of LRT and the IS in plasma and urine was established (i) during 3 consecutive 
freeze·thaw cycles. in which the samples were put at room temperature for 30 min after thawing, and 
(ii) during an overnight incubation at 37°C. The concentrations used were 20.0 and 75.0 ng/ml for 
plasma and 250 and 2500 ng/ml for urine, and were analyzed using the assay for the determination of 
total LRT in plasma and urine. 
The selectivity of the assays was tested by the degree of separation of the compounds of interest 
and possible other chromatographic peaks caused by endogenous components andlor potentially co-
administered dmgs. The interference from endogenous material for LRT and the IS in human plasma 
and urine was detemlined by visual inspection of HPLC profiles of 5 processed blank plasma and 
urine samples obtained from 5 healthy volunteers. Interference from potentially co·administered 
drugs was tested at a spiked concentration of 1 0 ~lg/ml in a blank plasma extract for the assay of total 
LRT in plasma and urine, and at 10 Jig/ml i!125 mM aqueous ammonium acetate (pH 3.0) forLRT in 
the sensitive urine assay. The tested compounds included acetaminophen, alizapride, codeine, 
dexamethasone, domperidon. metoclopramide. morphine, leucovorin, lorazepam. paroxetine. and 
ranitidine. 
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RESULTS AND DISCUSSION 
In approaching the present analytical procedures, we used our own previous RP~HPLC procedure 
for the quantitative determination of total nonliposomal LRT (lactone plus carboxylate forms) in 
human whole blood as a starting point [I8J. Because of the pH-dependent instability of the rJ.-
hydroxy·o-Iactone moiety in the core stmcture ofLRT, resulting in the ring-opened carboxylate from 
at hight pH and the ring-closed lactone foml at low pH, we decided to focuss only on measurement of 
total concentrations in the present study, since dismption of liposomes while maintaining the 
physiologic lactone to carboxylate ratio may not be feasible. The choice of the IS, 6,7-dimethoxy-4-
methyJcoumarin, and the optimal fluorescence wavelength couple ofLRT (378/420 Iml) \ws based 
on earlier work descibed for detemlination ofLRT in human blood and dog plasma by Selinger et al. 
[I9J and Stafford and St. Claire [20J, respectively. 
For the purpose of assay validation, all QC samples were prepared with the carboxylate foml of 
LRT, to ensure a quantitative conversion to the lactone species of the total amount of LRT, prior to 
measurement, present in plasma and urine of clinical samples. 
Assay of total LRT in plasma and udne 
Initially, the assay of total LRT in plasma and urine was validated with only LLQ and QC samples 
of noniiposomal LRT (free base) in plasma and urine, using an extraction time of 15 min. The 
calibration curves were linear in the range of 1.00 to 100 nglml with Pearson's regression correlation 
coefficients ranging from 0.9986 to 0.9997, by lIsing weighted (Ilx) linear least~squares regression 
analysis. The retention times ofLRT and the IS were II and 15 min respectively. with an overall run 
time of 20 min. 
One of the tested blank plasma sample specimens showed a minor (unknown) interfering peak in 
the chromatogram for LRT, and was replaced by a new blank plasma obtained from a healthy 
volunteer to enable accurate detemlination of the LLQ. No interfering peaks with retention times 
around the IS were found in the tested blank plasma samples. In the 5 (40-fold diluted) blank human 
urine samples, no interfering peaks were found for LRT; however, all tested urine samples showed a 
small peak with the same retention time as the IS, but this interference did not significantly alter the 
obselVed data. The tested drugs potentially co-administered with NX 211 did not interfere with the 
analytes of interest. Some minor peaks were found with retention times of 1 to 3 minutes, causing no 
problem for the detennination ofLRT in plasma and urine. 
The LLQ was established in plasma at 1.00 nglml and in urine at 100 nglml, with 95% of the LLQ 
samples fulling within the acceptable accuracy range of 80 to 120% (17]. The within-run and 
between-run precisions at the 5 tested concentrations in plasma, including the LLQ, were <7.5% and 
<4.1%, respectively, with the accuracy ranging from 96 to 110% (Table 2). The within-nm and 
between-nm precisions in urine at the 3 tested concentrations were <6.7% and <4.4%, respectively, 
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Table 2: Validation characteristics of total LRT in plasma and urine. 
Matrix Nom.conc. Mean WRP' BRP' ACC' 
(nglml) (nglml) (%) (%) (%) 
Plasma 1.00 b 0.959 7.5 4.1 96 
4.00 3.84 7.4 c 96 
20.0 22.0 2.7 1.0 110 
75.0 81.4 2.3 2.1 109 
750 789 2.8 2.4 105 
Urine 100 b 96.8 6.7 4.4 97 
250 269 3.0 0.12 108 
2500 2525 4.3 2.1 101 
" 
Abbrcviations: WRP, within·run prcrision; BRP, between-run precision; ACC, awragc accuracy 
b: Lower limit of quantitation sample 
" 
No additional variation was obser.cd as a result ofpcrforming the assay in different runs 
with an accuracy range of97 to 108% (Table 2). The extraction recoveries, estimated by comparing 
peak heights obtained by direct injection of standard solutions containing 25.0 nglml LRT and IS in 
blank plasma extracts to those obtained in extracted plasma samples of the calibration curves, were 
89±8.2% (mean ± standard deviation) and 67±4.8% for LRT and the IS, respectively. No loss ofLRT 
was estimated at the tested concentrations after 3 freeze-thaw cycles or during overnight incubation 
of the samples at 37°C (data not shown). 
Using an extraction time of 15 min, we noted that the extraction recovery of plasma samples 
containing NX 21 I (Iiposomal LRT) was approximately 10% lower for LRT as compared to plasma 
samples spiked with nonliposomal LRT (free base). The extraction efficiency of the samples 
containing NX 211 was eventually increased by extending the vortex-mixing time to 30 min, at 
which maximum recovery was reached (data not shown). The assays of total LRT in plasma and urine 
were re-validated during 3 analytical runs (with a 30-min mixing time during sample extraction), and 
the calibration curves were assayed in duplicate with the 4 QC samples of LRT and 2 RC samples 
containing NX 211 spiked at concentrations of 20.0 and 750 ng/ml, both in plasma, in triplicate. The 
Pearson's regression correlation coefficients in the re-validation runs ranged from 0.9995 to 0_9998, 
and the range of the within-mn and between~run precisions of the QC samples containing LRT were 
1.8 to 3.6% and 0.73 to 2.5% respectively, with an overall accuracy between 99 and 104%. The 
within-run precisions of the RC samples were 1.9 and 2.5%, respectively, for the samples containing 
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20.0 and 750 ng/ml, whereas the respective between-run precisions were 2.3 and 7.3%. The 
extraction recoveries ofLRT in the QC and RC samples containing 20.0 nglml LRT and NX 211 
were 90±2.1% and 85±3.9%, respectively, and 83±3.0% (LRT) and 82±3.0% (NX 211) for the 
samples containing 750 nglm!. 
Representative RP-HPLC chromatograms derived from a blank human plasma pool and a 
plasma sample spiked to contain 10.0 nglml LRT (free base) are shown in figs. 2A and 2B. An 
additional chromatographic peak was found in the RC samples containing NX 211 with a 
retention time of approximately 48 min. This peak was later identified as a photochemical 
A B IT c IT 
o 5 10 15 20 o 5 10 15 20 o 5 10 15 20 
Time (min) 
Fig. 2: Chromatograms of a blank human plasma sample (A), a plasma sample spiked with 10.0 
nglml LRT free base (B) and a plasma sample obtained from a patient 8 h after the 
administration ofNX 211 at a dose level of 0.8 mg (C). Peaks labeled I and II correspond 
to LRT and the IS, respectively. 
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degradation product ofNX 211 by comparison of the compound's chromatographic behavior on 
the RP-HPLC column and spectroscopic properties with a pure reference standard. Isolation, 
purification and structural identification, in addition to the role of this compound in the overall 
drug disposition will be described separately. 
Assay for the sensitive determination of LRT in urine 
Previous studies have shown that renal clearance of LRT in patients treated with nonliposomal 
drug was low, with approximately 10-14% of the delivered dose excreted as unchanged parent drug 
in urine [6]. In order to 'allow detennination of low concentrations ofLRT in urine, which can be 
anticipated following treatment with NX 211 at low dosages, an assay was also required with 
increased sensitivity as compared to the assay described for total LRT concentrations in plasma and 
urine with an LLQ (for urine) of 100 nwml (see above). The sensitivity of this assay could 
theoretically be improved by decreasing the dilution factor used for urine samples prior to extraction. 
However, this will likely result in substantially prolonged run times in order to get suft1cient 
separation between the peaks of inter~t (i.e. LRT and the IS) and those resulting from the presence of 
endogenous material, which would in turn compromise assay sensitivity. 
Eventually, the assay sensitivity could be significantly improved, in part, by increasing the 
fluorescence intensity ofLRT through a modification of the detection procedure. LRT is known to be 
slightly light sensitive [19] and since photochemical reactor units in combination with HPLC has 
been described for a wide variety of other compounds [21-25], where increased detector signal 
outputs have been described from 2 to 80 folds, we have evaluated the impact of post-column 
photodegradation on the fluorescence activity of LRT. Post-column exposure of LRT to UV light 
(254 nm) results in a loss of the piperazinomethylene moiety on C7 of the LRT molecule, as 
detennined by electro-spray ion-trap mass spectromet!)' [m/z=409 (LRT-C7 side chain)]. The 
influence of the photochemiCal reaction unit on the fluorescence ofLRT was estimated by injections 
of 50 ~I of 5 nwml LRT in 25 mM ammoniulll acetate (PH 3.0) onto the HPLC system as described 
for this assay. The flow rate was varied from 0.50 to 2.00 mllmin, resulting in irradiation times of300 
to 75 s. At each flow rate, 2 injections were perfomled, one with the lamp of the photochemical 
reaction unit on and another one with the lamp switched off The ratios of the peak heights obtained 
with the lamp on and off were calculated. As displayed in fig. 3, the fluorescence intensity of LRT 
increased 9 to 15-fold depending on the flow rate used (0.50 to 2.00 mVmin). The use of a flow rate 
set at 0.75 mllmin (i.e. and irradiation time of 200 s) resulted in a 14~fold increased fluorescence 
signal ofLRT, and was associated with an acceptable total run time (35 min) with retention times of 
19 and 24 min for LRT and the IS, respectively. 
Fig. 4 shows representative chromatograms of a blank human urine sample and a sample spiked 
with 2.50 nwml LRT (free base). The calibration curves ofLRT were linear in the range of 0.500 to 
10.0 ng/ml, with Pearson's correlation coefficients ranging from 0.9954 to 0.9994, also using 
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Fig. 3: Influence of the photochemical reaction unit on the fluorescence intensity ofLRT. 
weighted (l/x) least~squares linear regression analysis. No analytical interference was found between 
LRT or the IS and of the tested dmgs potentially co~administered with NX 211. However, a number 
of three additional peaks were found with retention times of6, 7 and 10 minutes. Since these elute in 
the big front of the chromatograms of urine and high concentrations of the drugs were spiked these 
peaks have no impact on the detennination of low concentration ofLRT in urine. Small peaks with 
the same retention time as LRT and the IS were found in all of the tested blank urine samples, so the 
LLQ could not be established below a concentration of 0.500 ngiml, with 80% of all samples in the 
acceptable range of accuracy. The within~mn and between·nm precisions at the 4 tested 
concentrations were <5.5 and <10%, respectively, with the accuracy ranging from 97 to 108% (Table 
3). Taking into consideration that only approximately half of the added volume of the organic layer 
was evaporated, the extraction recoveries were around 80 and 92% for LRT and IS respectively. 
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Table 3: Validation characteristics of total LRT urine (sensitive assay). 
Nom.conc. Mean WRP' BRP' 
(nglml) (nglml) (%) (%) 
0.500 b 0.539 5.5 c 
1.25 L31 3.0 3.1 
7.50 7.27 2.S 6.7 
250 243 4.2 10 
a: Abbre\iations: WRP, \,ithin·run precision; BRP, between-run prccision;ACC, average accuracy 
b: Lower limit of quantitation sample 
c: No additional variation was observed as a m>ult of performing the assay in different runs 
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Fig. 4: Chromatograms of a blank human urine sample (A), a urine sample spiked with 2.50 
nglml LRT free base (B) and a urine sample obtained from a patient, collected 12-24 h 
afier the administration ofNX 211 at a dose level ofO.S mg (C). Peaks labeled I and II 
correspond to LRT and the IS, respectively. 
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Assay application 
The suitability of the developed methods for clinical use was demonstrated by the detennination 
of LRT in biological specimens obtained from a patient treated with NX 211 at a dose of 0.8 mg. 
Examples of the patient's sample trace are shown in Fig. 2C (plasma) and Fig. 4C (urine). Distinct 
peaks were obtained for LRT in both matrices that were well resolved from endogenous components. 
CONCLUSION 
In conclusion, we have developed and evaluated new liquid chromatographic methods for 
measuring total LRT levels in human plasma and urine. The primary elements of novelty 
described in this work are the use of human plasma as biological matrix containing liposomal 
LRT (NX 211) and the utilization of a photochemical reaction unit to increase the native 
fluorescence intensity of LRT in order to achieve sub-nanogram per milliliter determinations. 
The methods were shown to meet the current requirements as to validation of bioanalytical 
methodologies [17], providing excellent precision and accuracy. The described methods permit 
the analysis of patient samples, and will be implemented in an ongoing clinical trial to 
investigate the disposition ofLRT in cancer patients receiving NX 211. 
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ABSTRACf 
This study was designed to evaluate the disposition of lip os orne-encapsulated lurtotecan (NX 211) 
in 6 cancer patients receiving the drug as a 30~min i.v. infusion (dose, 1.6-4.3 mglm\ Serial plasma, 
whole blood, urine, and feces samples were collected for 96 h and analyzed by reversed-phase high-
perfomlance liquid chromatographic assays. The pharmacokinetic profile in plasma was 
characterized by a slow systemic clearance ofO. 78±0.88 Llh/rn2 (mean±SD) with a mono-exponential 
decline, and a steady-state volume of distribution approximating the blood volume (3.5±2.6 Lim'). In 
addition, the total lurtotecan blood:plasma concentration ratios averaged 0.66±0.13, indicating 
limited dmg accumulation in blood cells. Urinary excretion was 8.2±4.7% of the delivered dose, 
indicating that renal clearance is a minor route of elimination of the unchanged drug. Total fecal 
excretion amounted to 9.?±6.2% of the dose, and 2 potential metabolites could be identified from 
fecal extracts. Overall, these data indicate that NX 211 administration results in significantly 
increased plasma exposure as compared to non-liposomal lurtotecan, which may be a potential 
advantage with phannacodynamic importance. 
INfRODUCfION 
Lurtotecan is a totally synthetic analog of 20-(SJ-camptothecin, a natural product isolated from 
Camploflieca aCllminafa [1]. Stmcturally, lurtotecan is unique among camptothecin dmgs, because 
of a dioxolane moiety on the A-ring and a bulky 4-methyl-piperazinomethylene group on the C-? 
position (fig. 1). These molecular modifications have resulted in enhanced aqueous solubility as 
compared to the original agent and increased affinity of the compound for DNA topoisomerase I, the 
cellular locus through which camptothecin analogues produce their antitumor activity. The 
cytotoxicity of these so-called topoisomerase I inhibitors is distinctly S-phase specific, and various 
preclinical studies with lurtotecan as well as other camptothecin drugs have suggested that prolonged 
exposure, achieved either by repeated doses or prolonged infusion, might be beneficial for efficacy 
profiles (reviewed in [2]). In order to exploit this apparent schedule dependency, several clinical trials 
have been conducted with lurtotecan focussing on intermittent (daily for 5 days every 3 weeks [3-5]) 
or prolonged i.v. dosing schedules (72-h infhsion every 4 weeks [6] or 7-, 14-, or 21-day infusions 
[7]). These studies have shown that the phannacokinetic behaviour of lurtotecan is influenced 
significantly by a chemical, pH-dependent hydrolysis of the lactone functionality in the core 
structure, generating a ring-opened carboxylate fonn, which is devoid of biological activity [8]. Based 
on this finding, considerable effort has been put recently in the development of alternative 
phamlaceutical vehicles that would allow prolonged systemic exposure to the active lactone fonn. 
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Fig. 1: Chemical stmcture oflurtotecan. 
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Among various approaches, liposomal encapsulation of call1ptothecin analogues was shown to be 
vel)' efficient against lactone hydrolysis and, in fact, increased antitumor activity in mouse models by 
enhancement of tissue distribution and systemic drug availability [9-13]. Here, we have examined the 
disposition ofa new liposomal fonnulation oflurtotecan (NX 211) in a group of cancer patients to 
investigate the clinical utility of this concept. 
PATIENTS AND METHODS 
Patients and treatment 
Patients with a histologically confirmed diagnosis of advanced solid tumor refractory to 
standard therapy were eligible for the present study. Additional eligibility criteria included: age 
~18 years; Eastern Cooperative Oncology Group performance status ~2; no previous treatment 
with antineoplastic agents for at least 3 weeks (4 weeks in case of carboplatin or any 
investigational agent and 6 weeks in case of nitrosureas or mitomycin C); adequate 
hematopoietic (absolute neutrophil count >1.5x1091L, and platelet count >lOOxI09!L), renal 
(serum creatinine within normal limits), and hepatic function (total serum bilirubin within 
normal limits, and aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) 
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levels ~ 2.5 times upper normal limits); and no known hypersensitivity to systemic liposomal 
formulations or any drug chemically related to lurtotecan. The current clinical protocol was 
approved by the Rotterdam Cancer Institute Review Board, and all patients signed informed 
consent before study entry. 
NX 2Il was formulated as a sterile Iiposomal dispersion oflurtotecan in a buffer composed 
of lO-mM ammonium chloride and 9% sucrose and was obtained from Gilead Sciences Inc. 
(San Dimas, CA, USA). The drug product was supplied in 50-mL vials containing 5 mg 
lurtotecan. Each vial contained 80 mg hydrogenated-soy phosphatidylcholine, 19 mg 
cholesterol, 0.9 g sucrose, 2 mg citric acid, 5 mg ammonium chloride to a total volume of 10 
mL. Dose solutions for administration were prepared in polyvinyl chloride-free infusion 
containers protected from light and under aseptic conditions by dilution of the pharmaceutical 
preparation with sterile 5% dextrose (D5\V) to a volume of25 mL. The NX 211 dose (1.6, 3.2 
or 4.3 mg/m2) was administered as a 30-min Lv. infusion. 
Sample collection and preparation 
Blood samples for pharmacokinetic analysis were drawn from a vein in the arm opposite to 
that used for drug infusion, and collected in 5-ruL glass tubes containing lithium heparin as 
anticoagulant. Duplicate samples were obtained before drug administration and at 0.5 (end of 
infusion), I, 1.5,2.5,4,6,8,24,48,72, and 96 h after start of infusion. At each sampling time 
point, I aliquot of whole blood was immediately transferred to a polypropylene vial and stored 
at ~80°C. while another was processed to plasma by centrifugation for 5 min at 3000xg (4°C), 
which was then also stored at -80°C until the time of analysis. Complete urine collections were 
obtained for the duration of the study in 12-h or 24-b portions, and aliquots were stored frozen 
in polypropylene vials. Complete collections of feces were also obtained in polystyrene 
containers, and stored immediately at -80°C. After thawing, these samples were homogenized 
individually in 4 volumes of phosphate buffered saline (PBS) using an Ultra-Turrax T25 
homogenizer (IKA-Labortechnik, Dottingen, Germany). 
Analytical methods 
Lurtotecan dihydrochloride monohydrate (lot: U2044fl64fl, containing 78.[[% of the free base) 
was supplied by Gilead Sciences Inc. (San Dimas, CA, USA) and was used as standard for all 
reversed-phase high-perfonnance liquid chromatographic assays (HPLC). Plasma and urine 
concentrations of lurtotecan were detennined using validated HPLC assays as described previously 
[14]. The sample pretreatment for the analysis of total plasma concentrations (i.e., the total oflactone 
plus carboxylate levels) consists of protein precipitation with 10% (w/v) aqueous perchloric acid-
acetonitrile (2: 1, v/v). Lurtotecan was separated from endogenous compounds on an Inertsil-ODS 
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80A column. with a mobile phase composed of 1 M aqueous ammonium acetate~water~acetonitrile 
(100:725:175, v/v/v). The flow rate was set at 1.25 mUmin, the temperature was maintained at 60'C 
and the column effluent was monitored with excitation and emission wavelengths of 378 and 420 
nm, respectively. Urine concentrations oflurtotecan were quantified after a solvent extraction with II~ 
butanol-diethyl ether (3:4, v/v), using the same column and mobile phase. The flow rate was set at 
0.75 mL/min and the fluorescence signal of lurtotecan was increased 14-fold prior to detection by 
exposure of the effluent to UV light (254 run) in a photochemical reactor unit. The LLQs were 1.00 
and 0.50 nglmL for the detennination of total lurtotecan concentrations in human' plasma and urine. 
respectively. 
For the detennination of lurtotecan in whole blood and feces, the assay for total plasma 
concentrations was modified as outlined below. The HPLC systems consisted of a constaMetric 3200 
solvent delivery system (LDC Analytical, Riviera Beach, FL), a Waters 717plus autosampler 
(Milford, MA), a Inertsil-ODS 80A analytical column (150x4.6 mm I.D., 5 I.m particle size; Alltech 
Applied Sciences, Breda, The Netherlands) maintained at 60'C by a model SpH99 column oven 
(Spark Holland, Meppe!, The Netherlands), a Beam Boost photochemical reactor unit supplied with a 
coil of 25m x 0.3mm I.D. (lCT-ASS-Chem, Bad Homburg, Gennany), and a Jasco FP-920 
fluorescence detector (lasco. Maarssen, The Netherlands) operating at excitation and emission 
wavelengths of378 and 420 nm (40 run band width), respectively. The mobile phases consisted of 1 
M aqueous ammonium acetate-water-acetonitrile (100:725:175, v/v/v), with the flow rates set at 1.25 
and 0.75 mUmin for the detennination of total lurtotecan levels in blood and fecal samples, 
respectively. 
Aliquots of 50 I.L heparinized whole blood were pretreated with 500 I.L of 5% (w/v) aqueous 
perchloric acid-acetonitrile (5:1, v/v) in 1.5-mL polypropylene tubes (Eppendorf Hamburg, 
Gerumny). The samples were 'vigorously vortex~mixed for 30 min on a multi~tube vortex mixer. 
followed by centrifugation for 5 min at 23,000xg at ambient temperature. A volume of250 I.L of the 
clear supernatant was transferred to a low volume insert of glass. from which 200 p,L were injected 
into the HPLC system. The calibration curves were constructed in PBS in concentrations of 0.25, 
0.50, 1.00, 5.00, 10.0 and 25.0 ng/mL, by serial dilutions of a lurtotecan working solution containing 
0.10 mg/mL (expressed as free base). Three pools of quality-control samples were prepared in 
heparinized whole blood at concentrations of 0.40, 20_0 and 2000 ng/mL, by addition of appropriate 
volumes oflurtotecan in PBS to the whole blood. In addition. to minimize potential differences with 
clinical samples, a recovery control sample containing 7.50 ng/mL lurtotecan (as NX 211), was also 
analyzed simultaneously. The sample containing 2000 ng/mL was diluted 100-fold in PBS prior to 
extraction. 
Aliquots of 100 I.L feces homogenates were deproteinized and acidified with 1000 ~L of 5% 
(w/v) aqueous perchloric acid-acetonitrile (5:1, v/v) containing 100 ng/mL 6,7-dimethoxy-4-
methylcoumarin (Sign,., st. Louis, MO, USA), which was used as the internal standard. 
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Subsequently. the samples were vigorously vortexMmixed for 15 min on a multiMtube vortex mixer, 
followed by centrifugation at ambient temperature at 23,00Oxg for 5 min. A volume of I 00 ~IL 
supernatant was transferred to a limited volume insert of glass, from which 10 ~IL were injected onto 
the analytical column. Spiked homogenized fecal samples used as calibration standards in 
concentrations of 10, 25, 50, 100 and 250 ngimL were prepared by addition of"1O pL of serial 
dilutions in PBS from the lurtotecan working solution to 240 pL dmg-free feces homogenates. Three 
pools of quality-control samples containing 40, 200 and 2000 ngimL lurtotecan were prepared by 
addition of appropriate volumes oflurtotecan in PBS to blank human feces homogenates. The sample 
containing 2000 ngimL was diluted IO-fold in a mixture of PBS and the extraction solution (1:10, 
v/v) prior to injection. 
Validation of both assays included a set of calibration samples assayed in duplicate, with lower limit 
of quantitation and quality-control samples in qUintuplicate, and was perfonned on 4 separate 
occasions. The lower limit of quantitation samples were prepared daily in drug-free heparinized 
whole blood samples and fecal homogenates of 5 healthy volunteers. Within-run and between-run 
precisions were calculated by one-way ANOYA for each concentration using the run-day as variable. 
The extraction recoveries for lurtotecan and the internal standard in the assay for Ilirtotecan in feces 
specimens were calculated by comparing peak heights obtained from an extracted sample containing 
100 ngimL lurtotecan in PBS to those obtained in extracted calibration samples. The extraction 
recoveries for llirtotecan in the assay in whole blood were calculated using the data of the quality and 
recovery-control samples in comparison to calibration standards. 
Table 1: Characteristics of the studied patients 
Patient Dose Gender Age Tumor type BSA Ht 
No. (mgim') (yrs) (m') (L/L) 
1.6 Female 61 NSCLC' 1.63 0.30 
2 1.6 Female 74 sarcoma 1.56 0.28 
3 3.2 Female 57 myosarcoma 2.09 OAO 
4 3.2 Female 40 SCLC 2.06 0.37 
5 3.2 Male 52 bile duct carcinoma 1.88 OAI 
6 4.3 Male 55 bladder carcinoma 1.98 0.36 
a: NSCLC, non-small cell lung cancer, SCLC, small-ceillungcancer; BSA, body-surface area; lIt, hematocrit on day I 
182 
Disposition ofNX 211 ill huwalls 
Pharmacokinetic analysis 
Individual plasma and whole blood concentrations of lurtotecan were fit to a model with 
multi-exponential functions using the Siphar version 4.0 software package (SIMED, Creteil, 
France), using Powell's method. In all cases, concentration-time profiles were best fit to a 
mono-exponential equation after zero-order input with weighting according to Yobs" (not 
shown). The disposition half-life was calculated as In21k, in which k is the elimination rate 
constant in h". The total plasma clearance of lurtotecan was calculated by dividing the dose 
(expressed in mg base equivalents per squared meter of body surface area) by the observed 
AUC. The volume of distribution at steady state was calculated using the same program. 
RESULTS 
Complete phamlacokinetic studies were performed in 6 patients entered onto a phase I clinical 
trial ofliposomallurtotecan (NX 211) given as a 30-min i.v. infhsion [15]. Full clinical toxicities and 
treatment responses will be reported in detail elsewhere in due course. The group consisted of 4 
females and 2 males ranging in age from 40 to 74 years (Table I). The median clinical chemistry 
values for these patients included total bilirubin levels of 6 f,M (range 5-11), serum creatinine 
levels of 90 ~M (range 75-108), ASAT and ALAT of 27 unitslL (range 19-47) and 20 unitslL 
(range 8-57 unitslL), respectively. 
Analytical methods 
The lurtotecan plasma concentration values for patients treated with NX 211 reported here 
are the sum of both encapsulated and non-encapsulated drug. In order to gain a pr~liminary 
insight into the disposition and elimination of NX 211 in humans, the assay procedures as 
described recently [14] were slightly modified ror the determination of total lurtotecan 
concentrations in human whole blood and fecal homogenates. PBS was used as matrix for the 
construction of the calibration standards for the determination of total lurtotecan levels in 
human heparinized whole blood, since pools of drug-free heparinized whole blood were not 
available. Because of this, we focussed on an extraction procedure with quantitative (i.e., 100%) 
recovery. Eventually, the extraction recoveries for lurtotecan, using the described method, were 
103, 100 and 97% for the quality-control samples containing 1.25, 20.0 and 2000 ng/mL of 
lurtotecan and 101 % for the recovery-control sample containing 7.50 ng/mL of NX 211. 
However, the extraction recovery for the internal standard still did not reach 100% (data not 
shown), and, hence, no internal standard was used in this assay. The calibration curves were 
linear over the entire range studied, with the validation characteristics of the quality control 
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Figure 2: Chromatograms of whole blood samples of patient 6; blank (A), a 100-fold diluted sample 
obtained at the end of the infusion containing 1265 nglmL lurtotecan (3) and a sample 
taken 96 h after the start ofthe infusion containing 3.7 nglmL lurtotecan (C). Peak labeled 
I correspond to iurtotecan. 
samples summarized in Table 2. Fig. 2 shows representative chromatograms of iurtotecan in 
whole blood samples of patient 6 after the administration ofNX 211. Similar data were obtained 
for the determination of lurtotecan in feces homogenates (Table 2), with recoveries of lurtotecan 
and the internal standard of 100 and 98.5%, respectively. Representative chromatograms of 
lurtotccan in fecal extracts of the same patient are shown in fig 3. 
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Figure 3: Chromatograms of fecal extracts of patient 6: blank (A), an undiluted fecal homogenate from 
a feces sample collected at 54 h after the start of the infusion with 2 potential metabolites 
(8) and the same sample to·fold diluted after extraction containing 976 ng'mL lurtotecan 
(C). Peaks labeled I, II and M correspond to lurtotecan, internal standard and potential 
metabolites, respectively. 
Disposition of lurtotecan 
In table 3, the pharmacokinetic data are summarized of total iurtotecan, which could best be 
fitted with a mono-exponential decline, in plasma as well as in whole blood. Characteristic were 
the slow plasma clearances of the dmg of 0.10 - 2.38 Llh/m2, the mono-exponential decline 
with a half life of 2.42 - 11.2 h and the low steady state volume of distribution, ranging from 
1.58 - 8.31 L/m2 . The mean blood:plasma totallurtotecan concentration ratio of O.66±0.13 is 
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indicative for liposomal encapsulation of lurtotecan in the plasma compartment, since no or 
limited drug is accumulated into the red blood cells (fig 4). Figure 5 shows the kinetic profile of 
total lurtotecan of patient 6 in plasma and whole blood. An additional chromatographic peak 
was found in the plasma samples with a retention time of approximately 50 minutes (not 
shown), which had an equal retention time as the chromatographic peak in the recovery control 
samples as described recently [14]. Structural identification as well as pharmacologic properties 
of this compound will be discussed in a separate communication shortly_ 
The urinary and fecal excretions of the unchanged parent compound iurtotecan are listed in 
table 3. The total excretion of lurtotecan in urine and feces ranged from 8.5 - 38% in the 6 
studied patients, suggesting extensive metabolism of lurtotecan. Inspection of the HPLC 
chromatograms from fecal extracts revealed 2 major additional peaks, which were absent in the 
blank fecal extracts, that might represent lurtotecan metabolites (fig 3). In fig 6, the cumulative 
excretions oflurtotecan in urine and feces of patient 6 are shown. 
Table 2: Validation characteristics of quality-control samples for the two HPLC assays 
Nominal 
(nglmL) 
Observed 
(nglmL) 
Lurlolecan il1 whole blood 
0.25b 0.24 
1.25 
20.0 
2000 
1.29 
20.2 
1950 
Lurlolecan illfeces homogenale 
lOb II 
40 
200 
2000 
41 
203 
1926 
WRP' 
(%) 
7.8 
11.4 
8.7 
13.2 
5.0 
4.3 
2.9 
3.6 
BRP 
(%) 
12.4 
5.1 
7.5 
c 
3.9 
6.9 
6.7 
8.6 
ACC 
(%) 
94.9 
103 
101 
98.0 
106 
101 
101 
96.3 
a: WRP. within-run precision·, BRP, between-run precision; ACe, accuracy. b: Lower lirrllt of quantitation samples. c: NQ additional 
\·ariation \\a'l observed as a result of performing the assay in dift""crcnt runs. 
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DISCUSSION 
In the present study, we have described for the first time the human pharmacokinetics of a 
liposome-encapsulated camptothecin analogue in plasma, whole blood, urine and feces. 
Of the greatest importance for the antitumor activity of lurtotecan treatment is the disposition of 
the agent in plasma. Lurtotecan has shown to be an active compound in animal models as well as in 
clinical trials. In general, for topoisomerase I inhibitors, prolonged exposure to the agent has been 
associated with an increase in cytotoxicity. Of particular note, the phase I data for free lurtotecan 
suggest that antitumor activity may be enhanced with continuous infusion, since responses were 
observed in the 72-h and 21·day continuous infusion schedules [6,7] As far as toxicity is concerned, 
although prolonged infusion is associated with an increase in thrombocytopenia, it has not been 
associated with an increase in the incidence and severity of neutropenia. Therefore, the use of a 
liposomal fonnulation of lurtotecan, as administered here, may also improve efficacy by increasing 
exposure to the active (lactone) drug fonn and modiJYing the safety profile, thus enhancing the 
therapeutic index of the parent compound. 
Table 3: Pharmacokinetic parameters oflurtotecan after NX 211 administration 
Patient CL' Vd,ss TV2 Fe" Fer Ratio 
No. 
, (LIMn) (Lim') (h) (%) (%) bllpl 
2.38 8.31 2.65 5.4 9.1 0.80 
2 0.67 3.94 3.99 4.9 3.6 0.70 
3 0.10 1.58 11.2 8.2 6.4 0.54 
4 0.28 1.76 4.18 6.l b 6.2 0.81 
5 1.15 3.63 2.42 7.3 11.7 0.57 
6 0.11 1.65 10.6 17.4 21.0 0.52 
mean 0.78 3.48 5.84 8.6 9.7 0.66 
SD 0.88 2.59 3.99 5.1 6.2 0.13 
CV 113% 74% 68% 59% 64% 20% 
a: CL, total plasma clearance; 11R.T, mean residence time; Vdp, volume of distribution at steady-state; T 111, half-life of the terminal 
disposition phase; Fe~, fraction oftne delivered dose excreted as unchanged drug in urine within 96 h; Fer, fraction of the delivered 
dose excreted as unchanged drug in feces "ithin 96 h; %CV, coefficient of variation. b: Incomplete recovery (0-12 h urine sample 
missing), not used for calculations. 
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Here, we have shown that the disappearance of lurtotecan after NX 211 administration was 
characterized by a mono-exponential decline with a tenninal disposition half-life in plasma of 
approximately 6 h. This is in contrast to the multiphasic elimination from plasma demonstrated by 
lurtotecan, which displays a tenninal half-life, estimated as 9.6±4.8 h in a cohort of 14 patients [4J. 
The basis for the longer elimination half-life of non-liposomal lurtotecan is most likely due to the 
slow elimination of the larger fraction of drug initially distributed to tissue. With NX 211, a 
prolonged association of lurtotecan within circulating intact liposomes in the plasma compartment 
would be assumed to release free drug over a period of time, quite possible resulting in the same 
terminal half-life as lurtotecan, but with concentrations below the lower limit of quantitation of the 
assay. The totallurtotecan plasma clearance from NX 211, on average 0.78 LIhIm2, is 25 times slower 
than the clearance of the freedmg, which \%s established at 21±9.6 Uhlm' [4]. The observed steady 
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Figure 4: Disposition oflurtotecan in the blood compartment in the studied patients (mean ± S.D.). 
188 
Disposition of NX 211 in humalls 
state volume of distribution of3.48±2.59 Urn' and the blood/plasma ratio ofO.66±0.13 are indicative 
for encapsulation of lurtotecan in the liposomes, which are mainly located in the plasma 
compartment. 
The observed variability in the pharmacokinetic behavior oflurtotecan after the administration 
ofNX 211 is slightly higher to that reported for the free dmg, with an interpatient variability in the 
plasma clearance of 113% for NX 211, versus 46% [4] for free lurtotecan, while these values for the 
volume of distribution were 74% and 52% [4], respectively. 
Urinary excretion of the unchanged dmg was 8.6± 5.1% in the 6 studied patients, which is similar 
with earlier findings of 14J ± 7.0% [3] and 11% [4] after a 30 min infusion offree dmg, indicating 
that renal clearance plays also a minor role in the elimination ofNX 211. Since also the total amount 
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Figure 5: Kinetic profile oflurtotecan in plasma (closed circles) and whole blood (open circles) in 
patient 6 after administration of8.5 mg NX211. 
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of lurtotecan in feces accounted for only 9.7% of the administered dose, lurtotecan is probably 
extensively metabolized. At least 2 potential metabolites of lurtotecan were observed in the 
chromatograms offecal homogenates, which will be part of further research regarding the metabolism 
ofNX 211. 
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Figure 6: Cumulative excretion of unchanged dmg in urine (open circles) and feces (closed circles) 
of patient 6 after administration efS.5 mg NX211. 
In conclusion, administration of liposome-encapsulated lurtotecan significantly reduces the 
plasma clearance of the drug, which in tum might prove beneficial for phannacodynamic outcome. 
Toxicity and anti-tumor response in relation to the pharmacokinetics are currently under investigation 
in a clinical phase I trial. 
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Summary alld conclusiolls 
Over the last decade, several analogues of the topoisomerase I inhibitor camptothecin, 
including topotecan, irinotecan, lurtotecan and 9-aminocamptothecin, have been introduced into 
clinical practice. Topoisomerase I is a nuclear enzyme involved in the replication of DNA, by 
fomling a covalent binding with DNA, the cleavable complex. This cleavable complex is stabilized 
by these camptothecins, resulting in a single strand breakage of the DNA, which finally leads to cell 
death. 
The camptothecin analogues share a pH-dependent reversible conversion between the 
pharmacologically active' ring-closed lactone form and its inactive, lactone ring-opened, 
carboxylate form. A quantitative measurement of these analogues is rather complex because of 
the chemical instability of the lactone moieties of the camptothecin analogues. 
Methodologies for the quantitative determination of the topoisomerase I inhibitors topotecan, 
9-aminocamptothecin and lurtotecan are described and the applicability of these assays is shown 
in this thesis. 
In Chap tel' 1, an overview is given of the methodologies currently used for the determination 
of topotecan, irinotecan, 9-aminocamptothecin and lurtotecan. Since these camptothecins have 
strong fluorescence characteristics, the analytes were quantified by fluorescence detection. As 
mentioned, the camptothecin analogues have a pH-dependent reversible conversion between the 
pharmacologically active lactone form and the inactive carboxylate form, which necessitates 
rapid centrifugation of the blood samples to collect the plasma. Also when only total 
concentrations, i.e. lactone plus carboxylate, are to be measured, this direct blood processing is 
crucial, since the lactone form is able to diffuse across the cell membranes of red blood cells, 
and thus a change in the lactone to carboxylate ratio has an effect on the total drug 
concentrations in the plasma compartment. Stabilization of the lactone to carboxylate ratio by 
direct freezing of the plasma sample is the most convenient approach for the determination of 
the lactone only concentrations. On the day of analysis all samples can be handled at once by 
solid-phase or liquid-liquid extraction techniques, in which only the lipophilic lactone form is 
extracted, while the carboxylate form is discarded. The total drug concentrations are measured 
in a second analysis after acidification of the samples. Another, simple way of stabilizing the 
lactone to carboxylate ratio is by cold methanolic deproteinization of plasma samples, 
immediately after collection of the plasma. The lactone and carboxylate concentrations are 
measured simultaneously in one analytical run. However, up to now, this approach has only 
been shown to be feasible for the determination of the two forms oftopotecan and irinotecan. 
Pharmaceutical and biomedical aspects of topotecan, a semisynthetic water-soluble 
camptothecin analogue, are described in chapter 2. The intravenous formulation of topotecan 
(Hycamtin®) has been registered for the treatment of ovarian cancer in Europe and the USA, 
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while an oral formulation is still under clinical investigation. 
In chapter 2a the simultaneous determination of the lactone and carboxylate forms of 
topotecan in human plasma and of the total concentration in human urine is described. The 
plasma clean up is based on simple methanolic protein precipitation, which stabilizes the 
lactone to carboxylate ratio when stored at -SO°c. The lower limit of quantitation for the lactone 
as well the carboxylate form is established at 0.10 ng/ml, with an overall run time of 10 min, 
which enables analysis of complete runs of patient samples during day time. Total topotecan 
concentrations in human urine samples, with a lower limit of quantitation of 10 ng/ml, are 
measured in the form oftopotecan lactone, after acidification with orthophosphoric acid. 
The influence of third spaces, such as pleuralM and ascitic fluid, on the pharmacokinetics of 
topotecan and the penetration of topotecan into these fluids is described in chapter 2b, in 4 
patients in the presence and absence of third space volumes. The apparent topotecan clearance, 
the terminal disposition halfMlives and the Aue ratios of lactone to total drug in plasma 
remained unchanged within the same patient in the presence or absence of pleural or ascitic 
fluid. The penetration of topotecan into the pleural and ascitic fluid showed a mean lag time of 
1.61 h and ratios with plasma concentration increased with time after dosing in all patients, with 
a mean ratio of third space topotecan total drug AUC to that in plasma of 0.55. So, topotecan can 
be safely administered to patients with pleural effusions or ascites, with substantial penetration 
of to po tee an into these third spaces for local antitumor effects. 
In chap tel' 2c, the pharmacokinetic interactions. and sequence dependent effects of orally 
administered topotecan in combination with i.v. cisplatin were studied in a phase I and 
pharmacological study. Cisplatin was given to a total of 49 patients at a fixed dose of75 mg/m2 
as a 3Mhour infusion, before topoteean on day 1 or after topotecan on day 5, in combination with 
oral topotecan at dose levels of 0.75 to 2.3 mg/m' for 5 days, repeated every 3 weeks. When 
topotecan was preceded by cisplatin, a more severe myelosuppression was induced, compared to 
the alternate sequence. The MTD for the most toxic sequence, cisplatin followed by topoteean, 
was established at a dose of 1.25 mg/m'/dx5 of topotecan, while for the reversed sequence the 
MTD was found at a dose of2.0 mg/m'/dx5 oftopotecan. The possible effect of drug sequence 
on the, pharmacokinetics of topotecan and cisplatin was investigated in the first 18 patients, 
which were randomized in a crossover design for the administration sequence. No significant 
differences in the topotecan pharmacokinetics were found when topotecan was preceded or 
followed by cispiatin. As for topotecan, the pharmacokinetics of cisplatin were not influenced 
by the administration sequence. The antitumor efficacy at the MTD of both schedules should be 
evaluated in a randomized phase II study. 
In the clinical practice of medical oncology, most antiMcancer drugs are commonly dosed based 
on the bodYMsurface area of the individual patient, with the aim reducing interMpatient variability in 
drug exposure, which is based on an assumed relationship between the clearance of a compound and 
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the body-surface area of tlle individual patient. In chapte!' 2d, the relevance of body-surface area 
based dosing of orally administered topotecan in adult cancer patients is evaluated, by estimation of 
the intra~ and inter-patient variabilities in topotecan lactone phannacokinetics. The intra-patient 
variability in the topotecan lactone AVe, using the data of 47 patients who were sampled for 3 - 6 
days, was 24 ± 13% (median 20%) with a range of7.6 - 61% The inter-patient variabilities in the 
apparent clearance of topotecan lactone, expressed in Llh/m2 as well as in LIh, were 38 and 42%, 
respectively. In view of the relatively high intra- and inter-patient variabilities in the AVe and 
apparent clearance of topotecan lactone and the relatively small range in observed body-surface 
area of 12%, oral topotecan can be added to the list of agents where body-surface area adjusted 
dosing does not appear definitely better. Moreover, accurate dosing of oral topotecan based on 
body-surface area is also not feasible, since for oral use the drug is now only available as gelatine 
capsules containing 1.0 and 0.25 mg respectively, resulting in the necessity of rounding of the 
absolute dose to the nearest quartile mg. We recommend a fixed dose regimen for future use in 
clinical trials, which is more convenient for the oncologist and the pharmacist, is more cost-
effective and last but not least, a fixed dose regimen is less cumbersome for the patients. Further 
randomized clinical studies are needed to fully explore the advantages of fixed dose regimens 
over body-surface area based dosing of orally administered topotecan in adult patients. 
In chapte .. 2e, the gender-dependent differences in topotecan pharmacokinetics in adult 
cancer patients after oral as well i.v. administration and the explanation of this phenomenon is 
described. A significant 1.4-fold faster apparent clearance of topotecan lactone was found in 
males as compared to females treated with oral topotecan< After correction for the body-surface 
area, the apparent topotecan lactone clearance remains significantly 1.3-fold faster in males. In 
addition, a significant l.3-fold higher lactone to total ratio of the AVe in females was found. 
Linear regression analysis between the significantly different biochemical characteristics body-
surface area and hematocrit and the apparent clearance of topotecan lactone, expressed in 
L/h/m2, resulted in a significant correlation of the apparent clearance with the hematocrit but not 
with the body-surface area. As in the oral study, female patients enrolled in a continuous Lv. 
study also had a higher lactone to total steady state plasma concentration ratio. In ill vitro studies 
with altered hematocrit values, a strong significant correlation was found between the 
hematocrit value and the lactone to total concentrations. In addition, the lactone to total plasma 
concentration ratio, in in vitro experiments, was significantly higher in blood of female 
volunteers as compared to male volunteers, with significantly higher topotecan lactone 
concentrations in the plasma compartment of the blood samples of the female volunteers. The 
implications of this gender-related difference in topotecan pharmacokinetics on the 
pharmacodynamics and tumor responses have to be evaluated in a large study in which 
topotecan is administered at a fixed dose. 
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Chapter 2f is describing a clinical phase I study with increased oral topotecan dosages, in 
comparison with the dosages used in chapter 2c, in combination with a lower fixed dose of 50 
mg/m2 ofi.v. administered cisplatin. The dose-limiting toxicities consisted of myelosuppression 
and gastrointestinal toxicity at a topotecan dose-level of 1.75 mg/m2/d administered on day 1-5, 
preceded by 50 mg/m2 cispiatin on day 1. The pharmacokinetics of to po tee an and cisplatin were 
similar to earlier data. The MTD of Lv. cisplatin at a dose-level of 50 mg/m2 on day I, directly 
followed by 5 days of oral topotecan at a dose of 1.50 mg/m2, has no advantage as compared to 
our previous recommended schedule for phase n studies of i.v. cisplatin at a dose of75 mg/m2 
on day 1 in combination with 1.25 mg/m2/d for 5 days of oral topotecan (chapter 2c), since only 
a minor dose escalation of topotecan could be achieved by a dose-reduction of 33% of cispiatin. 
The poor water-soluble synthetic camptothecin derivative 9-aminocamptothecin, which has 
shown promising anti-tumor efficacy in xenograft models, is discussed in chapter 3. Due to the 
water solubility problems, 9-aminocamptothecin seemed to be inappropriate for furtlIer clinical 
development. Since a colloidal dispersion formulation has been developed, phase I and n 
clinical trials with Lv. administered 9-aminocamptothecin have been conducted, while gelatin 
capsules were developed for oral administration. 
In chapter 3a, two high-performance liquid chromatographic methods for the determination 
of the lactone and total (i.e. lactone plus carboxylate) 9-aminocamptothecin concentrations in 
human plasma are described, with lower limits of quantitation of 50 and 100 pg/ml. respectively. 
The lactone form of 9-aminocamptothecin was extracted from the plasma by a single liquid-
liquid extraction. The sample preparation for the determination of total plasma levels consists of 
a simple deproteinization/acidiflcation step, in which the carboxylate form is converted to the 
lactone form. Both assays are sensitive, selective, accurate and reproducible and have been 
implemented in several clinical and ;n vitro studies. 
The factors responsible for the phenomenon of rebound concentrations in the kinetic profile 
of total 9-aminocamptotheicn after a bolus i.v. infusion, at approximately 2-3 hours after dosing, 
are described in chap tel' 3b. After a 5-min bolus infusion, 9-aminocamptothecin is rapidly 
hydrolyzed. with less than 10% present in the pharmacologically active lactone form at 3 hours 
after dosing. In ;11 vitro experiments, in which 9-aminocamptothecin was incubated in fresh 
human heparinized whole blood, the lactone instantaneously accumulated in the red blood cells, 
resulting in low plasma concentrations of 9-aminocamptothecin. Subsequently, the lactone form 
is hydrolyzed to the ring-opened carboxylate form, which is not able to pass cell membranes. So 
in time, higher concentrations of total 9-aminocamptdthecin were detected in the plasma 
compartment. In addition, the carboxylate form of 9-aminocampthothecin has a high affinity for 
human serum albumin, resulting in a shift of the equilibrium towards the carboxylate form, 
which in turn is responsible for the rebound concentrations of total 9-aminocamptothecin in the 
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plasma compartment of cancer patients, after a i.v. bolus infusion. The absence of the rebound 
peak in preclinical murine xenograft models is most likely related to differences in the lactone to 
carboxylate ratios compared to humans, with percentiles of 9~aminocamptothecin present in the 
lactone form at equilibrium in solutions of human or murine serum albumin ofrespectively 0.63 
and 35.0 %. 
In chapter 3c the clinical pharmacokinetics of 9~aminocampthotecin in adult cancer patients 
are described in plasma and saliva after oral administration, and relationships have been made 
with the pharmacodynamics. In contrast to other camptothecin derivatives, such as topotecan, 
lurtotecan and irinotecan, the conversion of the lactone form into the carboxylate form appeared 
to be much faster, with the equilibrium favoring the carboxylate form. The pharmacokinetics 
were linear and dose-independent and the intra~patient variability in lactone AVes were 
extremely low, while the inter~patient variability in the lactone AVes were high. The 9~ 
aminocampothecin lactone concentration ratio in plasma and unstimulated saliva were patient 
dependent and highly variable, indicating that unstimulated saliva is an unreliable matrix for 
pharmacokinetic analysis of 9~aminocamptothecin. From one patient, also pleural samples were 
collected and analyzed for 9-aminocamptothecin. As for topotecan (described in chapter 2b). 
pleural effusions are not a major compartment for 9~aminocamptothecin distribution. The AVe 
of the pharmacologically active lactone form significantly correlates with hematological 
toxicities like percentage decrease in total white blood cells, platelets and neutrophils. Since the 
intra~patient variability in drug exposure was very small, 9~aminocamptothecin could be 
individually dosed, using a target AVe as endpoint, in future clinical trials. 
In chaptel' 4, pharmaceutical and biomedical aspects of lurtotecan, a semisynthetic 
camptothecin analogue are described. In order to improve the efficacy of lurtotecan in cancer 
patients, the drug was encapsulated in liposomes. 
Chapter 4a, IS describing reversed-phase fluorescence high~performance liquid 
chromatographic methods for the determination of total lurtotecan concentrations in human 
plasma and urine in samples of patients after administration of NX 211 (i.e. a liposomal 
formulation of lurtotecan). For the determination of total plasma concentrations, the sample 
pretreatment consists ofa simple deproteinization/acidification step, resulting in a lower limit of 
quantitation of 1.00 nglml. This method has also been validated for the analysis of iurtotecan in 
urine samples, in which the urine was diluted 40~fold in blank human plasma, with the lower 
limit of quantitation established at 100 nglml urine. Lurtotecan concentrations in urine <100 nglml 
were detennined by a modified procedure, using a single solvent extraction technique. The 
fluorescence signal of lurtotecan was increased prior to detection by post-column exposure to UV 
light (254 nrn) in a photochemical reaction unit, in which the piperazinomethylene moiety on C7 of 
the molecule is lost, resulting in a 14~fold higher fluorescence signal compared to the parent 
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compound. The LLQ oftllis assay was 0.500 nglm\. The methods meet the current requirements as 
to validation of bioanalytical methodologies and are implemented in an ongoing clinical phase I 
trial ofNX Zll. 
The clinical applications of the assays described in chapter 4a, are described in chapter 4b, in 
which preliminary phammcokinetics are shown of lurtotecan in patients treated with NX 211. In 
addition to the described assays in chapter 4a, in this chapter also assays and pharmacokinetics of 
lurtotecan in human whole blood and feces are described. As in the assay for the determination of 
total lurtotecan plasma concentrations, the sample treatment procedures of whole blood and feces 
samples consist of a simple protein precipitation/acidification step. In both assays, the photo-
chemical reactor unit vms used to increase the fluorescence signal of lurtotecan, resulting in lower 
limits of quantitation of 0.Z5 and 10 nglml in whole blood and feces, respectively. The 
phannacokinetic profile in plasma was characterized by a clearance of 0.78 LIhIm2, which is 25 times 
slower than these for the free drug, with a mono-exponential decline with a half-life of approximately 
6 h, and a steady-state volume of distribution of approximately the blood volume. The low volume of 
distribution and the observed blood/plasma ratio of 0.66 are indicative for encapsulation of the drug 
in liposomes, which are mainly located in the plasma compartment. Urinary and fecal excretions of 
the parent compound lurtotecan were low, with mean values of respectively 8.6% and 9.7%, 
indicating that lurtotecan in probably extensively metabolized. In the chromatograms of the fecal 
homogenates 2 potential metabolites of lurtotecan were observed. The significantly reduced plasma 
clearance of iurtotecan by encapsulation of the drug in liposomes, might be beneficial for 
phannacodynamic outcome. Toxicity and anti-tumor response in relation to the pharmacokinetics are 
currently under investigation in a clinical phase I trial. 
Conclusions and future perspectives 
The camptothecins belong to the class of topoisomerase I inhibitors and have shown 
antitumor activity against a broad range of human malignancies, including refractory ovarian and 
colorectal cancers. Over the last decades, several methodologies have been developed and 
validated for the determination of the lactone, carboxylate and total concentrations of 
camptothecin analogues in biological matrices. Since the lactone form is the pharmacological 
active form of these compounds, and the equilibrium between the lactone and carboxylate forms 
in plasma of the camptothecins differs from derivative to derivative and from species to species, 
the analysis of the lactone form is of great importance for pharmacokinetic-pharmacodynamic 
relationships. 
In the future, the camptothecins will be increasingly combined with other drugs, because of 
which sensitive, selective, accurate and reproducible analytical methods for the determination of 
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camptothecin analogues, especially for the lactone forms of these drugs, are needed to get 
insight into possible pharmacokinetic interactions and their implications for the 
pharmacodynamics. 
Generally, in the future, dosing of anti-cancer agents will hopefully be individualized, based 
on the pharmacokinetics of each individual patient, especially when more is known about 
pharmacogenetics, in order to get more efficient and less toxic therapies. 
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Salllellvallillg ell COllclllsies 
In de strijd tegen kanker worden steeds nieuwe methoden gezocht om de ongebreidelde groei 
van tumorcellen af te remmen. Een van de nieuwste methoden is het blokkeren van het 
topoisomerase I enzym, dat betrokken is bij de deling van DNA en dus mede verantwoordelijk is 
voor de vermeerdering van cellen. DNA is een keten van nucleotiden dat in zich in een 
opgedraaide vorm in de celkern bevindt. Het topoisomerase I enzym rolt dit DNA af, waardoor 
andere enzymen voor de vermenigvuldiging kunnen zorgen, waarna het topoisomerase I enzym 
het DNA weer in zijn oorspronkelijke vorm terugbrengt. Door dit DNA-enzym complex te 
blokkeren, breekt het DNA, wat uiteindelijk resulteert in celdood. De laatste decennia zijn er 
diverse analoga van de topoisomerase I remmer camptothecine, zoals topotecan, irinotecan, 
lurtotecan en 9-aminocamptothecine ontwikkeld en getest in klinische studies. 
Al de tot nu toe klinisch gebruikte derivaten van camptothecine hebben gemeen, dat er een 
zuurgraad afhankelijk even wicht is tussen een farmacologisch werkzame lactonvorm en een niet 
werkzame carboxylaatvorm. Kwantitatieve bepalingen van deze topoisomerase I remmers 
worden door deze chemische instabiliteit van de lactonvorm bemoeilijkt. 
Analytische methoden voor de concentratiebepaling van de topoisomerase I remmers 
topotecan, 9-aminocamptotecine en lurtotecan in plasma, bloed, urine en feces worden in dit 
proefschrift beschreven. Daarnaast worden er toepassingen van deze analyse methoden in zowel 
preklinische als klinische studies beschreven. 
In hoofdstuk 1, wordt een overzicht gegeven van analyse methoden, zoals die momenteel 
wereldwijd voor concentratiebepalingen van topotecan, irinotecan, 9-aminocamptothecine en 
lurtotecan worden gebmikt. Aangezien deze camptothecinederivaten sterk fluorescerende 
eigenschappen hebben, worden deze stoff en gedetecteerd met behulp van fluorescentie, na te 
zijn gezuiverd en gescheiden van andere endogeen voorkomende stoffen met behulp van 
hogedruk vloeistofchromatografle. Hierbij worden componenten op grond van chemische en 
fysische eigenschappen gescheiden. Aangezien de camptothecinederivaten een zuurgraad 
afhankelijke omzetting kennen vall de lacton- naar de carboxylaatvorm, en visa versa, is het 
noodzakelijk dat bloedmonsters direct na afname gecentrifugeerd worden om het plasma te 
verzamelen, waarin de concentraties van de camptothecinederivaten bepaaJd worden. Daar 
aileen de werkzame lactonvorm in staat is om celmembranen te passeren, inclusief die van de 
rode bloedcellen, is het tevens noodzakelijk het bloed direct af te draaien wanneer aileen de 
totale concentratie van de camptothecinederivaten wordt bepaald. Een verschlliving van het 
even wicht tussen de lacton- en carboxylaatvorm in het bloed heeft namelijk een direct gevolg 
voor de totale concentratie van de camptothecine in het plasma. Nadat het plasma is verzameld 
kan dit het beste direct ingevroren worden, zodat de omzetting van lacton- naar carboxylaatvorm 
wordt gestopt. Voor de bepaling van de lactonconcentraties kllnnen de plasmamonsters op de 
dag van analyse ontdaan worden van onder andere eiwitten en de carboxylaatvorm door middel 
van vaste fase- of vloeistofextracties. In beide gevallen wordt op grond van wateroplosbaarheid 
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de lacton- van de carboxylaatvorm gescheiden. De totale concentraties van de 
camptothecinederivaten worden in een tweede analyse gemeten door het aanzuren van het 
plasmamonster, waardoor de totale hoeveelheid van de camptothecine in de lactonvorm komt. 
Naast het direct invriezen van plasmamonsters kan het evenwicht tussen de lacton- en 
carboxylaatvorm ook gestabiliseerd worden door het plasma direct te onteiwitten met koude 
methanol en dit extract in te vriezen. De lacton- en carboxylaatconcentraties kunnen dan in een 
analytische bepaling gemeten worden. Doordat de diverse camptothecinederivaten verschillende 
chemische en fysische eigenschappen hebben, is de laatste methode in de praktijk aileen 
mogelijk gebleken voor topotecan en irinotecan. 
In hoofds.uk 2 worden de fannaceutische en biomedische aspecten van het wateroplosbare 
camptothecineanaloog topotecan beschreven. De intraveneuze formulering van topotecan 
(Hycamtin®) is voor de behandeling van eierstokkanker geregistreerd in Europa en de Verenigde 
Staten. De orale formulering van topotecan is nog in de rase van klinisch onderzoek. 
De gelijktijdige bepaling van de lacton- en carboxylaatvorm van topotecan in humaan 
plasma, na stabilisatie van het even wicht door middel van een extractie met ijskoude methanol, 
en van totale topotecanconcentraties in humane urine is beschreven in hoofdstuk 2a. De laagste 
concentratie die nog adequaat en precies bepaald kon worden, voar zowel de lacton- als de 
carboxylaatvorm, werd gesteld op 0.10 ng/ml. Hiermee mag deze methode tot een van de 
gevoeligste worden gerekend. Totale concentraties van topotecan in urine worden gemeten in de 
Iactonvorm na aanzuring van het monster, met een laagste bepalingsgrens van 10 ng/m!. 
Een toepassing van de in hoofdstuk 2a beschreven analytische methode is beschreven in 
hoofdstuk 2b. Hierin wordt de invloed van derde ruimtes, zoals ascites en pleuravocht, op de 
plasmakinetiek van topotecan beschreven bij 4 patienten. De derde ruimtes fungeerden niet als 
'sink' voor topotecan en hadden geen invloed op de farmacokinetiek van zowel de lacton- als 
carboxylaatvorm van topotecan. De ratio's tussen de concentratie in de derde mimte en het 
plasma nam bij aile patienten toe in de tijd na orale toediening, met een gemiddeld oppervlak 
onder de concentratie tijdcurve ratio van 0.55. Topotecan kan dus veilig aan patienten met 
ascites en/ofpleuravocht worden gegeven zonder dat de plasmakinetiek verandert, terwijl er wei 
farmacologisch actieve concentraties in de ascites en het pleuravocht gevonden werden. 
Hoofdstuk 2c beschrijft een klinische fase I studie in 49 patienten, waarin een vaste dosis 
cispJatin van 75 mg/m2 werd gecombineerd met toenemende orale topotecan doseringen van 
0.75 tot 2.30 mg/m2. Cisplatin werd door middel van een 3-uur durend intraveneus infuus 
toegediend, vlak voor of na een 5-daagse orale toediening van topotecan, welke elke drie weken 
werd herhaald. Farmacokinetische interacties tussen de twee cytostatica en schema afhankelijke 
bijwerkingen werden bestudeercl. Cisplatin toegediend voor topotecan gaf aanzienlijk ernstigere 
bijwerkingen, in de vorm van beenmergschade, dan het omgekeerde schema. De hoogst haalbare 
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doseringen van topotecan waren respectievelijk 1.25 en 2.00 mg/m2. In de eerste 18 patienten 
werd een mogelijk farmacokinetische interactie van de twee cytostatica onder invloed van het 
schema onderzocht in een gerandomiseerde 'cross-over' studie. De farmacokinetiek van zowel 
topotecan als cisplatin werd niet beInvloed door de volgorde van toediening. In een 
gerandomiseerde fase II studie zal moeten worden uitgezocht welke van de twee schema's de 
meeste antitumor-activiteit laat zien. 
De meeste cytostatica worden vandaag de dag nog steeds aan de hand van het 
lichaamsoppervlak van de individuele patient gedoseerd. Dit heeft als doel de 
interpatientvariatie in de expositie aan het betreffende cytostaticum te verminderen. In 
hoofdstuk 2d wordt de relevantie van lichaamsoppervlak-gebaseerde dosering van oraal 
topotecan in volwassen patienten bediscussieerd aan de hand van de intra- en interpatientvariatie 
in topotecan expositie. De intrapatientvariatie in de oppervlakte onder de plasmaconcentratie 
tijdcurve van topotecan lacton was 24 ± 13% (mediaan 20%, range 7.6 - 61%) in 47 patienten. 
De interpatientvariatie in de plasmaklaring van de lactonvorm was 38 en 42%, respectievelijk 
uitgedrukt in Llh/m2 en in Llh. De kleine variatie in het lichaamsoppervlak van de bestudeerde 
patienten van 12% staat in schril contrast tot de gevonden intra- en interpatientvariaties in de 
plasma-expositie en -klaring. Een ander probleem voor exacte toediening van oraal topotecan is 
het reit dat er aileen capsules beschikbaar zijn met 0.25 en 1.00 mg, zodat aile doseringen 
sowieso moeten worden afgerond. Oraal toegediend topotecan kan worden toegevoegd aan d~ 
lijst met cytostatica, waarbij doseTing gebaseerd op lichaamsoppervlak niet beter is dan gelijke 
dosering van iedere patient. Hierbij dient tevens te worden opgemerkt dat een gelijke dosering 
makkelijker is voor de apotheker en oncoloog, kostenefficienter is en veer minder omslachtig is 
voor de patient. Om het nut van gelijke dosering bij iedere volwassen patient aan te tonen, zal er 
een gerandomiseerde klinische studie uitgevoerd moeten worden, waarbij de farmacokinetiek, 
bijwerkingen en tumorrespons worden onderzocht. 
Geslachtsafhankelijke verschillen in de plasmakinetiek van topotecan en de verklaring voor 
dit verschil worden in hoofdsfuk 2e beschreven. Na orale toediening werd er een significante 
1.4 keer snell ere plasmaklaring van de lactonvorm van topotecan geconstateerd bij mannelijke 
patienten in vergelijking met vrouwelijke patienten. Na correctie voor de lichaamsoppervlakken 
bleef de plasmaklaring significant 1.3 keer sneller bij mannen. Daarnaast werd er een significant 
1.3 keer hogere ratio bij vrouwen gemeten in de oppervlakte onder de plasmaconcentratie 
tijdcurven van topotecan lacton tot deze van topotecan totaal. Zowel de hematocriet waarde als 
het lichaamsoppervlak waren significant verschillend tussen de bestudeerde mannen en 
vrouwen. Er werd een significante linea ire relatie gelegd tussen de plasmaklaring van topotecan 
gecorrigeerd voor het Iichaamsoppervlak en de hematocriet waarde, terwijl deze relatie niet kon 
worden gelegd tussen de plasmaklaring en het lichaamsoppervlak Ook in een studie waarbij 
topotecan gedurende 21 dagen met een continu infuus werd toegediend, hadden vrouwen een 
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significant hogere lacton tot totaal 'steady state' concentratieratio. Bij Iaboratorium-
experimenten, waarbij de hematocriet waarde kunstmatig veranderd was, werd een zeer goede 
significante relatie gevonden tussen de hematocriet waarde en de lacton tot totaal topotecan 
concentratieratio in het piasmacompartiment van de bloedmonsters. Oak in bloedmonsters van 
vrouwelijke vrijwilligers werd een significant hogere lacton tot totaal topotecan 
plasmaconcentratieratio gemeten in vergelijking met bloedmonsters van mannelijke vrij will igers 
na incubatie met topotecan. In het plasmacompartiment van de bloedmonsters van vrouwen 
werd ook een significant hogere concentratie van de lactonvorm gevonden in vergelijking me~ 
de lactonconcentratie in de bloedmonsters van mannen. De implicaties van deze 
geslachtsafhankelijke topotecan plasmakinetiek ten aanzien van de tumorrespons en toxiciteit 
zullen in een grote studie met geselecteerde patienten maeten worden bestudeerd, waarbij aile 
mannen en vrouwen een gelijke dosis topotecan krijgen toegediend. 
Hoofd,luk 2f beschrijft een klinische fase I studie mel als doel: het ophogen van de dosis 
topotecan, in vergelijking met de studie die beschreven is in hoofdstuk 2c, in comb ina tie met 
een lagere doseTing van 50 mg/m2 cisplatin. De dosislimiterende bijwerkingen waren 
beenmergslJppressie en klachten betrekking hebbend op het maagdarmstelsel bij een dosis van 
1.75 mg/m2 topotecan gedurende 5 dagen, voorafgegaan door een enkelvoudige dosis cisplatin. 
Er werden geen verschiJlen in de plasmakinetiek van zowel topotecan als cispiatin gevonden in 
vergelijking met eerdere studies. De hoogst haalbare dosis van 1.50 mg/m2 topotecan gedurende 
5 dagen in combinatie met 50 mg/m2 cisplatin op dag I is waarschijnlijk niet effectiever dan het 
geadviseerde schema van 75 mg/m2 cisplatin op dag 1 gevolgd door 1.25 mg/m2 lopotecan 
gedurende 5 dagen. De cisplatin closering dient namelijk met 33% verminderd te worden om een 
minimale verhoging in de topotecan dosering mogelijk te maken. 
In hoofdstuk 3 wordt het slecht wateroplosbare camptothecinederivaat 9-
aminocamptothecine besproken. Aangezien 9-aminocamptothecine fen van de meest effectieve 
middelen in preklinische modenen bleek te zijn, is er lang gezocht naar een goede formulering 
voor klinische toepassing. Sindsdien zijn er verscheidene intraveneuze fase 1- en II- en orale fase 
I studies uitgevoerd. 
Hoofd,luk 3a beschrijft hogedruk vloeislofchromatografie methoden voor de bepaling van 
de 9-aminocamptothecine lactonconcentraties en vaor de totale concentraties in humaan plasma. 
De lactonvorm werd geextraheerd door middel van een vloeistofextractie, waarbij de iaagst 
adequaat meetbare concentratie 50 pg/ml was. In een tweede analyse werd de totale concentratie 
bepaald na cen simpele onteiwittingsstap, waarbij de totale hoeveelheid 9-aminocamptothecine 
in de lactonvorm werd gebracht. De laagst adequaat en precies meetbare concentratie bij de 
laatstgenoemde methode was 100 pg/ml. 
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Na een 5~minuten durende intraveneuze toediening van 9~aminocamptothecine werd er een 
zogenaamde 'rebound peak' in het kinetisch profiel van de totale concentratie van 9-
aminocamptothecine in humaan plasma geconstateerd. De factoren die deze 'rebound peak' 
veroorzaken, worden in hoofdstuk 3b beschreven. De toegediende lactonvorm van 9~ 
aminocamptothecine bleek in humaan bloed zeer snel omgezet te worden in de niet werkzame 
carboxylaatvorm, waarbij 3 lIue na toediening minder dan 10% zich nag in de lactonvorm 
beyond. Bij laboratoriumexperimenten, waarbij 9-aminocamptothecine aan vers bloed werd 
toegevoegd, verdeelde het zich direct over de rode bloedcellen en het plasma. Aangezien de 
toegevoegde lactonvonn zeer snel werd omgezet in de carboxylaatvorm, die niet in staat is am 
passier de membranen van de rode bloedcellen te passeren, nam de concentratie van 9-
aminocamptothecine in het piasmacompartirnent in de tijd toe. In tegenstelling tot onder andere 
topotecan heeft de carboxylaatvorm van 9~aminocamptothecine een hoge affiniteit voor hurnaan 
serumalburnine. Hierdoor kornt het evenwicht aan de kant van de carboxylaatvorm te liggen, 
zodat de totale plasmaconcentraties toenemen. Deze 'rebound peak' werd niet waargenomen bij 
preklinische studies in rnuizen. Dit kan verklaard worden doordat de percentages 9-
arninocamptothecine die zich - na het instellen van het evenwicht - nog in de lactonvorm 
bevinden, in oplossingen van humaan- of muizen serumalbumine respectievelijk 0.63 en 35.0% 
zijn. 
In hoofdstuk 3c wordt de kinetiek van 9~arninocamptothecine in plasma en speeksel na orale 
toediening beschreven. Tevens worden relaties gelegd tussen de plasmakinetiek en de 
bijwerkingen. De lactonvorm van 9-amino"Camptothecine wordt, in tegenstelling tot deze andere 
bekende camptothecinederivaten, zoals topotecan, lurtotecan en irinotecan, zeer sne! omgezet in 
de carboxylaatvorm. De plasmakinetiek was lineair met de dosis met zeer lage 
intrapatientvariaties in de expositie van de lactonvorm, terwijJ de interpatientvariaties in deze 
expositie relatief hoog waren. Concentratieratio's tussell ongestimuleerd speeksel en plasma 
waren zeer variabel, zodat plasma niet vervangen kan worden door ongestimuleerde speeksel 
voor de bepaling van het kinetisch profiel van 9~aminocamptothecine. Tevens werd bij een 
patient met pleuravocht onderzocht welk effect deze derde ruimte op de plasmakinetiek heeft. 
Net als voor topotecan (beschreven in hoofdstuk 2b) hoopt 9-aminocamptothecine zich niet in 
deze derde ruimte op en kan 9~aminocamptothecine aan patienten met pleuravocht worden 
gegeven zonder dat de expositie in het plasma afneemt. Ten aanzien van bijwerkingen correleert 
de oppervlakte onder de pJasmaconcentratie tijdcurve van de Jactonvorm met het percentage 
daJing in witte bloedcellen en trombocyten. In toekomstige klinische studies met oraal 
toegediende 9-aminocamptothecine kunnen patienten individueel gedoseerd worden met een 
vooraf bepaalde opperviakte onder de plasmaconcentratie tijdcurve als farmacokinetisch 
eindpunt, aangezien de intrapatientvariatie extreern laag is. 
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In het een na laatste hoofdstllk van dit proefschrift worden analytische methoden beschreven 
voor de bepating van de liposomaal geformuleerde topoisomerase I rem mer lurtotecan, terwijl in 
het laatste hoofdstllk een toepassing van deze methoden wordt beschreven. 
Hoofdstuk 4a beschrijft een hogedruk vloeistofchromatografische methode voor de bepaling 
van totale lurtotecan concentraties in plasma en urine van patienten na de toediening van NX 
2l1, de liposomaal geformuleerde lurtotecan. Totale plasmaconcentraties worden bepaald na het 
onteiwitten en aanzuren van het monster, waarbij de laagst adequaat meetbare concentratie op 
1.00 ng/ml gesteld is. Deze methode werd ook gevalideerd voor de bepaling van lurtotecan 
concentraties in urine die hoger zijn dan 100 nglml, door de urine voor extractie 40 keer te 
verdunnen in lurtotecan-vrije piasmamonsters. Voar lurtotecan concentraties in urine lager dan 
100 ng/mt werd een andere methode ontwikkeld die gebruik maakt van een vloeistofextractie. 
Tevens werd het fluorescerende vermogen van lurtotecan bij deze methode verhoogd door het 
eluaat voor detectie bloot te stell en aan ultraviolet licht, waarbij de piperazinomethyleen groep 
van het molecuul werd afgesplitst, resulterend in een 14 keer hoger flllorescerend signaal. 
Concentraties tot en met 0.500 ng/rot konden nog nauwkeurig en accuraat worden gemeten. 
Deze twee analytische bepalingsmethoden worden gebruikt in een lopende fase I studie met NX 
211. 
De toepassingen van de hierboven genoemde methoden worden beschreven in hoofdstuk 4b, 
waarin de kinetiek van lurtotecan wordt beschreven bij 6 patienten die experimenteel NX 211 
toegediend hebben gekregen. Tevens worden twee nieuwe methodieken beschreven voor de 
bepating van lurtotecan concentraties in bloed- en fecesmonsters. De monstervoorbewerking 
bestaat voor beide methoden uit een onteiwittingsstap in combinatie met aanzuren. Doordat ook 
hier het fluorescerend vermogen werd verhoogd door middel van ultraviolet licht, werden de 
laagst adequaat meetbare concentraties in bloedmonsters en gehomogeniseerde fecesmonsters 
respectievelijk gesteld op 0.25 en 10 ng/ml. De plasmakinetiek van lurtotecan kon in aIle 
gevallen het best worden beschreven met een mono~exponentiele afilame, met een halfwaarde 
tijd van gemiddeld 6 till£. De plasmaklaring was gemiddeld 0.78 L/uur/m', wat 25 keer 
langzamer is dan de plasmaklaring van niet liposamaal toegediende lurtotecan. Het distributie 
volume op "steady state" was ongeveer net zo groct als het totate bloedvolume van de patienten 
en de bloed tot plasma totaallurtotecan concentratieratio was gemiddeld 0.66. Deze parameters 
zijn indicatief dat lurtotecan zich nog in de liposomen bevindt, die zich voornamelijk in het 
plasmacompartiment ophouden. Zowel de urinaire als de fecale excretie van onveranderd 
lurtotecan was laag met respectievelijk gemiddelde waarden van 8.6% en 9.7%. Een groot deel 
van lurtotecan zal dus waarschijnlijk omgezet worden in metabolieten. In de chromatogrammen 
van gehomogeniseerde fecesmonsters werden 2 extra pieken gevonden, die afwezig waren in de 
blanco fecesmonsters van de patienten. Momenteel wordt in een lopende fase I studie gekeken 
naar de toxiciteit ell mogelijke anti-tumor res pOllS in relatie tot de farmacokinetiek. 
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Conclusies en toelmmstdromen 
De camptothecinederivaten behoren tot de klasse van de topoisomerase I remmers, die niet 
meer weg te denken zijn uit de kankergeneeskunde. Effectiviteit is onder andere aangetoond 
tegen eierstokM en dikkedarmkanker. Om de concentraties van deze topoisomerase I remmers in 
verschillende biologische monsters adequaat te kunnen bepalen zijn vele methodieken 
ontwikkeld die voornamelijk gebaseerd zijn op hogedruk vloeistofchromatografie in combinatie 
met fluorescentie detectie. Aangezien aIleen de lactonvorm werkzaam is, en het evenwicht 
tussen de lacton- en carboxyJaatvorm in het plasmacompartiment varieert tussen de 
verschillende analoga en kan varieren van mens tot proefdier, blijven goede analysemethoden 
voor de bepaling van de lactonvorm zeer belangrijk om goede relaties te kunnen leggen tussell 
de (plasma)kinetiek van een camptothecine en de bijwerkingen en/of tumorrespons. 
Ter verhoging van de effectiviteit zullen in de toekomst de topoisomerase I remmers steeds 
vaker worden gecombineerd met cytostatica met andere werkingsmechanismen. Aangezien in 
cornbinatietherapieen de doseringen van de cytostatica meestal lager zijn, blijven gevoelige, 
selectieve, accurate en reproduceerbare bepalingsmethoden nodig om inzicht te krijgen in 
mogelijke farmacokinetische interacties en de hieruit voortvloeiende bijwerkingen enlof 
tumorrespons. 
Ik dreom van een toekomst waarin anti-kankermiddelen individueel worden gedoseerd, 
gebaseerd op het farmacokinetisch profiel van het betreffende cytostatica in iedere afzonderlijke 
patient, met het doel om de bijwerkingen te verlagen, terwijl de effectiviteit van het middel 
verbetert. Met het oog op de vorderende kennis van genetische verschillen in onder andere 
enzymsystemen, verantwoordelijk voor bijvoorbeeld detoxificatie van allerhande stoffen, zon de 
realiteit van deze droam tach niet heel ver weg hoeven te zijn 
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